<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":6242,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d 1303, 103 U.S.P.Q.2d 1681 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/be1a650e379e823802dd9ef4a4e4ed93'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/be1a650e379e823802dd9ef4a4e4ed93'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1I46EO003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I46EO003">Previous Result: <span>Carraher v. Astrue, Civil No. 11-3017, 2...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1I46F6003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I46F6003">Next Result: <span>McKiney v. Holland, No. 2:12-cv-2112 CKD...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation negative" title="Negative"></div>
<div class='title left' title='Ass&amp;#x27;n for Molecular Pathology v. U.S. Patent &amp; Trademark Office, 689 F.3d 1303, 103 U.S.P.Q.2d 1681 (Fed. Cir. 2012), Court Opinion'>
Ass&#x27;n for Molecular Pathology v. U.S. Patent &amp; Trademark Office, 689 F.3d 1303, 103...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d 1303, 103 U.S.P.Q.2d 1681 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1I45SK003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office</div>
<div class='displayCitation'>103 U.S.P.Q.2d 1681</div>
<div class='displayCitation'>2012 BL 208695</div>
<div class='displayCitation'>2012 BL 210726</div>
<div class='displayCitation'>689 F.3d 1303</div>
<div class='displayCitation'>bna a0d4e1e5y4</div>
<div class='displayCitation'>bna a0d4e1y3b3</div>
<div class='displayCitation'>bna a0d4y8g9w5</div>
<div class='displayCitation'>wkffecase:26282954</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1I45SK003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Ass'n for Molecular Pathology v. U.S. Patent &amp; Trademark Office, 689 F.3d 1303, 103 U.S.P.Q.2d 1681 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Ass'n for Molecular Pathology v. U.S. Patent &amp; Trademark Office" />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1I45SK003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1I45SK003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1I45SK003" /><input id="title" name="title" type="hidden" value="Ass'n for Molecular Pathology v. U.S. Patent &amp; Trademark Office, 689 F.3d 1303, 103 U.S.P.Q.2d 1681 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="NEGATIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="be1a650e379e823802dd9ef4a4e4ed93" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1I45SK003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2Fbe%31a%36%35%30e%33%37%39e%38%32%33%38%30%32dd%39ef%34a%34e%34ed%39%33%2Fdocument%2FX%31I%34%35SK%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/bcite/X1I45SK003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/bcite/X1I45SK003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/bcite/X1I45SK003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/related_content/X1I45SK003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1722479673347";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">689 F.3d 1303</div>
<div class="cite" data-cite-type="ReporterOfDecisions">103 U.S.P.Q.2d 1681</div>
<div class="cite" data-cite-type="DocketNumber">2010-1406</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 210726</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
The ASSOCIATION FOR MOLECULAR PATHOLOGY, The American College of Medical
Genetics, The American Society for Clinical Pathology, The College of
American Pathologists, Haig Kazazian, MD, Arupa Ganguly, PhD, Wendy Chung,
MD, PhD, Harry Ostrer, MD, David Ledbetter, PhD, Stephen Warren, PhD, Ellen
Matloff, M.S., Elsa Reich, M.S., Breast Cancer Action, Boston Women's Health
Book Collective, Lisbeth Ceriani, Runi Limary, Genae Girard, Patrice
Fortune, Vicky Thomason, and Kathleen Raker, Plaintiffs-Appellees, v. UNITED
STATES PATENT AND TRADEMARK OFFICE, Defendant, and Myriad Genetics, Inc.,
Defendant-Appellant, and Lorris Betz, Roger Boyer, Jack Brittain, Arnold B.
Combe, Raymond Gesteland, James U. Jensen, John Kendall Morris, Thomas
Parks, David W. Pershing, and Michael K. Young, in their Official Capacity
as Directors of the University of Utah Research Foundation,
Defendants-Appellants.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 2010-1406.
</center></p>
<p><center>
August 16, 2012.
</center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924785" href="#headnote_ref_pq2-dec_924785">[1]</a> <span>Jurisdiction &mdash; Subject matter jurisdiction &mdash;
Case or controversy </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=405.0703" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="405.0703">&#9658;405.0703</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Parties; standing </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.07" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.07">&#9658;410.07</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Only one of 20 plaintiffs has standing to seek declaratory judgment that composition and method patents directed to &ldquo;isolated&rdquo;
gene sequences (BRCA1 and BRCA2), and mutations in those sequences associated with predisposition to breast and ovarian cancers, are drawn to patent-ineligible subject matter under 35 U.S.C. &sect;101, even though all plaintiffs, who include medical organizations, researchers, genetic counselors, and patients, assert that they are unable to engage in desired BRCA-related activities due to patentee's enforcement of its patent rights, since all but three plaintiffs fail to allege injury traceable to patentee, and of those who allege that patentee directed affirmative patent enforcement actions at them, only one plaintiff avers sufficiently real and imminent injury based on his stated intention to actually and immediately engage in allegedly infringing activities related to patents in suit; federal district court erroneously held that all plaintiffs had standing based on &ldquo;the widespread understanding that one may engage in BRCA1/2 testing at the risk of being sued for infringement liability by&rdquo; patentee, since mere disagreement with existence of patent, or suffering attenuated, non-proximate effect from patent, does not meet requirement for adverse legal controversy of sufficient immediacy and reality to warrant issuance of declaratory judgment. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924786" href="#headnote_ref_pq2-dec_924786">[2]</a> <span>Jurisdiction &mdash; Subject matter jurisdiction &mdash;
Case or controversy </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=405.0703" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="405.0703">&#9658;405.0703</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Parties; standing </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.07" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.07">&#9658;410.07</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">
Article III case or controversy exists if patentee asserts rights under patent based on certain identified ongoing or planned activity of another party, and if that party contends that it has right to engage in accused activity without license; in present action, university researcher has standing to seek declaratory judgment that certain composition and method claims directed to &ldquo;isolated&rdquo; gene sequences (BRCA1 and BRCA2), and mutations in those sequences associated with predisposition to breast and ovarian cancers, are drawn to patent-ineligible subject matter under 35 U.S.C. &sect;101, since patentee and plaintiff have taken adverse legal positions regarding whether or not plaintiff can engage in BRCA genetic testing without infringing any valid claim to isolated BRCA DNAs or methods of &ldquo;analyzing&rdquo; or &ldquo;comparing&rdquo;
BRCA sequences, as recited in patents, since plaintiff has alleged controversy of sufficient reality and immediacy, in that he has resources and expertise to immediately undertake BRCA genetic testing, he states unequivocally that he will immediately begin such testing, and relevant circumstances surrounding patentee's assertion of its patent rights have not changed despite passage of time, and since favorable decision is likely to redress plaintiff's alleged injury, in that declaration that claims are invalid would remove absolute barrier posed to plaintiff's ability to undertake BRCA diagnostic testing activities, and although there may be other claims directed to BRCA probes and primers that prevent such testing free of infringement liability, patentee has not identified specific unchallenged claim that would have that effect, and plaintiff, according to counsel, can sequence BRCA genes without using such probes and primers.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924787" href="#headnote_ref_pq2-dec_924787">[3]</a> <span>Patent grant &mdash; Inventions patentable </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=105.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="105.05">&#9658;105.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Subject matter </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.05">&#9658;115.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnote_text">
One distinction between product of nature and human-made invention, for purposes of patent eligibility under 35 U.S.C. &sect;101, turns on change in claimed composition's identity compared with what exists in nature; compositions that have similar characteristics as in nature are not patent eligible, even if arrayed in useful combinations or harnessed to exploit newly discovered properties, whereas compositions that have characteristics that are &ldquo;markedly different&rdquo; or &ldquo;distinctive&rdquo; from those in nature due to human intervention are patent eligible. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924788" href="#headnote_ref_pq2-dec_924788">[4]</a> <span>Patent grant &mdash; Inventions patentable </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=105.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="105.05">&#9658;105.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_7" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_7" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Subject matter </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.05">&#9658;115.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_8" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_8" class="headnoteContent"></div>
<div class="headnote_text">
Composition claims directed to &ldquo;isolated&rdquo; gene sequences
(BRCA1 and BRCA2), and mutations in those sequences associated with predisposition to breast and ovarian cancers, are drawn to patentable subject matter under 35 U.S.C. &sect;101, since isolated DNA results from human intervention to cleave or synthesize discrete portion of &ldquo;native&rdquo;
chromosomal DNA, imparting on that isolated DNA distinctive chemical identity as compared to native DNA existing in human body,  since claims, therefore, cover molecules that are markedly different from molecules existing in nature, and since decision that isolated DNA molecules are patent-eligible comports with long-standing practice of U.S. Patent and Trademark Office, and U.S. Congress has not indicated that PTO's position is inconsistent with Section 101; in nature, claimed isolated DNAs  are covalently bonded to other genetic materials, such that, when cleaved, isolated DNA molecule is not purified form of natural material, but distinct chemical entity obtained by human intervention, and &ldquo;cDNAs&rdquo; claimed in present case, which lack noncoding introns present in genomic BRCA1 gene, are even more distinct from natural DNA.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924789" href="#headnote_ref_pq2-dec_924789">[5]</a> <span>Patent grant &mdash; Inventions patentable </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=105.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="105.05">&#9658;105.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_9" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_9" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Subject matter </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.05">&#9658;115.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_10" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_10" class="headnoteContent"></div>
<div class="headnote_text">
Composition claims directed to &ldquo;isolated&rdquo; gene sequences
(BRCA1 and BRCA2), and mutations in those sequences associated with predisposition to breast and ovarian cancers, are drawn to patentable subject matter under 35 U.S.C. &sect;101, even though isolated DNAs retain same nucleotide sequences, and thus have same informational properties, as &ldquo;native&rdquo; DNAs, since it is distinctive nature of DNA molecules as isolated compositions of matter that determines their patent eligibility, rather than their physiological use or benefit, since genes are materials having chemical nature and, as such, are best described in patents by their structures rather than their functions, and since claimed DNA molecules are distinct from their natural existence as portions of larger entities, and their informational content is irrelevant to that fact; federal district court erred in creating categorical rule excluding isolated genes from patent eligibility, since Section 101 applies equally to all putative inventions, and isolated DNA is not, and should not be, considered special case for purpose of patent eligibility under existing law.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924790" href="#headnote_ref_pq2-dec_924790">[6]</a> <span>Patent grant &mdash; Inventions patentable </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=105.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="105.05">&#9658;105.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_11" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_11" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Subject matter </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.05">&#9658;115.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_12" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_12" class="headnoteContent"></div>
<div class="headnote_text">
Proposed &ldquo;magic microscope&rdquo; test for determining whether claims directed to &ldquo;isolated&rdquo; gene sequences are drawn to patentable subject matter under 35 U.S.C. &sect;101, which would find claim to cover ineligible product of nature if imaginary microscope could focus in on claimed DNA molecule as it exists in human body, is rejected, since test misunderstands difference between science and invention and fails to account for existence of molecules as separate chemical entities, and since ability to visualize DNA molecule when bonded to other genetic material is vastly different from possessing isolated DNA molecule that is in hand and usable.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924791" href="#headnote_ref_pq2-dec_924791">[7]</a> <span>Patent grant &mdash; Inventions patentable </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=105.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="105.05">&#9658;105.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_13" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_13" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Subject matter </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.05">&#9658;115.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_14" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_14" class="headnoteContent"></div>
<div class="headnote_text">
Concern that permitting patents on isolated DNA molecules claimed in present case preempts others from using those molecules is misplaced, since claimed isolated gene sequences (BRCA1 and BRCA2), and mutations in those sequences associated with predisposition to breast and ovarian cancers, are compositions of matter, not mere reflections of law of nature, and permitting patents on isolated genes thus does not preempt law of nature, and since limited preemption is inherent in every patent, regardless of nature of invention; although compositions at issue follow laws of nature, as all materials do, they are products of human intervention, not products of nature. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924792" href="#headnote_ref_pq2-dec_924792">[8]</a> <span>Patent grant &mdash; Inventions patentable </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=105.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="105.05">&#9658;105.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_15" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_15" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Subject matter </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.05">&#9658;115.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_16" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_16" class="headnoteContent"></div>
<div class="headnote_text">
Claims directed to methods of &ldquo;comparing&rdquo; or &ldquo;analyzing&rdquo; &ldquo;isolated&rdquo; gene sequences (BRCA1 and BRCA2) with normal sequences to identify cancer-predisposing mutations claim only abstract mental processes, and thus are not drawn to patentable subject matter under 35 U.S.C. &sect;101, since claims recite nothing more than abstract mental steps necessary to compare two different nucleotide sequences, since restricting comparison solely to BRCA genes or to identification of particular alterations does not render claimed process patent-eligible, since claims do not apply step of comparing two nucleotide sequences in any larger process, since additional steps of &ldquo;extracting&rdquo; DNA from sample and &ldquo;sequencing&rdquo; BRCA DNA molecule cannot be read into claims so as to render them transformative, and since claims do not include any other putatively transformative step, and claimed comparison of two nucleotide sequences thus can be accomplished by mere inspection alone.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924793" href="#headnote_ref_pq2-dec_924793">[9]</a> <span>Patent grant &mdash; Inventions patentable </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=105.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="105.05">&#9658;105.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_17" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_17" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Subject matter </span> <a href="http://www.bloomberglaw.com/document/1722479673347/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.05" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.05">&#9658;115.05</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_18" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_18" class="headnoteContent"></div>
<div class="headnote_text">
Claim directed to method for screening potential cancer therapeutics via changes in growth rates of transformed cells is drawn to patentable subject matter under 35 U.S.C. &sect;101, since claim recites steps of growing host cells &ldquo;transformed&rdquo; with altered BRCA1 gene in presence or absence of potential cancer therapeutic, determining growth rate of host cells with or without potential therapeutic, and comparing growth rate of host cells, since &ldquo;transformed&rdquo;
host cells are derived by altering cell to include foreign gene, resulting in man-made, transformed cell with enhanced function and utility, and claim thus includes more than abstract mental step of looking at two numbers and &ldquo;comparing&rdquo; two host cells' growth rates, since claim applies certain steps to transformed cells that are product of human intervention, not of nature, and thus does not merely apply conventional steps to law of nature, since transformed, non-naturally occurring nature of host cells makes claim patent-eligible, and inclusion of steps of determining cells' growth rates and comparing those growth rates does not change that fact, and since claim does not cover all cells, all compounds, or all methods of determining therapeutic effect of compound, but is instead tied to specific host cells transformed with specific genes and grown in presence or absence of specific type of therapeutic.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the Southern District of
New York, Robert W. Sweet, Senior District Judge.
</p></div>
<span CLASS="page_no" data-cite="689 f 3d 1304" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1304" data-primary-citation="689 F.3d 1303">[*1304]</span> <div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="689 f 3d 1305" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1305" data-primary-citation="689 F.3d 1303">[*1305]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="689 f 3d 1306" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1306" data-primary-citation="689 F.3d 1303">[*1306]</span> 
</p></div>
</div>
<div id="para2" printdualcolumn="true"><p>
<span CLASS="page_no" data-cite="103 uspq 2d 1684" data-cite-type="ReporterOfDecisions" data-cite-pageno="1684" data-primary-citation="103 U.S.P.Q.2d 1681">[**1684]</span> Christopher A. Hansen, American Civil Liberties Union Foundation, of New
York, NY, argued for plaintiffs-appellees. With him on the brief were Sandra
S. Park, Aden Fine, and Lenora M. Lapidus. Of counsel on the brief were
Daniel B. Ravicher and Sabrina Y. Hassan, Public Patent Foundation, Benjamin
N. Cardozo, School of Law, of New York, NY.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Gregory A. Castanias, Jones Day, of Washington, DC, argued for all
defendant-appellants. With him on the brief were Jennifer L. Swize, of
Washington, DC, Israel Sasha Mayergoyz and Dennis Murashko, of Chicago, IL,
Brian M. Poissant, Laura A. Coruzzi and Eileen Falvey, of New York, NY. Of
counsel were Benjamin Jackson, and Jay Z. Zhang, Myriad Genetics, of Salt
Lake City, UT.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Melissa N. Patterson, Attorney, Civil Division, Appellate Staff, United
States Department of Justice, of Washington, DC, argued for amicus curiae,
United States. With her on the brief were Stuart F. Delery, Acting Assistant
Attorney General, Beth S. Brinkmann, Deputy Assistant Attorney General and
Scott R. Mcltosh, Attorney. Of counsel was Mark R. Freeman.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Thomas J. Kowalski, Vedder Price PC, of New York, New York, for amicus
curiae Protein Sciences Corporation. With him
<span CLASS="page_no" data-cite="689 f 3d 1307" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1307" data-primary-citation="689 F.3d 1303">[*1307]</span> 
on the brief were Deborah L. Lu; and Robert S. Rigg, of Chicago, IL.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Robert A. Armitage, Eli Lilly and Company, Indianapolis, IN, for amicus
curiae, Eli Lilly and Company. With him on the brief was James J. Kelley.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Christopher M. Holmah, University of Missouri-Kansas City School of Law, of
Kansas City, MO, for amicus curiae Law Professor Christopher M. Holman.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Charles R. Macedo, Amster Rothstein &amp; Ebenstein, LLP, of New York, NY, for
amicus curiae, New York Intellectual Property Law Association. Of counsel on
the brief were Ronald M. Daignault and Matthew B. McFaflane, Robins, Kaplan,
Miller &amp; Ciresi, L.L.P. of New York, NY.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Lori B. Andrews, IIT Chicago-Kent College of Law, of Chicago, IL, <span CLASS="page_no" data-cite="2012 bl 210726 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> for amicus
curiae, The American College of Embryology, et al. Of counsel was Joshua D.
Sarnoff, DePaul University College of Law, of Chicago, IL.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Debra L. Greenfield, UCLA Institute for Society and Genetics, of Los
Angeles, CA, for amici curiae, The National Women's Health Network, et al.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Krista L. Cox, Knowledge Ecology International, of Washington, DC, for
amicus curiae, Knowledge Ecology International, et al.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Richard F. Phillips, Intellectual Property Owners Association, of
Washington, DC, for amicus curiae, Intellectual Property Owners Association.
With him on the brief was Kevin H. Rhodes. Of counsel on the brief were Paul
H. Berghoff, Kevin E. Noonan and Jeffrey P. Armstrong, McDonnell Boehnen
Hulbert &amp; Berghoff, LLP, of Chicago, IL. Of counsel were Herbert C. Wamsley,
Intellectual Property Owners, of Washington, DC, and Douglas Kent Norman,
Eli Lilly &amp; Company, of Indianapolis, IN.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Barbara R. Rudolph, Finnegan, Henderson, Farabow, Garrett &amp; Dunner, LLP, of
Washington, DC, for amicus curiae, American Intellectual Property Law
Association. With her on the brief were Robert D. Litowitz, Erika Harmon
Arner and David S. Forman. Of counsel on the brief was William G. Barber,
American Intellectual Property Law Association, of Arlington, VA. Of counsel
were David Warren Hill, American Intellectual Property, of Arlington, VA,
and Robert C. Stanley, Finnegan, Henderson, Farabow, Garrett &amp; Dunner, LLP,
of Atlanta, GA.
</p></div>
<div id="para2" printdualcolumn="true"><p>
William T. Robinson, III, American Bar Association, of Chicago, IL, for
amicus curiae, American Bar Association. Of counsel on the brief were John
P. Elwood, Vinson &amp; Elkins, LLP, of Washington, DC; and Michael A. Valek,
Stephen C. Stout, of Austin, TX.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Mark J. Gatschet, Mark John Gatschet, P.L.L.C. of Houston, TX, for amicus
curiae, Mark J. Gatschet and Richard W. Knight. Of counsel on the brief was
Richard W. Knight, R.W. Knight P.C. of San Antonio, TX.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Claire Laporte, Foley Hoag, LLP, of Boston, MA, for amicus curiae Federal
Circuit Bar Association. With her on the brief was James M. Flaherty, Jr.
</p></div>
<div id="para2" printdualcolumn="true"><p>
John L. Hendricks, Hitchcock Evert, LLP, of Dallas, TX, for amicus curiae,
AARP, et al. With him on the brief were Megan M. O'Laughlin and John T.
Tower. Of counsel was Michael R. Schuster.
</p></div>
<div id="para2" printdualcolumn="true"><p>
J. Timothy Keane, Harness, Dickey &amp; Pierce, PLC, of St. Louis, MO, for
amicus curiae, BioGenerator, et al.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Susan E. McBee, Baker, Donelson, Bearman, Caldwell, and Berkowitz, P.C. of
Washington, DC, for amicus curiae, Immatics Biotechnologie, GmbH. With her
on the brief was Bryan W. Jones.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Seth P. Waxman, Wilmer Cutler Pickering Hale and Dorr, LLP, of Washington,
DC, for amicus curiae, Biotechnology Industry
<span CLASS="page_no" data-cite="689 f 3d 1308" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1308" data-primary-citation="689 F.3d 1303">[*1308]</span> 
Organization, et al. With him on the brief was Thomas G. Saunders. Of
counsel on the brief was Mark C. Fleming, of Boston, MA, and Hansjorg
Salter, Biotechnology Industry Organization, of Washington, DC. Of counsel
was Allen C. Nunnally, Wilmer Cutler Pickering Hale and Dorr, LLP, of
Boston, MA.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Jennifer Gordon, Baker Botts, L.L.P. of New York, NY, for amicus curiae,
Croplife International. With her on the brief were Steven Lendaris and
Jennifer C. Tempesta.
<span CLASS="page_no" data-cite="2012 bl 210726 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> </p></div>
<div id="para2" printdualcolumn="true"><p>
Matthew J. Dowd, Wiley Rein LLP, of Washington, DC, for amicus curiae, James
D. Watson. With him on the brief was James H. Wallace, Jr.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Kurt G. Calia, Covington &amp; Burling, LLP, of Redwood Shores, CA, for amicus
curiae, Pharmaceutical Research and Manufacturers of America. With him on
the brief were Robert A. Long, Jr. and Allison E. Kerndt, of Washington, DC,
and Alexa R. Hansen, of San Francisco, CA.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Eileen M. Kane, Penn State Dickinson School of Law, of University Park, PA,
for amicus curiae, Professor Eileen M. Kane.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Genevieve E. Scott, Yale School of Law, of Brooklyn, NY, for amicus curiae,
Information Society Project at Yale Law School Scholars. With her on the
brief was Priscilla J. Smith.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Robert Sachs, Fenwick &amp; West, LLP, of San Francisco, CA, for amicus curiae,
Advanced Biological Laboratories, SA.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before LOURIE, BRYSON, and MOORE, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
LOURIE, Circuit Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Opinion for the court filed by Circuit Judge LOURIE. Opinion concurring in
part filed by Circuit Judge MOORE. Opinion concurring in part and dissenting
in part filed by Circuit Judge BRYSON.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad Genetics, Inc. and the Directors of the University of Utah Research
Foundation (collectively, "Myriad") appeal from the decision of the United
States District Court for the Southern District of New York holding that an
assortment of medical organizations, researchers, genetic counselors, and
patients (collectively, "Plaintiffs") have standing under the Declaratory
Judgment Act to challenge Myriad's patents. <i>Ass'n for Molecular Pathology v.</i>
<i>U.S. Patent &amp; Trademark Office</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20f%20supp%202d%20365&amp;summary=yes#jcite">669 F.Supp.2d 365</a> (S.D.N.Y.2009) ("<i>DJ Op.</i>").
Myriad also appeals from the district court's decision granting summary
judgment that all of the challenged claims are drawn to non-patentable
subject matter under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20usc%20101&amp;summary=yes#jcite">35 U.S.C. &sect; 101</a>. <i>Ass'n for Molecular Pathology v. U.S.</i>
<i>Patent &amp; Trademark Office</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1D8KQI003?jcsearch=702%20f%20supp%202d%20181&amp;summary=yes#jcite">702 F.Supp.2d 181</a> (S.D.N.Y. 2010) ("<i>SJ Op.</i>"). We
affirm in part and reverse in part.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This appeal has returned to us as, a petition for certiorari having been
filed from our decision of July 29, 2011, the Supreme Court of the United
States granted the petition, vacated our decision, and remanded the case to
us for further consideration in light of its decision in <i>Mayo Collaborative</i>
<i>Services v. Prometheus, Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20S.Ct.%201289&amp;summary=yes#jcite">566 U.S. ___</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">132 S.Ct. 1289</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=182%20l%20ed%202d%20321&amp;summary=yes#jcite">182 L.Ed.2d 321</a>
(2012). <i>Ass'n for Molecular Pathology v. Myriad Genetics, Inc.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=132%20S.%20Ct.%201794&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=132%20supreme%20court%201794&amp;summary=yes#jcite">132 S.Ct. 1794</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=182%20l%20ed%202d%20613&amp;summary=yes#jcite">182 L.Ed.2d 613</a> (2012). We invited and
received briefing by the parties and interested amici and held oral argument
on July 20, 2012. Our decision on remand follows. It both decides the issues
that were before us in the original appeal and evaluates the effect of <i>Mayo</i>
on those issues.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On the threshold issue of jurisdiction, we affirm the district court's
decision to exercise declaratory judgment jurisdiction because we conclude
that at least one plaintiff,
<span CLASS="page_no" data-cite="689 f 3d 1309" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1309" data-primary-citation="689 F.3d 1303">[*1309]</span> 
Dr. Harry Ostrer, has standing to challenge the validity of Myriad's
patents. On the merits, we reverse the district court's decision that
Myriad's composition claims to "isolated" DNA molecules cover
patent-ineligible products of nature under &sect; 10.1 because each of the
claimed molecules represents a nonnaturally occurring composition of matter.
We also reverse the district court'<span CLASS="page_no" data-cite="2012 bl 210726 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> s decision that Myriad's method claim to
screening potential cancer therapeutics via changes in cell growth rates of
transformed cells is directed to a patent-ineligible scientific principle.
We affirm the court's decision, however, that Myriad's method claims
directed to "comparing" or "analyzing" DNA sequences are patent ineligible;
such claims include no transformative steps and cover only patent-ineligible
abstract, mental steps.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Plaintiffs brought suit against Myriad, challenging the patentability of
certain composition and method claims relating to human genetics. <i>See DJ</i>
<i>Op.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20f%20supp%202d%20365&amp;summary=yes#jcite">669 F.Supp.2d at 369-76</a>. Specifically, Plaintiffs sought a declaration
that fifteen claims from seven patents assigned to Myriad are drawn to
patent-ineligible subject matter under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20usc%20101&amp;summary=yes#jcite">35 U.S.C. &sect; 101</a>: claims 1, 2, 5, 6,
7, and 20 of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">U.S. Patent 5,747,282</a> ("the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>"); claims 1, 6, and 7
of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2I0CE44GGJ?jcsearch=usp%205837492&amp;summary=yes#jcite">U.S. Patent 5,837,492</a> ("the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2I0CE44GGJ?jcsearch=usp%205837492&amp;summary=yes#jcite">492 patent</a>"); claim 1 of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HH4643GOJ?jcsearch=usp%205693473&amp;summary=yes#jcite">U.S. Patent
5,693,473</a> ("the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HH4643GOJ?jcsearch=usp%205693473&amp;summary=yes#jcite">473 patent</a>"); claim 1 of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO0I94I8J?jcsearch=usp%205709999&amp;summary=yes#jcite">U.S. Patent 5,709,999</a> ("the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO0I94I8J?jcsearch=usp%205709999&amp;summary=yes#jcite">999
patent</a>"); claim 1 of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO400008J?jcsearch=usp%205710001&amp;summary=yes#jcite">U.S. Patent 5,710,001</a> ("the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO400008J?jcsearch=usp%205710001&amp;summary=yes#jcite">001 patent</a>"); claim 1 of
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOK64208J?jcsearch=usp%205753441&amp;summary=yes#jcite">U.S. Patent 5,753,441</a> ("the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOK64208J?jcsearch=usp%205753441&amp;summary=yes#jcite">441 patent</a>"); and claims 1 <span CLASS="page_no" data-cite="103 uspq 2d 1685" data-cite-type="ReporterOfDecisions" data-cite-pageno="1685" data-primary-citation="103 U.S.P.Q.2d 1681">[**1685]</span> and 2 of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X300C682HOJ?jcsearch=usp%206033857&amp;summary=yes#jcite">U.S. Patent
6,033,857</a> ("the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X300C682HOJ?jcsearch=usp%206033857&amp;summary=yes#jcite">857 patent</a>").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The challenged composition claims cover two "isolated" human genes, <i>BRCA1</i>
and <i>BRCA2</i> (collectively, "<i>BRCA&frac12;</i>" or "<i>BRCA</i>"), and certain alterations, or
mutations, in these genes associated with a predisposition to breast and
ovarian cancers. Representative composition claims include claims 1, 2, and
5 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      1. An isolated DNA coding for a BRCA1 polypeptide, said
    polypeptide having the amino acid sequence set forth in SEQ <cite>ID</cite> NO:2.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      2. The isolated DNA of claim 1, wherein said DNA has the
    nucleotide sequence set forth in SEQ <cite>ID</cite> NO:1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      5. An isolated DNA having at least 15 nucleotides of the DNA of
    claim 1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
&prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> col. 153 1.55 &mdash; col. 154 1.56.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> SEQ <cite>ID</cite> NO:2 depicts the
amino acid sequence of the BRCA1 protein, and SEQ <cite>ID</cite> NO:1 depicts the
nucleotide sequence of the <i>BRCA1</i> DNA coding region; the latter sequence is
colloquially referred to as cDNA. <i><cite>Id</cite>.</i> col. 19 ll.48-50.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  All but one of the challenged method claims cover methods of "analyzing"
or "comparing" a patient's <i>BRCA</i> sequence with the normal, or wild-type,
sequence to identify the presence of cancer-predisposing mutations.
Representative method claims include claims 1 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO0I94I8J?jcsearch=usp%205709999&amp;summary=yes#jcite">999</a> and &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO400008J?jcsearch=usp%205710001&amp;summary=yes#jcite">001</a> patents:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      1. A method for detecting a germline alteration in a BRCA1 gene,
    said alteration selected from the group consisting of the
    alterations set forth in Tables 12A, 14, 18 or 19 in a human which
    comprises <i>analyzing</i> a sequence of a BRCA1 gene or BRCA1 RNA from a
    human sample or <i>analyzing</i> a sequence of BRCA1 cDNA made from mRNA
    from said human sample with the proviso that said germline
    alteration is not a deletion of 4 nucleotides corresponding to base
    numbers 4184-4187 of SEQ <cite>ID</cite> NO: 1.
<span CLASS="page_no" data-cite="689 f 3d 1310" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1310" data-primary-citation="689 F.3d 1303">[*1310]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
&prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO0I94I8J?jcsearch=usp%205709999&amp;summary=yes#jcite">999 patent</a> col. 161 ll.17-25 (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      1. A method for screening a tumor sample from a human subject for
    a somatic alteration in a BRCA1 gene in said tumor which comprises
    [] <i>comparing</i> a first sequence selected from the group consisting of
    a BRCA1 gene from said tumor sample, BRCA1 RNA from said tumor
    sample and BRCA1 cDNA made from mRNA from said <span CLASS="page_no" data-cite="2012 bl 210726 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> tumor sample with a
    second sequence selected from the group consisting of BRCA1 gene
    from a nontumor sample of said subject, BRCA1 RNA from said nontumor
    sample and BRCA1 cDNA made from mRNA from said nontumor sample,
    wherein a difference in the sequence of the BRCA1 gene, BRCA1 RNA or
    BRCA1 cDNA from said tumor sample from the sequence of the BRCA1
    gene, BRCA1 RNA or BRCA1 cDNA from said nontumor sample indicates a
    somatic alteration in the BRCA1 gene in said tumor sample.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
&prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO400008J?jcsearch=usp%205710001&amp;summary=yes#jcite">001 patent</a> col.155 ll.2-17 (emphasis added).<a HREF="#fn200" name="fnref_fn200">[fn2]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The final method claim challenged by Plaintiffs is directed to a method of
screening potential cancer therapeutics. Specifically, claim 20 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282
patent</a> reads as follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      20. A method for screening potential cancer therapeutics which
    comprises: growing a <i>transformed eukaryotic host cell</i> containing an
    altered BRCA1 gene causing cancer in the presence of a compound
    suspected of being a cancer therapeutic, growing said <i>transformed</i>
    <i>eukaryotic host cell</i> in the absence of said compound, determining
    the rate of growth of said host cell in the presence of said
    compound and the rate of growth of said host cell in the absence of
    said compound and comparing the growth rate of said host cells,
    wherein a slower rate of growth of said host cell in the presence of
    said compound is indicative of a cancer therapeutic.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
&prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> col. 156 ll.13-24 (emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The challenged claims thus relate to isolated gene sequences and
diagnostic methods of identifying mutations in these sequences. To place
this suit in context, we take a step back to provide background on the
science involved, including the identification of the <i>BRCA</i> genes, and the
Plaintiffs' connections to the invention and to Myriad.
<span CLASS="page_no" data-cite="103 uspq 2d 1686" data-cite-type="ReporterOfDecisions" data-cite-pageno="1686" data-primary-citation="103 U.S.P.Q.2d 1681">[**1686]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Human genetics is the study of heredity in human beings.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> The human
genome, the entirety of human genetic information, contains approximately
22,000 genes, which form the basis of human inheritance. The majority of
genes act by guiding the production of polypeptide chains that form
proteins. Proteins in turn make up having matter and catalyze a variety of
cellular processes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Chemically, the human genome is composed of deoxyribonucleic acid ("DNA").
Each DNA molecule is made up of repeating units of four nucleotide bases &mdash;
adenine ("A"), thymine ("T"), cytosine ("C"), and guanine ("G") &mdash; which are
covalently linked, or bonded,<a HREF="#fn400" name="fnref_fn400">[fn4]</a> together via a sugarphosphate,
<span CLASS="page_no" data-cite="689 f 3d 1311" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1311" data-primary-citation="689 F.3d 1303">[*1311]</span> 
or phosphodiester, backbone. DNA generally exists as two DNA strands
intertwined as a double helix in which each base on a strand pairs, or
hybridizes, with a complementary base on the other strand: A pairs with T,
and C with G. Figure 1 below depicts the structure of a DNA double helix and
the complementary pairing of the four nucleotide bases, represented by A, T,
C, and G.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1I45SK003?documentName=72546_a">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The linear order of nucleotide bases in a DNA molecule is referred to as
its "sequence." The sequence of a gene is thus denoted by a linear sequence
of As, Ts, Gs, and Cs. "DNA sequencing" or "gene sequencing" refers to the
process by which the precise linear order of nucleotides in a DNA segment or
gene is determined. A gene's nucleotide sequence <span CLASS="page_no" data-cite="2012 bl 210726 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> in turn encodes for a
linear sequence of amino acids that comprise the protein encoded by the
gene, <i>e.g.</i>, the <i>BRCA1</i> gene encodes for the BRCA1 protein. Most genes have
both "exon" and "intron" sequences. Exons are DNA segments that are
necessary for the creation of a protein, <i>i.e.</i>, that code for a protein.
Introns are segments of DNA interspersed between the exons that, unlike
exons, do not code for a protein.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The creation of a protein from a gene comprises two steps: transcription
and translation. First, the gene sequence is "transcribed" into a different
nucleic acid called ribonucleic acid ("RNA"). RNA has a chemically different
sugar-phosphate backbone than DNA, and it utilizes the nucleotide base
uracil ("U") in place of thymine ("T"). During transcription, the DNA double
helix is unwound and each nucleotide on the non-coding, or template, DNA
strand is used to make a complementary, single-stranded RNA molecule that
mirrors the coding DNA strand, <i>i.e.</i>, adenine on the template DNA strand
results in uracil in the RNA molecule, thymine results in adenine, guanine
in cytosine, and cytosine in guanine. The resulting "pre-RNA," like the DNA
from which it was generated, contains both exon and intron sequences. Next,
the introns are <span CLASS="page_no" data-cite="103 uspq 2d 1687" data-cite-type="ReporterOfDecisions" data-cite-pageno="1687" data-primary-citation="103 U.S.P.Q.2d 1681">[**1687]</span> physically excised from the pre-RNA molecule, followed by
"splicing" the exons to produce a messenger RNA ("mRNA"). Figure 2 below
shows the steps of transcribing a gene that contains three exons (exon 1-3)
and two introns (intron 1 and 2) into a pre-RNA, followed by RNA excising
the introns and splicing of the exons to produce an mRNA containing only
exon sequences.
<span CLASS="page_no" data-cite="689 f 3d 1312" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1312" data-primary-citation="689 F.3d 1303">[*1312]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1I45SK003?documentName=72546_b">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following transcription and splicing, the resulting mRNA is "translated"
into the encoded protein. Genes, and their corresponding mRNAs, encode
proteins via three-nucleotide combinations called co-dons. Each codon
triplet corresponds to one of the twenty amino acids that make up all
proteins or a "stop" signal that terminates protein translation. For
example, the codon adenine-thymine-guanine (ATG, or AUG in the corresponding
mRNA), encodes the amino acid methionine. The relationship between the
sixty-four possible codon sequences and their corresponding amino acids is
known as the genetic code. Figure 3 below represents an mRNA molecule that
translates into a protein of six amino acids (Codon 1, AUG, methionine;
Codon 2, ACG, threonine; Codon 3, GAG, glutamic acid; Codon 4, CUU, leucine;
Codon 5, CGG, arginine; Codon. 6, AGC, serine), and ends with one of the
three stop codons, UAG.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1I45SK003?documentName=72546_c">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Changes, or mutations, in the sequence of a human gene can alter the
production, structure, and/or function of the resulting protein. Small-scale
changes include point mutations in-which a change to a single nucleotide
alters a single amino acid in the encoded protein. For example, a base
change in the codon GCU to CCU changes an alanine in the encoded protein to
a proline. Larger scale variations include the deletion, rearrangement, or
duplication of larger DNA segments &mdash; ranging from several hundreds to over a
million nucleotides &mdash; and
<span CLASS="page_no" data-cite="689 f 3d 1313" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1313" data-primary-citation="689 F.3d 1303">[*1313]</span> 
can result in the elimination, misplacement, or duplication of an entire
gene <span CLASS="page_no" data-cite="2012 bl 210726 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> or genes. While some mutations have little or no effect on the body's
processes, others result in disease or an increased risk of developing a
particular disease. DNA sequencing is used in clinical diagnostic testing to
determine whether a gene contains mutations associated with a particular
disease or disease risk.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nearly every cell in, the human body contains an individual's entire
genome. DNA in the cell, called "native", or "genomic" DNA, is packaged into
twenty-three pairs of chromosomes. Chromosomes are complex structures
comprising a single extended DNA molecule wrapped around proteins called
histones, as shown in Figure 4 below.
<span CLASS="page_no" data-cite="103 uspq 2d 1688" data-cite-type="ReporterOfDecisions" data-cite-pageno="1688" data-primary-citation="103 U.S.P.Q.2d 1681">[**1688]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1I45SK003?documentName=72546_d">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Each chromosome contiguously spans millions of bases and encompasses many
discrete genes. Humans have twenty-two pairs of autosomal chromosomes,
numbered one to twenty-two according to size from largest to smallest, and
one pair of sex chromosomes, two X chromosomes in females and one X and one
Y chromosome in males.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Genomic DNA can be extracted from its cellular environment using a number
of well-established laboratory techniques. A particular segment of DNA, such
as a gene, can then be excised or amplified from the DNA to obtain the
isolated DNA segment of interest. DNA molecules can also be synthesized in
the laboratory. One type of synthetic DNA molecule is complementary DNA
("cDNA"). cDNA is synthesized from mRNA using complementary base pairing in
a manner analogous to RNA transcription. The process results in a
double-stranded DNA molecule with a sequence corresponding to the sequence
of an mRNA produced by the body. Because it is synthesized from mRNA, cDNA
contains only the exon sequences, and thus
<span CLASS="page_no" data-cite="689 f 3d 1314" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1314" data-primary-citation="689 F.3d 1303">[*1314]</span> 
none of the intron sequences, from a chromosomal gene sequence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Certain mutations in the <i>BRCA</i> genes correlate with an increased risk of
breast and ovarian cancer. The average woman in the United States has around
a twelve to thirteen percent risk of developing breast cancer in her
lifetime. Women with <i>BRCA</i> mutations, in contrast, face a cumulative risk of
between fifty to eighty percent of developing breast cancer and a cumulative
risk of ovarian cancer of between twenty to fifty percent. Diagnostic
genetic testing for the existence of <i>BRCA</i> mutations <span CLASS="page_no" data-cite="103 uspq 2d 1689" data-cite-type="ReporterOfDecisions" data-cite-pageno="1689" data-primary-citation="103 U.S.P.Q.2d 1681">[**1689]</span> is therefore an
important consideration in the provision of clinical care for breast or
ovarian cancer. This testing provides a patient with information on her risk
for hereditary breast and ovarian cancers, and thus aids in the difficult
decision regarding whether to undertake preventive options, including
prophylactic surgery. Diagnostic results can also be an important factor in
structuring an appropriate course of cancer treatment, since certain forms
of therapy are more effective in treating cancers related to <i>BRCA</i> mutations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The inventors of the patents in suit identified the genetic basis of
<i>BRCA1-</i> and <i>BRCA2-related</i> cancers using an analysis called positional
cloning. Relying on a large set of DNA samples from families with inherited
breast and ovarian cancers, the inventors correlated <span CLASS="page_no" data-cite="2012 bl 210726 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> the occurrence of
cancer in individual family members with the inheritance of certain marker
DNA sequences. This allowed the inventors to identify, or "map," the
physical location of the <i>BRCA</i> genes within the human genome and to isolate
the <i>BRCA</i> genes and determine their exact nucleotide sequences. This in turn
allowed Myriad to provide <i>BRCA</i> diagnostic testing services to women.<a HREF="#fn500" name="fnref_fn500">[fn5]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad, however, was not the only entity to implement clinical <i>BRCA</i>
testing services. Starting in 1996, the University of Pennsylvania's Genetic
Diagnostic Laboratory ("GDL"), co-directed by plaintiffs Haig H. Kazazian,
Jr., M.D. and Arupa Ganguly, Ph.D., provided <i>BRCA&frac12;</i> diagnostic services to
women. By 1999, however, accusations by Myriad that GDL's <i>BRCA</i> testing
services infringed its patents forced the lab to stop providing such
services.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The first sign of a dispute came in early 1998. At that time, Dr. Kazazian
recalls a dinner with Dr. Mark Skolnick, inventor and Chief Science Officer
at Myriad. At the dinner, Skolnick informed Kazazian that Myriad was
planning to stop GDL from providing clinical <i>BRCA</i> testing in light of
Myriad's patents. A month or two later, in May 1998, Kazazian received a
letter from William A. Hockett, Director of Corporate Communications at
Myriad. The letter stated that Myriad knew that Kazazian was currently
providing <i>BRCA1</i> diagnostic testing services, and that Myriad, as patent
holder of five U.S. patents covering the isolated <i>BRCA1</i> gene and diagnostic
testing, was making available to select institutions a collaborative
license. Attached to the letter was a copy of Myriad's collaborative
<span CLASS="page_no" data-cite="689 f 3d 1315" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1315" data-primary-citation="689 F.3d 1303">[*1315]</span> 
agreement, which proposed severely limiting GDL's testing services to
certain tests for patients of Ashkenazi Jewish descent. Plaintiff Harry
Ostrer, M.D., a researcher at New York University ("NYU") School of
Medicine, received the same letter and collaborative agreement in May 1998,
although his laboratory did not, at the time, provide such testing services.
Rather, Ostrer sent patient samples to GDL for <i>BRCA</i> genetic testing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Months later, in August 1998, Dr. Kazazian received a second letter, this
time from George A. Riley of the law firm O'Melveny &amp; Myers LLP. The letter
identified by number five Myriad patents "covering, among other things, the
BRCA1 gene sequence . . . and methods for detecting alterations in the BRCA1
sequence." J.A. 1145. The letter also indicated that it "has come to
Myriad's attention that you are engaged in commercial testing activities
that infringe Myriad's patents," and that "[u]nless and until a licensing
arrangement is completed . . . you should cease all infringing testing
activity." <i><cite>Id</cite>.</i> The letter noted, however, that the cease-and-desist
notification did not apply to research testing "for the purpose of
furthering non-commercial research programs, the results of which are not
provided to the patient and for which no money is received from the patient
or the" patient's insurance." <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In June 1999, Robert Terrell, the General Counsel for the University of
Pennsylvania, received a similar cease-and-desist letter from Christopher
<span CLASS="page_no" data-cite="2012 bl 210726 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> Wight, Myriad's General Counsel. The letter stated, "It has come to our
attention that Dr. Haig H. Kazazian, Jr. of the University of Pennsylvania
is continuing to willfully engage in commercial BRCA1 and BRCA2 genetic
testing activities, in violation of the University of Pennsylvania's
previous assurances that such commercial testing activities would be
discontinued." J.A. 2890. Terrell responded to Wight by letter on September
10, 1999, stating that "the University agrees that it will not accept
samples for BRCA1 research testing from third parties." J.A. 2891. Kazazian
thus informed Dr. Ostrer that GDL would no longer be accepting patient
<span CLASS="page_no" data-cite="103 uspq 2d 1690" data-cite-type="ReporterOfDecisions" data-cite-pageno="1690" data-primary-citation="103 U.S.P.Q.2d 1681">[**1690]</span> samples for <i>BRCA</i> testing from him or anyone else as a result of the patent
infringement assertions made by Myriad. As a result, Ostrer started sending
patient samples for <i>BRCA</i> genetic testing to Myriad, which became (and
remains today) the only provider of such services in the United States.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  During this period, Myriad also initiated several patent infringement
suits against entities providing clinical <i>BRCA</i> testing. Myriad filed suit
against Oncormed Inc. in 1997 and again in 1998, <i>Myriad Genetics v.</i>
<i>Oncormed</i>, Nos. 2:97-cv-922, 2:98-cv-35 (D.Utah), and the University of
Pennsylvania in 1998, <i>Myriad Genetics v. Univ. of Pa.</i>, <cite>No. 2:98-cv-829</cite>
(D.Utah). Both lawsuits were later dismissed without prejudice after each
defendant agreed to discontinue all allegedly infringing activity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  None of the plaintiffs besides Drs. Kazazian, Ganguly, and Ostrer, allege
that Myriad directed any letters or other communications regarding its
patents at them. Rather, the other researchers and medical organization
members state simply that knowledge of Myriad's vigorous enforcement of its
patent rights against others stopped them from engaging in clinical <i>BRCA</i>
genetic testing, although they have the personnel, expertise, and facilities
as well as the desire to provide such testing. The patient plaintiffs state
that they have been unable to obtain any <i>BRCA</i> genetic testing or their
desired <i>BRCA</i> testing, either covered by their insurance or at a price that
they can afford, because of Myriad's patent protection.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Like the other researchers, Dr. Kazazian states that if Myriad's patents
were
<span CLASS="page_no" data-cite="689 f 3d 1316" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1316" data-primary-citation="689 F.3d 1303">[*1316]</span> 
held invalid, he and Dr. Ganguly would be able to resume <i>BRCA</i> testing within
a matter of a few weeks. He notes, however, that this is only if they
"decided to resume BRCA testing." J.A. 2852. Ganguly concurs, stating that
if the patents were invalidated, "I would immediately consider resuming BRCA
testing in my laboratory." J.A. 2892. Dr. Ostrer<a HREF="#fn600" name="fnref_fn600">[fn6]</a> also indicates that
his lab has all the personnel, facilities, and expertise necessary to
undertake clinical <i>BRCA</i> testing and emphatically states that his lab "would
immediately begin to perform BRCA&frac12;-related genetic testing upon invalidation
of the Myriad patents." J.A. 2936-38.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  IV.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After Plaintiffs filed suit, Myriad moved to have the case dismissed,
alleging that the Plaintiffs lacked standing to bring a declaratory judgment
suit challenging the validity of its patents. The district court disagreed,
<span CLASS="page_no" data-cite="2012 bl 210726 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> however, holding that the Plaintiffs had established Article III standing
under the "all the circumstances" test articulated by the Supreme Court in
<i>MedImmune, Inc. v. Genentech, Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. 118</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">127</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=166%20l%20ed%202d%20604&amp;summary=yes#jcite">166 L.Ed.2d 604</a> (2007). <i>DJ Op.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20f%20supp%202d%20365&amp;summary=yes#jcite">669 F.Supp.2d at 385-92</a>. The court first
found that Myriad had engaged in sufficient "affirmative acts" based on the
company's assertion of its "right to preclude others from engaging in <i>BRCA&frac12;</i>
genetic testing through personal communications, cease-and-desist letters,
licensing offers, and litigation," the result of which was "the widespread
understanding that one may engage in <i>BRCA&frac12;</i> testing at the risk of being sued
for infringement liability by Myriad." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20F.%20Supp.%202d%20365&amp;summary=yes#jcite">Id. at 390</a>. Myriad's actions, the
court concluded, had placed "the Plaintiffs in precisely the situation that
the Declaratory Judgment Act was designed to address: the Plaintiffs have
the ability and desire to engage in <i>BRCA&frac12;</i> testing as well as the belief that
such testing is within their rights, but cannot do so without risking
infringement liability." <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20F.%20Supp.%202d%20365&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In so holding, the court rejected Myriad's argument that there must be
some act directed toward the Plaintiffs, noting that Myriad had, in fact,
taken affirmative acts toward plaintiffs Dr. Kazazian and Dr. Ganguly. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20F.%20Supp.%202d%20365&amp;summary=yes#jcite">Id.
at 387-88</a>. The court also rejected Myriad's arguments that the
cease-and-desist letter sent to plaintiff Kazazian was too old to support
declaratory judgment jurisdiction and that the legal actions brought against
third parties could not be considered in the jurisdictional analysis. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20F.%20Supp.%202d%20365&amp;summary=yes#jcite">Id. at
388-89</a>. The court concluded that rigid adherence to either of these
requirements would be inconsistent with <i>MedImmune's</i> mandate that the court
assess the facts alleged under all the circumstances. <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20F.%20Supp.%202d%20365&amp;summary=yes#jcite">Id</a>.<span CLASS="page_no" data-cite="103 uspq 2d 1691" data-cite-type="ReporterOfDecisions" data-cite-pageno="1691" data-primary-citation="103 U.S.P.Q.2d 1681">[**1691]</span> </i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court also found that the Plaintiffs had alleged sufficient
meaningful preparations for infringement to establish declaratory judgment
jurisdiction. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20F.%20Supp.%202d%20365&amp;summary=yes#jcite">Id. at 390-92</a>. With respect to the researchers, the court held
it was sufficient that they were all "ready, willing, and able" to begin
<span CLASS="page_no" data-cite="689 f 3d 1317" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1317" data-primary-citation="689 F.3d 1303">[*1317]</span> 
<i>BRCA&frac12;</i> testing within the normal course of their laboratories' research,
rejecting Myriad's argument that they needed to allege specific preparatory
activities. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20F.%20Supp.%202d%20365&amp;summary=yes#jcite">Id. at 390-91</a>. The court also rejected Myriad's argument that
plaintiffs Kazazian and Ganguly testified only that they would "consider"
engaging in allegedly infringing activities, concluding that the proper
focus of the inquiry is whether they are meaningfully prepared, not whether
they have made a final, conclusive decision to engage in such activities.
<i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20F.%20Supp.%202d%20365&amp;summary=yes#jcite">Id. at 391</a> n. 18.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The parties then moved for summary judgment on the merits of Plaintiffs' <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/1?citation=35%20U.S.C.%20%20101&amp;summary=yes#jcite">&sect;
101</a> challenge to Myriad's patent claims. The district court held for
Plaintiffs, concluding that the fifteen challenged claims were drawn to
non-patentable subject matter and thus invalid under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>. <i>SJ Op.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1D8KQI003?jcsearch=702%20f%20supp%202d%20181&amp;summary=yes#jcite">702 F.Supp.2d at 220-37</a>. Regarding the composition claims, the court held
that isolated DNA molecules fall within the judicially created "products of
nature" exception to <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a> because such isolated DNAs are not "markedly
different" from native DNAs. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1D8KQI003?jcsearch=702%20F.%20Supp.%202d%20181&amp;summary=yes#jcite">Id. at 222</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1D8KQI003?jcsearch=232&amp;summary=yes#jcite">232</a> (<span CLASS="page_no" data-cite="2012 bl 210726 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> quoting <i>Diamond v.</i>
<i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. 303</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=65%20l%20ed%202d%20144&amp;summary=yes#jcite">65 L.Ed.2d 144</a> (1980)). The court
relied on the fact that, unlike other biological molecules, DNAs are the
"physical embodiment of information," and that this information is not only
preserved in the claimed isolated DNA molecules, but also essential to their
utility as molecular tools. <i>Id.</i> at 228-32.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Turning to the method claims, the court held them patent ineligible under
this court's then-definitive machine-or-transformation test. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1D8KQI003?jcsearch=702%20F.%20Supp.%202d%20181&amp;summary=yes#jcite">Id. at 233</a>
(citing <i>In re Bilski</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X19S5TO003?jcsearch=545%20f%203d%20943&amp;summary=yes#jcite">545 F.3d 943</a> (Fed.Cir.2008) (en banc), <i>aff'd on other</i>
<i>grounds, Bilski v. Kappos</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=132%20S.%20Ct.%201794&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=130%20supreme%20court%203218&amp;summary=yes#jcite">130 S.Ct. 3218</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=130%20supreme%20court%203218&amp;summary=yes#jcite">3225</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=177%20l%20ed%202d%20792&amp;summary=yes#jcite">177 L.Ed.2d 792</a> (2010)). The court held that the claims covered "analyzing"
or "comparing" DNA sequences by any method, and thus covered mental
processes independent of any physical transformations. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1D8KQI003?jcsearch=702%20F.%20Supp.%202d%20181&amp;summary=yes#jcite">Id. at 233-35</a>. In so
holding, the court distinguished Myriad's claims from those at issue in <i>Mayo</i>
based on the "determining" step in the latter being construed to include the
extraction and measurement of metabolite levels from a patient sample. <i>SJ</i>
<i>Op</i>:, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1D8KQI003?jcsearch=702%20f%20supp%202d%20181&amp;summary=yes#jcite">702 F.Supp.2d at 234-35</a> (citing <i>Prometheus Labs., Inc. v. Mayo</i>
<i>Collaborative Servs.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1ENQ84003?jcsearch=628%20f%203d%201347&amp;summary=yes#jcite">628 F.3d 1347</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1ENQ84003?jcsearch=628%20f%203d%201347&amp;summary=yes#jcite">1350</a> (Fed. Cir.2010), <i>rev'd</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=132%20S.%20Ct.%201794&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">132 S.Ct. 1289</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=182%20l%20ed%202d%20321&amp;summary=yes#jcite">182 L.Ed.2d 321</a> (2012)). Alternatively, the
court continued, even if the claims could be read to include the
transformations associated with isolating and sequencing human DNA, these
transformations would constitute no more than preparatory data-gathering
steps. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1D8KQI003?jcsearch=702%20F.%20Supp.%202d%20181&amp;summary=yes#jcite">Id. at 236</a> (citing <i>In re Grams</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X4SA7I?jcsearch=888%20f%202d%20835&amp;summary=yes#jcite">888 F.2d 835</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X4SA7I?jcsearch=888%20f%202d%20835&amp;summary=yes#jcite">840</a> (Fed.Cir.1989)).
Finally, the court held that the one method claim to "comparing" the growth
rate of cells claimed a basic scientific principle and that the
transformative steps amounted to only preparatory data gathering. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1D8KQI003?jcsearch=702%20F.%20Supp.%202d%20181&amp;summary=yes#jcite">Id. at
237</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad appealed. We have jurisdiction pursuant to <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I. Declaratory Judgment Jurisdiction
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The first question we must address is whether the district court correctly
exercised declaratory judgment jurisdiction over this suit. The Declaratory
Judgment Act provides that, "In a case of actual controversy within its
jurisdiction . . . any court of the United States . . . may declare the
rights and other legal relations of any interested party seeking such
declaration, whether or not further relief is or could be sought."
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEINES003?jcsearch=28%20U.S.C.%20%202201(a)&amp;summary=yes#jcite">28 U.S.C. &sect; 2201</a>(a). The phrase "a case of actual controversy" in the Act
refers to the types of "cases" and "controversies" that are justiciable
under
<span CLASS="page_no" data-cite="689 f 3d 1318" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1318" data-primary-citation="689 F.3d 1303">[*1318]</span> 
Article <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/1?citation=USCONST%20Art.%20III&amp;summary=yes#jcite">III</a> of the U.S. Constitution. <i>Aetna Life Ins. v. Haworth</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVKE?jcsearch=300%20us%20227&amp;summary=yes#jcite">300 U.S. 227</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVKE?jcsearch=300%20us%20227&amp;summary=yes#jcite">239-40</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVKE?jcsearch=57%20supreme%20court%20461&amp;summary=yes#jcite">57 S.Ct. 461</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVKE?jcsearch=81%20l%20ed%20617&amp;summary=yes#jcite">81 L.Ed. 617</a> (1937).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although no bright-line rule exists for determining whether a declaratory
judgment action satisfies Article Ill's case-or-controversy requirement, the
Supreme Court has held that the dispute must be "definite and concrete,
touching the legal relations of parties having adverse legal interests,"
"real and substantial," and "admi[t] of specific relief through a decree of
a conclusive character, as distinguished from an opinion advising what the
law would be upon a hypothetical state of facts." <i>MedImmune</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. at 127</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a> (quoting <i>Aetna Life</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVKE?jcsearch=300%20us%20227&amp;summary=yes#jcite">300 U.S. at 240-41</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVKE?jcsearch=57%20supreme%20court%20461&amp;summary=yes#jcite">57 S.Ct. 461</a>). "Basically, the question in each case is whether the facts
alleged, under all the circumstances, show that there is a substantial
controversy, between parties having adverse legal interests, of sufficient
immediacy and reality to warrant the issuance of a declaratory <span CLASS="page_no" data-cite="2012 bl 210726 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> judgment."
<i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=549%20U.S.%20118&amp;summary=yes#jcite">Id</a>.</i> (quoting <span CLASS="page_no" data-cite="103 uspq 2d 1692" data-cite-type="ReporterOfDecisions" data-cite-pageno="1692" data-primary-citation="103 U.S.P.Q.2d 1681">[**1692]</span> <i>Md. Cas. Co. v. Pac. Coal &amp; Oil Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C07D?jcsearch=312%20us%20270&amp;summary=yes#jcite">312 U.S. 270</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C07D?jcsearch=312%20us%20270&amp;summary=yes#jcite">273</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C07D?jcsearch=61%20supreme%20court%20510&amp;summary=yes#jcite">61 S.Ct. 510</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C07D?jcsearch=85%20l%20ed%20826&amp;summary=yes#jcite">85 L.Ed. 826</a> (1941)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In applying <i>MedImmune's</i> all-the-circumstances test to a declaratory
judgment action, we are guided by the Supreme Court's three-part framework
for determining whether an action presents a justiciable Article III
controversy: standing, ripeness, and mootness. <i>See Caraco Pharm. Labs., Ltd.</i>
<i>v. Forest Labs., Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">527 F.3d 1278</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">1291</a> (Fed.Cir.2008). In this case, the
parties have framed the jurisdictional issue as one of standing. <i>See</i>
<i>MedImmune</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. at 128</a> n. 8, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a>. ("The justiciability problem
that arises, when the party seeking declaratory relief is himself preventing
the complained-of injury from occurring, can be described in terms of
standing . . . or . . . ripeness." (internal citations omitted)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "[T]he irreducible constitutional minimum of standing contains three
elements." <i>Lujan v. Defenders of Wildlife</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=504%20us%20555&amp;summary=yes#jcite">504 U.S. 555</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=504%20us%20555&amp;summary=yes#jcite">560</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=119%20l%20ed%202d%20351&amp;summary=yes#jcite">119 L.Ed.2d 351</a> (1992). "First, the plaintiff must have
suffered an injury in fact &mdash; an invasion of a legally protected interest
which is (a) concrete and particularized, and (b) actual or imminent, not
conjectural or hypothetical." <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=504%20U.S.%20555&amp;summary=yes#jcite">Id</a>.</i> (internal citations and quotations
omitted). "Second, there must be a causal connection between the injury and
the conduct complained of &mdash; the injury has to be 'fairly . . . trace [able]
to the challenged action of the defendant. . . .'" <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=504%20U.S.%20555&amp;summary=yes#jcite">Id.</a></i> (quoting <i>Simon v. E.</i>
<i>Ky. Welfare Rights Org.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C956?jcsearch=426%20us%2026&amp;summary=yes#jcite">426 U.S. 26</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C956?jcsearch=426%20us%2026&amp;summary=yes#jcite">41-42</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C956?jcsearch=96%20supreme%20court%201917&amp;summary=yes#jcite">96 S.Ct. 1917</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C956?jcsearch=48%20l%20ed%202d%20450&amp;summary=yes#jcite">48 L.Ed.2d 450</a>
(1976)). "Third, it must be 'likely,' as opposed to merely 'speculative,'
that the injury will be 'redressed by a favorable decision.'" <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=504%20U.S.%20555&amp;summary=yes#jcite">Id. at 561</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a> (quoting <i>Simon</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C956?jcsearch=426%20us%2026&amp;summary=yes#jcite">426 U.S. at 38</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C956?jcsearch=426%20us%2026&amp;summary=yes#jcite">43</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C956?jcsearch=96%20supreme%20court%201917&amp;summary=yes#jcite">96 S.Ct. 1917</a>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "Whether an actual case or controversy exists so that a district court may
entertain an action for a declaratory judgment of non-infringement and/or
invalidity is governed by Federal Circuit law." <i>MedImmune, Inc. v. Centocor,</i>
<i>Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XNRUNSII8BG0?jcsearch=409%20f%203d%201376&amp;summary=yes#jcite">409 F.3d 1376</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XNRUNSII8BG0?jcsearch=409%20f%203d%201376&amp;summary=yes#jcite">1378</a> (Fed.Cir.2005), <i>overruled on other grounds,</i>
<i>MedImmune</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. at 130-31</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a>. Following <i>MedImmune</i>, this
court has held that, to establish an injury in fact traceable to the
patentee, a declaratory judgment plaintiff must allege both (1) an
affirmative act by the patentee related to the enforcement of his patent
rights, <i>SanDisk Corp. v. STMicroelecs., Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X16I1RI003?jcsearch=480%20f%203d%201372&amp;summary=yes#jcite">480 F.3d 1372</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X16I1RI003?jcsearch=480%20f%203d%201372&amp;summary=yes#jcite">1380-81</a>
(Fed.Cir.2007), and (2) meaningful preparation to conduct potentially
infringing activity, <i>Cat Tech LLC v. TubeMaster, Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X18V58I003?jcsearch=528%20f%203d%20871&amp;summary=yes#jcite">528 F.3d 871</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X18V58I003?jcsearch=528%20f%203d%20871&amp;summary=yes#jcite">880</a>
(Fed.Cir.2008). We review the exercise of declaratory judgment jurisdiction
in light of a particular set of facts <i>de novo. SanDisk Corp.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X16I1RI003?jcsearch=480%20f%203d%201372&amp;summary=yes#jcite">480 F.3d at 1377</a>.
<span CLASS="page_no" data-cite="689 f 3d 1319" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1319" data-primary-citation="689 F.3d 1303">[*1319]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad challenges the district court's jurisdictional decision on the
grounds that Myriad and the Plaintiffs do not have adverse legal interests
and that Plaintiffs have failed to allege a controversy of sufficient
immediacy and reality to warrant the issuance of a declaratory judgment.
Specifically, Myriad argues that Plaintiffs have failed to allege any
"affirmative acts" by Myriad within the past ten years relating to the
patents in suit or directed at any Plaintiff. According to Myriad, the
district court erred by relying on "stale communications" directed at Drs.
Kazazian, Ganguly, and Ostrer over a decade ago, as well as ten-year-old
licensing and litigation activities directed at third parties, and thus
exercised jurisdiction based solely on Plaintiffs' subjective fear of suit,
arising from rumor and innuendo <span CLASS="page_no" data-cite="2012 bl 210726 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> in the research community.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Plaintiffs respond that they have standing under <i>MedImmune's</i>
all-the-circumstances test because, not only are they undisputedly prepared
to immediately undertake potentially infringing activities, but also Myriad
took sufficient affirmative acts with respect to the patents in suit.
Regarding the latter, Plaintiffs assert that Myriad sued, threatened to sue,
or demanded license agreements from every known institution offering <i>BRCA</i>
clinical testing, including university labs directed by plaintiffs Kazazian,
Ganguly, and Ostrer, forcing each to cease such testing. And, according to
Plaintiffs, the awareness of Myriad's vigorous assertion of its patent
rights still continues to suppress their ability to perform clinical <i>BRCA</i>
testing, placing Plaintiffs in the very dilemma the Declaratory Judgment Act
was intended to address: they must either proceed with BRCA-related
activities and risk liability for patent infringement, or refrain from such
activities despite believing Myriad's patents are invalid.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924785" href="#headnote_pq2-dec_924785">[1]</a> Under the facts alleged in this case, we conclude that one Plaintiff, Dr.
Ostrer, has established standing to maintain this declaratory judgment suit.
All Plaintiffs claim standing under the Declaratory Judgment Act based on
the same alleged injury: that they cannot undertake the BRCA-related
activities that they desire because of Myriad's enforcement of its <span CLASS="page_no" data-cite="103 uspq 2d 1693" data-cite-type="ReporterOfDecisions" data-cite-pageno="1693" data-primary-citation="103 U.S.P.Q.2d 1681">[**1693]</span> patent
rights covering <i>BRCA&frac12;.</i><a HREF="#fn700" name="fnref_fn700">[fn7]</a> Only three plaintiffs, however, allege an injury
traceable to Myriad; only Drs. Kazazian, Ganguly, and Ostrer allege
affirmative patent enforcement actions directed at them by Myriad. Of these
three, Dr. Ostrer clearly alleges a sufficiently real and imminent injury
because he alleges an intention to actually and immediately engage in
allegedly infringing BRCA-related activities. We address each in turn.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924786" href="#headnote_pq2-dec_924786">[2]</a> Although <i>MedImmune</i> relaxed this court's more restrictive "reasonable
apprehension of suit" test for declaratory judgment jurisdiction, <i>SanDisk</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X16I1RI003?jcsearch=480%20f%203d%201372&amp;summary=yes#jcite">480 F.3d at 1380</a>, it did not alter "the bedrock rule that a case or
controversy must be based on a <i>real</i> and <i>immediate</i> injury or threat of future
injury that is <i>caused by the defendants," Prasco, LLC v. Medicis Pharm.</i>
<i>Corp.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X19E76Q003?jcsearch=537%20f%203d%201329&amp;summary=yes#jcite">537 F.3d 1329</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X19E76Q003?jcsearch=537%20f%203d%201329&amp;summary=yes#jcite">1339</a> (Fed.Cir.2008). Accordingly, following <i>MedImmune</i>,
this court has continued to hold that declaratory judgment jurisdiction will
not arise merely on the basis that a party learns of
<span CLASS="page_no" data-cite="689 f 3d 1320" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1320" data-primary-citation="689 F.3d 1303">[*1320]</span> 
the existence of an adversely held patent, or even perceives that such a
patent poses a risk of infringement, in the absence of some affirmative act
by the patentee. <i>SanDisk</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X16I1RI003?jcsearch=480%20f%203d%201372&amp;summary=yes#jcite">480 F.3d at 1380-81</a>. Thus, without defining the
outer boundaries of declaratory judgment jurisdiction, we have held that
"where a patentee asserts rights under a patent based on certain identified
ongoing or planned activity of another party, and where that party contends
that it has the right to engage in the accused activity without license, an
Article III case or controversy will arise. . . ." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X16I1RI003?jcsearch=480%20F.3d%201372&amp;summary=yes#jcite">Id. at 1381</a>; <i>see also</i>
<i>Prasco</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X19E76Q003?jcsearch=537%20f%203d%201329&amp;summary=yes#jcite">537 F.3d at 1338</a> ("A patentee can cause . . . an injury [sufficient
to create an actual controversy] in a variety <span CLASS="page_no" data-cite="2012 bl 210726 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> of ways, for example, by
creating a reasonable apprehension of an infringement suit, [or] demanding
the right to royalty payments." (internal citations omitted)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In this case, Myriad demanded a royalty under its patents from Dr. Ostrer
based on his clinical BRCA-related activities. In May 1998, Myriad's
Director of Corporate Communications sent Ostrer a letter proposing a
collaborative license. The letter stated that Myriad was aware that Ostrer
was either currently providing, or was interested in initiating, <i>BRCA1</i>
diagnostic testing services and that Myriad, as holder of U.S. patents
covering the <i>BRCA1</i> gene and diagnostic testing of <i>BRCA1</i>, was making
available to his institution, NYU Medical Center, a limited collaborative
license. The collaborative license required NYU to make a payment to Myriad
for each non-research <i>BRCA</i> test performed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At the same time, as Ostrer was aware, Myriad was asserting its patent
rights against other similarly situated parties, a fact to be considered in
assessing the existence of an actual controversy under the totality of
circumstances. <i>See Micron Tech., Inc. v. Mosaid Techs., Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X18J6HE003?jcsearch=518%20f%203d%20897&amp;summary=yes#jcite">518 F.3d 897</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X18J6HE003?jcsearch=518%20f%203d%20897&amp;summary=yes#jcite">901</a> (Fed.Cir.2008). Soon after Ostrer received Myriad's letter, Dr. Kazazian
informed him that, because of Myriad's assertion of its patent rights
against him, GDL would no longer be accepting patient samples for <i>BRCA</i>
genetic testing. Myriad's assertion of its patent rights against Kazazian
escalated into a patent infringement suit by Myriad against the University
of Pennsylvania, which was later dismissed without prejudice after the
University agreed to cease all accused <i>BRCA</i> testing services. Myriad also
sued Oncormed for patent infringement based on its <i>BRCA</i> genetic testing
services. As a result of Myriad's patent enforcement actions, Dr. Ostrer was
forced to send all patient samples to Myriad, now the sole provider of <i>BRCA</i>
diagnostic testing services.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Ostrer, on the other hand, maintains that he could have proceeded with
his BRCA-related clinical activities without taking a license from Myriad.
This assertion is based on his belief that the patents Myriad claims cover
such activities are invalid because genes are patent-ineligible products of
nature. Acting on his belief, Ostrer seeks in this lawsuit a declaration of
his right to undertake BRCA-related clinical activities without a license.
Accordingly, Myriad and Dr. Ostrer have taken adverse legal positions
regarding whether or not Ostrer can engage in <i>BRCA</i> genetic testing without
infringing any valid claim to "isolated" <i>BRCA</i> DNAs or methods of "analyzing"
or "comparing" <i>BRCA</i> sequences, as recited in Myriad's patents. <i>See Aetna</i>
<i>Life</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVKE?jcsearch=300%20us%20227&amp;summary=yes#jcite">300 U.S. at 242</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVKE?jcsearch=57%20supreme%20court%20461&amp;summary=yes#jcite">57 S.Ct. 461</a> (holding declaratory judgment
jurisdiction existed when "the parties had taken adverse positions with
respect to their existing obligations" on an insurance contract).
<span CLASS="page_no" data-cite="103 uspq 2d 1694" data-cite-type="ReporterOfDecisions" data-cite-pageno="1694" data-primary-citation="103 U.S.P.Q.2d 1681">[**1694]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Ostrer has also alleged a controversy of sufficient reality and
immediacy, <i>MedImmune</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. at 127</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a>; he
<span CLASS="page_no" data-cite="689 f 3d 1321" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1321" data-primary-citation="689 F.3d 1303">[*1321]</span> 
has alleged a concrete and actual injury traceable to Myriad's assertion of
its patent rights, <i>see Lujari</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=504%20us%20555&amp;summary=yes#jcite">504 U.S. at 560</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a>. First,
Ostrer seeks to undertake specific <span CLASS="page_no" data-cite="2012 bl 210726 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> BRCA-related activities &mdash; <i>BRCA</i> diagnostic
testing &mdash; for which Myriad has demanded a license under specific patents &mdash;
those that cover the isolated <i>BRCA</i> genes and <i>BRCA</i> diagnostic testing. Thus,
Ostrer does not request "an opinion advising what the law would be upon a
hypothetical state of facts," <i>Aetna Life</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVKE?jcsearch=300%20us%20227&amp;summary=yes#jcite">300 U.S. at 241</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVKE?jcsearch=57%20supreme%20court%20461&amp;summary=yes#jcite">57 S.Ct. 461</a>, but
rather whether his proposed <i>BRCA</i> testing services are covered by valid
patent claims to "isolated" <i>BRCA</i> genes and methods of "comparing" the genes'
sequences. Second, Ostrer not only has the resources and expertise to
immediately undertake clinical <i>BRCA</i> testing, but also states unequivocally
that he will immediately begin such testing. In contrast to Ostrer, who
alleges an actual and imminent injury for purposes of standing, Drs.
Kazazian and Ganguly allege only that they will "consider" resuming <i>BRCA</i>
testing. These "'some day' intentions" are insufficient to support an
"actual or imminent" injury for standing "without . . . any specification of
<i>when</i> the some day will be." <i>Lujan</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=504%20us%20555&amp;summary=yes#jcite">504 U.S. at 564</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a>. As a
result, Drs. Kazazian and Ganguly do not have standing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad seeks to avoid this result based on the timing of its enforcement
actions. Specifically, Myriad argues that time has extinguished the
immediacy and reality of any controversy, relying on language that hearkens
back to our pre-<i>MedImmune</i> reasonable apprehension of suit test. <i>See, e.g.</i>,
Appellants' Br., <cite>2010 WL 4600106</cite>, at 26 ("[A] patentee's ten-year silence
presumptively extinguishes any reasonable objective fear of suit."). We
disagree. In many cases a controversy made manifest by a patentee's
affirmative assertion of its patent rights will dissipate as market players
and products change. In this case, however, the relevant circumstances
surrounding Myriad's assertion of its patent rights have not changed despite
the passage of time.<a HREF="#fn800" name="fnref_fn800">[fn8]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad's active enforcement of its patent rights forced Dr. Ostrer, as
well as every other similarly situated researcher and institution, to cease
performing the challenged <i>BRCA</i> testing services, leaving Myriad as the sole
provider of <i>BRCA</i> clinical testing to patients in the United States. Since
that time, neither the accused activities nor the parties' positions have
changed. First, Myriad does not allege that genetic testing technology has
changed in any way that renders its past assertions of its patent rights
irrelevant to Ostrer's currently proposed <i>BRCA</i> testing. Rather, the patents
cover, as Myriad asserted in the late 1990s, the basic components of any
such test: the isolated <i>BRCA</i> genes and the diagnostic step of comparing the
genes' sequences.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, ever since Myriad's enforcement efforts eliminated all
competition, Myriad and Ostrer have not altered their respective positions.
Ostrer, still laboring under Myriad's threat of infringement liability, has
not attempted to provide <i>BRCA</i> testing; yet, as a researcher, he remains in
the same position with respect to his ability and his desire to provide <i>BRCA</i>
testing as in the late 1990s. Furthermore, nothing in the record suggests
that any researcher or institution has
<span CLASS="page_no" data-cite="689 f 3d 1322" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1322" data-primary-citation="689 F.3d 1303">[*1322]</span> 
successfully attempted <span CLASS="page_no" data-cite="2012 bl 210726 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> to compete with Myriad, or that Myriad has in any way
changed its position with regard to its patent rights. Just as active
enforcement of one's patent rights against others can maintain a real and
immediate controversy despite the passage of time, <i>see Micron</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X18J6HE003?jcsearch=518%20f%203d%20897&amp;summary=yes#jcite">518 F.3d at 901</a>, so too can the successful assertion of such rights when the
relevant circumstances remain unchanged. Thus, consistent with the purpose
of the Declaratory Judgment Act, Ostrer need not risk liability and treble
damages for patent infringement before seeking a declaration of his
contested legal rights. <i>See MedImmune</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. at 134</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad also argues that the record refutes Ostrer's claim that he has been
restrained from engaging in BRCA-related gene sequencing. Specifically,
Myriad argues that since Myriad published its discoveries of the <i>BRCA1</i> and
<i>BRCA2</i> genes in October 1994 and March 1996, respectively, over 18,000
scientists have conducted research on the <i>BRCA</i> genes and over 8,600 research
papers have been published. Furthermore, according to Myriad, plaintiff
Wendy Chung concedes that her lab currently conducts sequencing of <i>BRCA</i>
genes. Yet, both Drs. Chung and Ostrer state that, although they conduct
gene sequencing, they are forbidden from informing their research subjects
of the results of their <i>BRCA</i> tests without first sending the samples to
Myriad. Accordingly, Ostrer is restrained <span CLASS="page_no" data-cite="103 uspq 2d 1695" data-cite-type="ReporterOfDecisions" data-cite-pageno="1695" data-primary-citation="103 U.S.P.Q.2d 1681">[**1695]</span> from the BRCA-related activity
that he desires to undertake: clinical diagnostic testing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad's communications with Dr. Ostrer confirm this understanding. The
licensing letter Myriad sent to Ostrer proposed a collaborative agreement
giving NYU the right to perform "Research Tests" without payment to Myriad.
J.A. 2967. "Research Tests" are defined as tests that further
"non-commercial research programs, the results of which <i>are not provided to</i>
<i>the patient</i> and for which no money is received." J.A. 2965 (emphasis added).
In contrast, the agreement requires payment to Myriad for each "Testing
Service" performed, with "Testing Services" defined as "medical laboratory
testing . . . for the presence or absence of BRCA1 mutations for the purpose
of determining or predicting predisposition to, or assessing the risk of
breast or ovarian cancer in humans." J.A. 2966-67. Thus, Myriad's patent
enforcement actions never targeted the non-clinical <i>BRCA</i> research now cited
by Myriad, and Ostrer's ability to perform such research does not address
the injury asserted here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Myriad argued in its reply brief and at oral argument that
Plaintiffs' declaratory action will not afford them the relief they want, a
requirement for standing. <i>Lujan</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=504%20us%20555&amp;summary=yes#jcite">504 U.S. at 560-61</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a>; <i>see</i>
<i>also MedImmune</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. at 127</a> n. 7, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a> ("[A] litigant may not
use a declaratory-judgment action to obtain piecemeal adjudication of
defenses that <i>would not finally and conclusively resolve</i> the underlying
controversy."). Specifically, Myriad asserts that because Plaintiffs have
challenged just fifteen composition and method claims, while admitting that
other unchallenged claims to <i>BRCA</i> probes and primers will still prevent them
from engaging in <i>BRCA</i> sequencing, <span CLASS="page_no" data-cite="2012 bl 210726 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[***17]</span> a favorable decision will not redress the
Plaintiffs' alleged injury. Again, we disagree.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court has required only that it is "likely," rather than
"merely 'speculative,'" that the alleged injury will be "redressed by a
favorable decision." <i>Lujan</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=504%20us%20555&amp;summary=yes#jcite">504 U.S. at 561</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a>. The Court has
not required certainty. For example, in <i>Village of Arlington Heights v.</i>
<i>Metropolitan Housing Development Corp.</i>, the Court held that the plaintiffs
had standing to challenge a suburb's
<span CLASS="page_no" data-cite="689 f 3d 1323" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1323" data-primary-citation="689 F.3d 1303">[*1323]</span> 
exclusionary zoning ordinance, as the ordinance stood as "an absolute
barrier" to the housing development Metropolitan Housing Development Corp.
("MHDC") had contracted to provide in the village. <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C997?jcsearch=429%20us%20252&amp;summary=yes#jcite">429 U.S. 252</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C997?jcsearch=429%20us%20252&amp;summary=yes#jcite">261</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C997?jcsearch=97%20supreme%20court%20555&amp;summary=yes#jcite">97 S.Ct. 555</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C997?jcsearch=50%20l%20ed%202d%20450&amp;summary=yes#jcite">50 L.Ed.2d 450</a> (1977). The Court noted that injunctive relief,
while removing the "barrier" of the ordinance, would not "guarantee" that
the housing would be built since MHDC still had to secure financing, qualify
for federal subsidies, and carry through with construction. <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C997?jcsearch=429%20U.S.%20252&amp;summary=yes#jcite">Id.</a></i> The Court
nevertheless recognized that "all housing developments are subject to some
extent to similar uncertainties," and concluded that it was sufficient that
there was a "substantial probability" that the housing development would be
built. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C997?jcsearch=429%20U.S.%20252&amp;summary=yes#jcite">Id. at 261</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C997?jcsearch=264&amp;summary=yes#jcite">264</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C997?jcsearch=97%20supreme%20court%20555&amp;summary=yes#jcite">97 S.Ct. 555</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In this case, Myriad's challenged composition and method claims
undisputedly provide "an absolute barrier" to Dr. Ostrer's ability to
undertake <i>BRCA</i> diagnostic testing activities, and a declaration of those
claims' invalidity would remove that barrier. <i>See </i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C997?jcsearch=429%20U.S.%20252&amp;summary=yes#jcite">id. at 261</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C997?jcsearch=97%20supreme%20court%20555&amp;summary=yes#jcite">97 S.Ct. 555</a>.
Moreover, while there may be other patent claims directed to <i>BRCA</i> probes and
primers that prevent Ostrer from performing <i>BRCA</i> diagnostic testing free of
infringement liability, Myriad has failed to direct us to any specific
unchallenged claim that will have that effect. And Plaintiffs' counsel
stated at the first oral argument in this case that his clients can sequence
the <i>BRCA</i> genes without using <i>BRCA</i> probes and primers. Oral Arg. at 34:07-25,
34:53-35:29 <i>available at</i> http://www.cafc.
uscourts.gov/oral-argument-recordings/2010-1406/all. Accordingly, we decline
to construe the asserted claims and decline to hold on this record that Dr.
Ostrer's proposed BRCA-related activities would infringe unchallenged claims
to primers and probes. We thus conclude that it is likely, not merely
speculative, that Dr. Ostrer's injury will be redressed by a favorable
decision.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although we affirm the district court's decision to exercise declaratory
judgment jurisdiction over this case, we do so on narrower grounds. The
district court failed to limit its jurisdictional holding to affirmative
acts by the patentee directed at specific Plaintiffs, <i>see SanDisk</i>, 480 F.3d
at 1380-S1, erroneously holding all the Plaintiffs had standing based on
"the widespread understanding that one may engage in <i>BRCA&frac12;</i> testing at the
risk of being sued for infringement liability by Myriad," <i>DJ Op.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1C29QK003?jcsearch=669%20f%20supp%202d%20365&amp;summary=yes#jcite">669 F.Supp.2d at 390</a>. We disagree, and thus we reverse the district court's
holding that the various plaintiffs other than Dr. Ostrer have standing to
maintain this declaratory judgment action. Simply disagreeing with the
existence of a patent on isolated DNA sequences or even suffering <span CLASS="page_no" data-cite="2012 bl 210726 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[***18]</span> an
attenuated, non-proximate, effect from the existence of a patent does not
meet the Supreme Court's requirement for an adverse legal controversy of
sufficient immediacy and reality to warrant <span CLASS="page_no" data-cite="103 uspq 2d 1696" data-cite-type="ReporterOfDecisions" data-cite-pageno="1696" data-primary-citation="103 U.S.P.Q.2d 1681">[**1696]</span> the issuance of a declaratory
judgment. <i>See MedImmune</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. at 127</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a>. The various
organizational plaintiffs in this suit in particular were not the target of
any enforcement action or offered license agreements by Myriad and had made
no preparation to undertake potentially infringing activities. They
accordingly suffered no injury and thus lack standing to bring this action.
<i>See Prasco</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X19E76Q003?jcsearch=537%20f%203d%201329&amp;summary=yes#jcite">537 F.3d at 1338-42</a>; <i>Cat Tech</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X18V58I003?jcsearch=528%20f%203d%20871&amp;summary=yes#jcite">528 F.3d at 880-81</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Having found one plaintiff with standing to maintain this declaratory
judgment action, <i>see Horne v. Flores</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1B97OS003?jcsearch=557%20us%20433&amp;summary=yes#jcite">557 U.S. 433</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1B97OS003?jcsearch=129%20supreme%20court%202579&amp;summary=yes#jcite">129 S.Ct. 2579</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1B97OS003?jcsearch=129%20supreme%20court%202579&amp;summary=yes#jcite">2592-93</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1B97OS003?jcsearch=174%20l%20ed%202d%20406&amp;summary=yes#jcite">174 L.Ed.2d 406</a> (2009), we may turn now to the merits of Myriad's appeal of
the district court's summary judgment decision, which held all fifteen
challenged composition and method claims invalid under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>.
<span CLASS="page_no" data-cite="689 f 3d 1324" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1324" data-primary-citation="689 F.3d 1303">[*1324]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II. Subject Matter Eligibility
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under the Patent Act, "Whoever invents or discovers any new and useful
process, machine, manufacture, or composition of matter, or any new and
useful improvement thereof, may obtain a patent therefor, subject to the
conditions and requirements of this title." <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20usc%20101&amp;summary=yes#jcite">35 U.S.C. &sect; 101</a>. The Supreme
Court has consistently construed <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20U.S.C.%20%20101&amp;summary=yes#jcite">&sect; 101</a> broadly, explaining that "[i]n
choosing such expansive terms . . . modified by the comprehensive 'any,'
Congress plainly contemplated that the patent laws would be given wide
scope." <i>Bilski v. Kappos</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=132%20S.%20Ct.%201794&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=130%20supreme%20court%203218&amp;summary=yes#jcite">130 S.Ct. 3218</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=130%20supreme%20court%203218&amp;summary=yes#jcite">3225</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=177%20l%20ed%202d%20792&amp;summary=yes#jcite">177 L.Ed.2d 792</a> (2010) (quoting <i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 308</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court, however, has also consistently held that <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>,
although broad, is not unlimited. <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20S.%20Ct.%203218&amp;summary=yes#jcite">Id</a>.</i> The Court's precedents provide three
judicially created exceptions to <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>'s broad patent-eligibility
principles: "'Laws of nature, natural phenomena, and abstract ideas' are not
patentable." <i>Mayo</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">132 S.Ct. at 1293</a> (quoting <i>Diamond v. Diehr</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA2P?jcsearch=450%20us%20175&amp;summary=yes#jcite">450 U.S. 175</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA2P?jcsearch=450%20us%20175&amp;summary=yes#jcite">185</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA2P?jcsearch=101%20supreme%20court%201048&amp;summary=yes#jcite">101 S.Ct. 1048</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA2P?jcsearch=67%20l%20ed%202d%20155&amp;summary=yes#jcite">67 L.Ed.2d 155</a> (1981)). The Court has
also referred to those exceptions as precluding the patenting of mental
processes, <i>Gottschalk v. Benson</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=409%20us%2063&amp;summary=yes#jcite">409 U.S. 63</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=409%20us%2063&amp;summary=yes#jcite">67</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=93%20supreme%20court%20253&amp;summary=yes#jcite">93 S.Ct. 253</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=34%20l%20ed%202d%20273&amp;summary=yes#jcite">34 L.Ed.2d 273</a> (1972), and products of nature, <i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 313</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a> ("[T]he relevant distinction for purposes of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a> is . . .
between products of nature . . . and human-made inventions."). The Court has
explained that, although not required by the statutory text, "[t]he concepts
covered by these exceptions are 'part of the storehouse of knowledge of all
men . . . free to all men and reserved exclusively to none.'" <i>Bilski</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20supreme%20court%203218&amp;summary=yes#jcite">130 S.Ct. at 3225</a> (quoting <i>Funk Bros. Seed Co. v. Kalo Inoculant Co.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">333 U.S. 127</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">130</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=92%20l%20ed%20588&amp;summary=yes#jcite">92 L.Ed. 588</a> (1948)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Plaintiffs challenge under &sect; 101 Myriad's composition claims directed to
"isolated" DNA molecules, its method claims directed to "analyzing" or
"comparing" DNA sequences, and its claim to a method for screening potential
cancer therapeutics. We address each in turn. Before reviewing the
applicability of the Supreme Court's <i>Mayo</i> holding to the claims of the
Myriad patents, however, it is important to state what this appeal is not
about. It is not about whether individuals suspected of having an increased
risk of developing breast cancer are entitled to a second opinion. Nor is it
about whether the University of Utah, the owner of the instant patents, or
Myriad, the exclusive licensee, has acted improperly in its licensing or
enforcement policies <span CLASS="page_no" data-cite="2012 bl 210726 p 19" data-cite-type="Bloomberg" data-cite-pageno="19" data-primary-citation="">[***19]</span> with respect to the patents. The question is also not
whether is it desirable for one company to hold a patent or license covering
a test that may save people's lives, or for other companies to be excluded
from the market encompassed by such a patent &mdash; that is the basic right
provided by a patent, <i>i.e.</i>, to exclude others from practicing the patented
subject matter. It is also not whether the claims at issue are novel or
nonobvious or too broad. Those questions are not before us. It is solely
whether the claims to isolated BRCA DNA, to methods for comparing DNA
sequences, and to a process for screening potential cancer therapeutics meet
the threshold test for patent-eligible subject matter under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20usc%20101&amp;summary=yes#jcite">35 U.S.C. &sect; 101</a>
in light of various Supreme Court holdings, particularly including <i>Mayo.</i> The
issue is patent eligibility, not patentability.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We would further note, in the context of discussing what this case is not
about, that patents on life-saving material and processes, involving large
amounts of risky investment, would seem to be precisely the types of subject
matter that should be subject to the incentives of exclusive rights. But
disapproving of patents on
<span CLASS="page_no" data-cite="689 f 3d 1325" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1325" data-primary-citation="689 F.3d 1303">[*1325]</span> 
medical methods and novel biological molecules are policy questions best
left to Congress, and other general questions relating to patentability and
use of patents are issues not before us. As will be seen, on the limited
questions before us, we conclude that the composition claims and the
screening claim involving growing a transformed host cell meet the standards
for patent eligibility, while the claimed methods for "analyzing" or
"comparing" do not.
<span CLASS="page_no" data-cite="103 uspq 2d 1697" data-cite-type="ReporterOfDecisions" data-cite-pageno="1697" data-primary-citation="103 U.S.P.Q.2d 1681">[**1697]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. Composition Claims: Isolated DNA Molecules
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  i.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The principal claims of the patents before us on remand relate to isolated
DNA molecules. <i>Mayo</i> does not control the question of patent-eligibility of
such claims. They are claims to compositions of matter, expressly authorized
as suitable patent-eligible subject matter in <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>. As to those claims, the
issue of patent-eligibility remains, as it was on the first appeal to this
court, whether they claim patent-ineligible products of nature. We hold that
they do not. The isolated DNA molecules before us are not found in nature.
They are obtained in the laboratory and are man-made, the product of human
ingenuity. While they are prepared from products of nature, so is every
other composition of matter. All new chemical or biological molecules,
whether made by synthesis or decomposition, are made from natural materials.
For example, virtually every medicine utilized by today's medical
practitioners, and every manufactured plastic product, is either synthesized
from natural materials (most often petroleum fractions) or derived from
natural plant materials. But, as such, they are different from natural
materials, even if they are ultimately derived from them. The same is true
of isolated DNA molecules.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  ii.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad argues that its challenged composition claims to "isolated" DNAs
cover patent-eligible compositions of matter within the meaning of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>.
According to Myriad, the district court <span CLASS="page_no" data-cite="2012 bl 210726 p 20" data-cite-type="Bloomberg" data-cite-pageno="20" data-primary-citation="">[***20]</span> came to a contrary conclusion by (1)
misreading Supreme Court precedent as excluding from patent eligibility all
"products of nature" unless "markedly different" from naturally occurring
ones; and (2) incorrectly focusing not on the differences between isolated
and native DNAs, but on one similarity: their informational content. Rather,
Myriad argues, an isolated DNA molecule is patent eligible because it is, as
claimed, "a nonnaturally occurring manufacture or composition of matter"
with "a distinctive name, character, and use." Appellants' Br.,
<cite>2010 WL 4600106</cite>, at 41-42 (quoting <i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 309-10</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>). Myriad contends that isolated DNA does not exist in nature
and that isolated DNAs, unlike native DNAs, can be used as primers and
probes for diagnosing cancer. Moreover, Myriad asserts that an
ultimately-derived-from "products of nature" exception not only would be
unworkable, as every composition of matter is, at some level, composed of
natural materials, but also would be contrary to this court's precedents,
the PTO's 2001 <i>Utility Examination Guidelines</i>, and Congress's role in
enacting the patent laws. Regarding <i>Mayo</i>, Myriad argues that the Supreme
Court's decision did not address or alter the established patent-eligibility
test for composition claims, such that the standards announced in
<i>Chakrabarty</i> still govern this appeal. To the extent that the general
principles discussed in <i>Mayo</i> bear on the DNA claims, Myriad maintains that
isolated DNA represents a nonnatural, man-made invention distinct from the
lack of human ingenuity underlying the method claims there at issue.
<span CLASS="page_no" data-cite="689 f 3d 1326" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1326" data-primary-citation="689 F.3d 1303">[*1326]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Plaintiffs respond that claims to isolated DNA molecules fail to satisfy <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect;
101</a> because such claims cover natural phenomena and products of nature.
According to Plaintiffs, Supreme Court precedent establishes that a product
of nature is not patent eligible even if, as claimed, it has undergone some
highly useful change from its natural form. Rather, Plaintiffs assert, to be
patent eligible a composition of matter must also have a distinctive name,
character, and use, making it "markedly different" from the natural product.
In this case, Plaintiffs conclude that because isolated DNAs retain part of
the same nucleotide sequence as native DNAs, they do not have any "markedly
different" characteristics. Furthermore, according to Plaintiffs, the
isolated DNA claims preempt products and laws of nature, excluding anyone
from working with the <i>BRCA</i> genes and the genetic information they convey.
Under <i>Mayo</i>, Plaintiffs assert that any structural differences relative to
the chromosomal <i>BRCA</i> genes do not add "enough" to the underlying natural
genetic sequences to render Myriad's isolated DNA molecules patentable under
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The government as amicus curiae does not defend the longstanding position
of the PTO, a government agency, that isolated DNA molecules are patent
eligible, arguing instead for a middle ground. Specifically, the government
argues that DNA molecules engineered by man, including cDNAs,<a HREF="#fn900" name="fnref_fn900">[fn9]</a> are
patent-eligible compositions of matter because, <span CLASS="page_no" data-cite="2012 bl 210726 p 21" data-cite-type="Bloomberg" data-cite-pageno="21" data-primary-citation="">[***21]</span> with rare exceptions, they
do not occur in nature, either in isolation or as contiguous sequences
within a chromosome. In contrast, the government asserts, <span CLASS="page_no" data-cite="103 uspq 2d 1698" data-cite-type="ReporterOfDecisions" data-cite-pageno="1698" data-primary-citation="103 U.S.P.Q.2d 1681">[**1698]</span> isolated and
unmodified genomic DNAs are <i>not</i> patent eligible, but rather
patent-ineligible products of nature, since their nucleotide sequences exist
because of evolution, not man.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At the first oral argument, the government illustrated its position by way
of a so-called "magic microscope" test (an invention in and of itself,
although probably not patent-eligible). Oral Arg. at 46:50-47:50. According
to the government's test then, if an imaginary microscope could focus in on
the claimed DNA molecule as it exists in the human body, the claim covers
ineligible subject matter. The government thus argued that because such a
microscope could focus in on the claimed isolated <i>BRCA1</i> or <i>BRCA2</i> sequences
as they exist in the human body, the claims covering those sequences are not
patent eligible. In contrast, the government contended, because an imaginary
microscope could not focus <i>in vivo</i> on a cDNA sequence, which is engineered
by man to splice together non-contiguous coding sequences (<i>i.e.</i>, exons),
claims covering cDNAs are patent eligible.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In sum, although the parties and the government appear to agree that
isolated DNAs are compositions of matter, they disagree on whether and to
what degree such molecules fall within the exception for products of nature.
As set forth below, we conclude that the challenged claims to isolated DNAs,
whether limited to cDNAs or not, are directed to patent-eligible subject
matter under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  iii.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While <i>Mayo</i> and earlier decisions concerning method claim patentability
provide valuable insights and illuminate broad, foundational principles, the
Supreme Court's decisions in <i>Chakrabarty</i> and <i>Funk Brothers</i> set out the
primary framework for deciding the patent eligibility of compositions of
matter, including isolated DNA molecules.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a>
<span CLASS="page_no" data-cite="689 f 3d 1327" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1327" data-primary-citation="689 F.3d 1303">[*1327]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Chakrabarty</i>, the Court addressed the question whether a man-made,
living microorganism is a patent-eligible manufacture or composition of
matter within the meaning of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>. <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 305</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">307</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.
The microorganisms were bacteria genetically engineered with four naturally
occurring DNA plasmids, each of which enabled the breakdown of a different
component of crude oil. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id. at 305</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=305&amp;summary=yes#jcite">305</a> n. 1, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>. The bacteria,
as a result, could break down multiple components of crude oil, a trait
possessed by no single naturally occurring bacterium and of significant use
in more efficiently treating oil spills. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id. at 305</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=305&amp;summary=yes#jcite">305</a> n. 2,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>. The Court held that the bacteria qualified as
patent-eligible subject matter because the "claim is not to a hitherto
unknown natural phenomenon, but to a non-naturally occurring manufacture or
composition of matter &mdash; a product of human ingenuity 'having a distinctive
name, character [and] use.'" <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id. at 309-10</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a> (quoting
<i>Hartranft v. Wiegmann</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=121%20us%20609&amp;summary=yes#jcite">121 U.S. 609</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=121%20us%20609&amp;summary=yes#jcite">615</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=7%20supreme%20court%201240&amp;summary=yes#jcite">7 S.Ct. 1240</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=30%20l%20ed%201012&amp;summary=yes#jcite">30 L.Ed. 1012</a>
(1887)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To underscore the point, the Court compared Chakrabarty's engineered
bacteria with the mixed bacterial cultures found unpatentable in <i>Funk</i>
<i>Brothers</i>, again casting this case, more relating <span CLASS="page_no" data-cite="2012 bl 210726 p 22" data-cite-type="Bloomberg" data-cite-pageno="22" data-primary-citation="">[***22]</span> to obviousness, in terms of
&sect; 101. <i>See Parker v. Flook</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C9KM?jcsearch=437%20us%20584&amp;summary=yes#jcite">437 U.S. 584</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C9KM?jcsearch=437%20us%20584&amp;summary=yes#jcite">591</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C9KM?jcsearch=98%20supreme%20court%202522&amp;summary=yes#jcite">98 S.Ct. 2522</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C9KM?jcsearch=57%20l%20ed%202d%20451&amp;summary=yes#jcite">57 L.Ed.2d 451</a>
(1978); <i>Benson</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=409%20us%2063&amp;summary=yes#jcite">409 U.S. at 67</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=93%20supreme%20court%20253&amp;summary=yes#jcite">93 S.Ct. 253</a>. In <i>Funk Brothers</i>, the patentee
discovered that certain strains of nitrogen-fixing bacteria associated with
leguminous plants do not mutually inhibit each other. <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">333 U.S. at 129-30</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>. Based on that discovery, the patentee produced (and claimed)
mixed cultures of nitrogen-fixing species capable of inoculating a broader
range of leguminous plants than single-species cultures. <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20U.S.%20127&amp;summary=yes#jcite">Id</a>.</i> The Court held
that the bacteria's cooperative qualities were, "like the heat of the sun,
electricity, or the qualities of metals," the "work of nature," and thus not
patentable. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20U.S.%20127&amp;summary=yes#jcite">Id. at 130</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>. The Court also held that applying the
newly discovered bacterial compatibility to create a mixed culture was not a
patentable advance because no species acquired a different property or use.
<i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20U.S.%20127&amp;summary=yes#jcite">Id. at 131</a>, <span CLASS="page_no" data-cite="103 uspq 2d 1699" data-cite-type="ReporterOfDecisions" data-cite-pageno="1699" data-primary-citation="103 U.S.P.Q.2d 1681">[**1699]</span> <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>. The <i>Chakrabarty</i> Court thus concluded that what
distinguished Chakrabarty's oil-degrading bacteria from the mixed cultures
claimed in <i>Funk Brothers</i>, and made the former patent-eligible, was that
Chakrabarty's bacteria had "markedly different characteristics from any
[bacterium] found in nature" based on the efforts of the patentee.
<i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 310</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924787" href="#headnote_pq2-dec_924787">[3]</a> One distinction, therefore, between products of nature and human-made
invention for purposes of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a> turns on a change in the claimed
composition's identity
<span CLASS="page_no" data-cite="689 f 3d 1328" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1328" data-primary-citation="689 F.3d 1303">[*1328]</span> 
compared with what exists in nature. Specifically, the Supreme Court has
drawn a line between compositions that, even if arrayed in useful
combinations or harnessed to exploit newly discovered properties, have
similar characteristics as in nature, and compositions that human
intervention has given "markedly different," or "distinctive,"
characteristics. <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id</a>.</i> (citing <i>Hartranft</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=121%20us%20609&amp;summary=yes#jcite">121 U.S. at 615</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=7%20supreme%20court%201240&amp;summary=yes#jcite">7 S.Ct. 1240</a>); <i>see</i>
<i>also Am. Fruit Growers v. Brogdex Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BUCI?jcsearch=283%20us%201&amp;summary=yes#jcite">283 U.S. 1</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BUCI?jcsearch=283%20us%201&amp;summary=yes#jcite">11</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BUCI?jcsearch=51%20supreme%20court%20328&amp;summary=yes#jcite">51 S.Ct. 328</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BUCI?jcsearch=75%20l%20ed%20801&amp;summary=yes#jcite">75 L.Ed. 801</a> (1931). Applying this test to the isolated DNAs in this case,
the challenged claims are drawn to patent-eligible subject matter because
the claims cover molecules that are markedly different &mdash; have a distinctive
chemical structure and identity &mdash; from those found in nature.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924788" href="#headnote_pq2-dec_924788">[4]</a> It is undisputed that Myriad's claimed isolated DNAs exist in a
distinctive chemical form &mdash; as distinctive chemical molecules &mdash; from DNAs in
the human body, <i>i.e.</i>, native DNA. Natural DNA exists in the body as one of
forty-six large, contiguous DNA molecules. Each of those DNA molecules is
condensed and intertwined with various proteins, including histones, to form
a complex tertiary structure known as chromatin that makes up a larger
structural complex, a chromosome. <i>See supra</i>, Figure 3. Inside living cells,
the chromosomes are further encapsulated within a series of membranes and
suspended in a complex intracellular milieu.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Isolated DNA, in contrast, is a free-standing portion of a larger, natural
DNA molecule. Isolated DNA has been cleaved (<i>i.e.</i>, had covalent bonds in its
backbone chemically severed) or synthesized to consist of just a fraction of
a naturally occurring DNA molecule. For example, the <i>BRCA1</i> gene in its
native state resides on chromosome 17, a DNA molecule of around eighty
million nucleotides. Similarly, <i>BRCA2</i> in its native <span CLASS="page_no" data-cite="2012 bl 210726 p 23" data-cite-type="Bloomberg" data-cite-pageno="23" data-primary-citation="">[***23]</span> state is located on
chromosome 13, a DNA of approximately 114 million nucleotides. In contrast,
isolated <i>BRCA1</i> and <i>BRCA2</i>, with introns, each consists of just 80,000 or so
nucleotides. And without introns, <i>BRCA2</i> shrinks to approximately 10,200
nucleotides and <i>BRCA1</i> to just around 5,500 nucleotides. Furthermore, claims
5 and 6 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> cover isolated DNAs, <i>e.g.</i>, primers or probes,
having as few as fifteen nucleotides of a <i>BRCA</i> sequence. Accordingly, <i>BRCA1</i>
and <i>BRCA2</i> in then-isolated states are different molecules from DNA that
exists in the body; isolated DNA results from human intervention to cleave
or synthesize a discrete portion of a native chromosomal DNA, imparting on
that isolated DNA a distinctive chemical identity as compared to native DNA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the above description indicates, isolated DNA is not just purified DNA.
Purification makes pure what was the same material, but was combined, or
contaminated, with other materials. Although isolated DNA is removed from
its native cellular and chromosomal environment, it has also been
manipulated chemically so as to produce a molecule that is markedly
different from that which exists in the body. Accordingly, this is not a
situation, as in <i>Parke-Davis &amp; Co. v. H.K. Mulford Co.</i>, in which
purification of adrenaline resulted in the <i>identical</i> molecule, albeit being
"for every practical purpose a new thing commercially and therapeutically."
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XFLB0H?jcsearch=189%20f%2095&amp;summary=yes#jcite">189 F. 95</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XFLB0H?jcsearch=189%20f%2095&amp;summary=yes#jcite">103</a> (C.C.S.D.N.Y.1911). Judge Learned Hand's opinion for the
district court in that oft-cited case held the purified "Adrenalin" to be
patent-eligible subject matter. <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XFLB0H?jcsearch=189%20F.%2095&amp;summary=yes#jcite">Id</a>.</i> The <i>In re Marden</i> cases are similarly
inapposite, directed as they are to the patent ineligibility of purified
natural elements &mdash; ductile uranium, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIDRLV?jcsearch=47%20F.2d%20957&amp;summary=yes#jcite">18 CCPA 1046</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIDRLV?jcsearch=47%20f%202d%20957&amp;summary=yes#jcite">47 F.2d 957</a> (1931), and
vanadium, 18 CCPA 1057, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIE30V?jcsearch=47%20f%202d%20958&amp;summary=yes#jcite">47 F.2d 958</a> (1931) &mdash; that are inherently ductile in
purified form. While purified natural products thus may or may not qualify
for patent under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>, the isolated
<span CLASS="page_no" data-cite="689 f 3d 1329" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1329" data-primary-citation="689 F.3d 1303">[*1329]</span> 
DNAs of the present patents constitute an <i>a fortiori</i> situation, where they
are not only purified; they are different from the natural products in
"name, character, and use." <i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 309-10</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.<a HREF="#fn1100" name="fnref_fn1100">[fn11]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i><span CLASS="page_no" data-cite="103 uspq 2d 1700" data-cite-type="ReporterOfDecisions" data-cite-pageno="1700" data-primary-citation="103 U.S.P.Q.2d 1681">[**1700]</span> Parke-Davis</i> and <i>Marden</i> address a situation in which claimed compound A is
purified from a physical mixture that contains compound A. In this case, the
claimed isolated DNA molecules do not exist in nature within a physical
mixture to be purified. They have to be chemically cleaved from their native
chemical combination with other genetic materials. In other words, in
nature, the claimed isolated DNAs are covalently bonded to such other
materials. Thus, when cleaved, an isolated DNA molecule is not a purified
form of a natural material, but a distinct chemical entity that is obtained
by human intervention. <i>See Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 313</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>
("the relevant distinction [is] between products of nature . . . and
human-made inventions"). In fact, some forms of isolated DNA may require no
purification at all, because DNAs can be chemically synthesized directly as
isolated molecules.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The above analysis holding the isolated DNA molecules to be
patent-eligible subject matter applies to all of the asserted composition
<span CLASS="page_no" data-cite="2012 bl 210726 p 24" data-cite-type="Bloomberg" data-cite-pageno="24" data-primary-citation="">[***24]</span> claims on appeal in this case. However, as the government has pointed out,
claim 2 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> is narrower than claim 1 and reads only on cDNAs,
which lack the non-coding introns present in the genomic <i>BRCA1</i> gene.<a HREF="#fn1200" name="fnref_fn1200">[fn12]</a>
While, as we have held, all of the claimed isolated DNAs are eligible for
patent as compositions of matter distinct from natural DNA, the claimed
cDNAs are especially distinctive, lacking the non-coding introns present in
naturally occurring chromosomal DNA. They are even more the result of human
intervention into nature and are hence patent-eligible subject matter. The
government, as noted earlier, has agreed with that conclusion. Br. United
States, <cite>2010 WL 4853320</cite>, at 14-17.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The dissent disparages the significance of a "chemical bond," presumably
meaning a covalent bond, in distinguishing structurally between one
molecular species and another. But a covalent bond is the defining boundary
between one molecule and another, and the dissent's citation of Linus
Pauling's comment that covalent bonds "make it convenient for the chemist to
consider [the aggregate] as an independent molecular species" underlines the
point.
<span CLASS="page_no" data-cite="689 f 3d 1330" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1330" data-primary-citation="689 F.3d 1303">[*1330]</span> 
The covalent bonds in this case connect different chemical moieties to one
another.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924789" href="#headnote_pq2-dec_924789">[5]</a> Plaintiffs argue that because the claimed isolated DNAs retain the same
nucleotide sequence as native DNAs, they do not have any "markedly
different" characteristics. This approach, however, looks not at whether
isolated DNAs are markedly different &mdash; have a distinctive characteristic &mdash;
from naturally occurring DNAs, as the Supreme Court has directed, but at one
similarity, albeit a key one: the information content contained in isolated
and native DNAs' nucleotide sequences. Adopting this approach, the district
court disparaged the patent eligibility of isolated DNA molecules because
their genetic function is to transmit information. We disagree, as it is the
distinctive nature of DNA molecules as isolated compositions of matter that
determines their patent eligibility rather than their physiological use or
benefit. Uses of chemical substances may be relevant to the nonobviousness
of these substances or to method claims embodying those uses, but the patent
eligibility of an isolated DNA is not negated because it has similar
informational properties to a different, more complex natural material. The
claimed isolated DNA molecules are distinct from their natural existence as
portions of larger entities, and their informational content is irrelevant
to that fact. We recognize that biologists may think of molecules in terms
of their uses, but genes are in fact materials having a chemical nature and,
as such, are best described in patents by their structures rather than by
their functions. In fact, many different materials may have the same
function (<i>e.g.</i>, aspirin, ibuprofen, and naproxen).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court in effect created a categorical rule excluding isolated
genes from patent eligibility. <i>See SJ Op.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1D8KQI003?jcsearch=702%20f%20supp%202d%20181&amp;summary=yes#jcite">702 F.Supp.2d at 228-29</a>. But the
Supreme Court has "more than once cautioned that courts 'should not read
<span CLASS="page_no" data-cite="2012 bl 210726 p 25" data-cite-type="Bloomberg" data-cite-pageno="25" data-primary-citation="">[***25]</span> into the patent laws limitations and conditions which the legislature has
not expressed,'" <i>Bilski</i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20supreme%20court%203218&amp;summary=yes#jcite">130 S.Ct. at 3226</a> (quoting <i>Diehr</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA2P?jcsearch=450%20us%20175&amp;summary=yes#jcite">450 U.S. at 182</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA2P?jcsearch=101%20supreme%20court%201048&amp;summary=yes#jcite">101 S.Ct. 1048</a>), and has repeatedly rejected new categorical exclusions from
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>'s scope, <i>see </i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20S.%20Ct.%203218&amp;summary=yes#jcite">id. at 3227-28</a> (rejecting the <span CLASS="page_no" data-cite="103 uspq 2d 1701" data-cite-type="ReporterOfDecisions" data-cite-pageno="1701" data-primary-citation="103 U.S.P.Q.2d 1681">[**1701]</span> argument that business
method patents should be categorically excluded from <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>); <i>Chakrabarty</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 314-17</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a> (same for living organisms). Contrary to
the conclusions of the district court and the suggestions of Plaintiffs and
some amici, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a> applies equally to all putative inventions, and isolated
DNA is not and should not be considered a special case for purposes of
patent eligibility under existing law. <i>See, e.g., SJ Op.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1D8KQI003?jcsearch=702%20f%20supp%202d%20181&amp;summary=yes#jcite">702 F.Supp.2d at 185</a> ("DNA represents the physical embodiment of biological
information, distinct in its essential characteristics from any other
chemical found in nature."); Appellees' Suppl. Br. at 4-5 ("Unlike other
chemicals, the information encoded by DNA reflects its primary biological
function. . . .").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under the statutory rubric of &sect; 101, isolated DNA is a tangible, man-made
composition of matter defined and distinguished by its objectively
discernible chemical structure. Whether its unusual status as a chemical
entity that conveys genetic information warrants singular treatment under
the patent laws as the district court did is a policy question that we are
not entitled to address. <i>Cf. Nat'l Fed'n of Indep. Bus. v. Sebelius</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=132%20S.%20Ct.%201794&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=132%20supreme%20court%202566&amp;summary=yes#jcite">132 S.Ct. 2566</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=132%20supreme%20court%202566&amp;summary=yes#jcite">2579</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=183%20l%20ed%202d%20450&amp;summary=yes#jcite">183 L.Ed.2d 450</a> (2012) ("[W]e possess
neither the expertise nor the prerogative to make policy judgments. Those
decisions are entrusted to our Nation's elected leaders, who can be thrown
out of office if the people disagree with them."). Congress is presumed to
have been aware of the issue, having enacted a comprehensive patent reform
act during the pendency of this case, and it is ultimately for Congress if
it wishes to overturn
<span CLASS="page_no" data-cite="689 f 3d 1331" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1331" data-primary-citation="689 F.3d 1303">[*1331]</span> 
case law and the long practice of the PTO to determine that isolated DNA
must be treated differently from other compositions of matter to account for
its perceived special function. We therefore reject the district court's
unwarranted categorical exclusion of isolated DNA molecules.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924790" href="#headnote_pq2-dec_924790">[6]</a> Because isolated DNAs, not just cDNAs, have a markedly different chemical
structure compared to native DNAs, we reject the government's earlier
proposed "magic microscope" test, as it misunderstands the difference
between science and invention and fails to take into account the existence
of molecules as separate chemical entities. The ability to visualize a DNA
molecule through a microscope, or by any other means, when it is bonded to
other genetic material, is worlds apart from possessing an isolated DNA
molecule that is in hand and usable. It is the difference between knowledge
of nature and reducing a portion of nature to concrete form, the latter
activity being what the patent laws seek to encourage and protect. The
government's microscope could focus in on a claimed portion of any complex
molecule, rendering that claimed portion patent ineligible, even though that
portion never exists as a separate molecule in the body or anywhere else in
nature, and may have an entirely different utility. <span CLASS="page_no" data-cite="2012 bl 210726 p 26" data-cite-type="Bloomberg" data-cite-pageno="26" data-primary-citation="">[***26]</span> That would discourage
innovation. One cannot visualize a portion of a complex molecule, including
a DNA containing a particular gene, and will it into isolation as a unique
entity. Visualization does not cleave and isolate the particular DNA; that
is the act of human invention.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924791" href="#headnote_pq2-dec_924791">[7]</a> The Supreme Court in <i>Mayo</i> focused on its concern that permitting patents
on particular subject matter would prevent use by others of, in <i>Mayo</i>, the
correlation recited in the method claims. Plaintiffs argue here that they
are preempted from using the patented DNA molecules. The answer to that
concern is that permitting patents on isolated genes does not preempt a law
of nature. A composition of matter is not a law of nature. Moreover, as
indicated earlier, a limited preemption is inherent in every patent: the
right to exclude for a limited period of time. <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEJ01G003?jcsearch=35%20U.S.C.%20%20154(a)(1)&amp;summary=yes#jcite">35 U.S.C. &sect; 154</a>(a)(1) ("Every
patent shall contain . . . a grant to the patentee, his heirs or assigns, of
the right to exclude others from making, using, offering for sale, or
selling the invention throughout the United States. . . ."). When the patent
expires, the public is entitled to practice the invention of the patent.
That is true of all inventions; during the term of the patent, unauthorized
parties are "preempted" from practicing the patent, but only for its limited
term. The seven patents being challenged here all expire by December 18,
2015.<a HREF="#fn1300" name="fnref_fn1300">[fn13]</a> Any preemption thus is limited, very limited in the case of the
present patents. Moreover, patents are rarely enforced against scientific
research, even during their terms.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The remand of this case for reconsideration in light of <i>Mayo</i> might
suggest, as Plaintiffs and certain amici state, that the composition claims
are mere reflections of a law of nature. Respectfully, they are not, any
more than any product of man reflects and is consistent with a law of
nature. Everything and everyone comes from nature, following its laws. But
the <span CLASS="page_no" data-cite="103 uspq 2d 1702" data-cite-type="ReporterOfDecisions" data-cite-pageno="1702" data-primary-citation="103 U.S.P.Q.2d 1681">[**1702]</span> compositions here are not natural products. They are the products of
man, albeit following, as all materials do, laws of nature.
<span CLASS="page_no" data-cite="689 f 3d 1332" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1332" data-primary-citation="689 F.3d 1303">[*1332]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The dissent indicates that "elemental lithium (like other elements) would
not be patentable subject matter, even if it could only be extracted from
nature through an isolation process." But the isolation here is not a simple
separation from extraneous materials, but conversion to a different
molecular entity. And again, these facts are not before us, so we do not
attempt to evaluate the patentability of one form of lithium over another.
Courts decide cases; they do not draft comprehensive legal treatises.
Suffice it to say, however, that if lithium is found in the earth as other
than elemental lithium because it reacts with air and water to form, for
example, lithium oxide or lithium hydroxide, it is a different material. A
lithium compound is not elemental lithium.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is also important to dispute the dissent's analogy to snapping a leaf
from a tree. With respect, no one could contemplate that snapping a leaf
from a tree would be worthy of a patent, whereas isolating genes to provide
useful diagnostic tools and medicines is surely what the <span CLASS="page_no" data-cite="2012 bl 210726 p 27" data-cite-type="Bloomberg" data-cite-pageno="27" data-primary-citation="">[***27]</span> patent laws are
intended to encourage and protect. Snapping a leaf from a tree is a physical
separation, easily done by anyone. Creating a new chemical entity is the
work of human transformation, requiring skill, knowledge, and effort. <i>See</i>
<i>Mayo</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">132 S.Ct. at 1294</a> ("While a scientific truth . . . is not a patentable
invention, a novel and useful structure created with the aid of knowledge of
scientific truth may be.") (quoting <i>Mackay Radio &amp; Tel. Co. v. Radio Corp.</i>
<i>of Am.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVVN?jcsearch=306%20us%2086&amp;summary=yes#jcite">306 U.S. 86</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVVN?jcsearch=306%20us%2086&amp;summary=yes#jcite">94</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVVN?jcsearch=59%20supreme%20court%20427&amp;summary=yes#jcite">59 S.Ct. 427</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BVVN?jcsearch=83%20l%20ed%20506&amp;summary=yes#jcite">83 L.Ed. 506</a> (1939)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The dissent also mentions several times in its opinion the
"breathtaking[]" breadth of certain claims as grounds for objecting to their
patentability. However, we do not have here any rejection or invalidation on
the various grounds relating to breadth, such as in <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVO003?jcsearch=35%20usc%20112&amp;summary=yes#jcite">35 U.S.C. &sect; 112</a>. The
issue before us is patent eligibility under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>, not the adequacy of the
patents' disclosure to support particular claims. Nor is it lack of
patentability for obviousness, as the dissent intimates, that is before us.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The dissent finally attempts to analogize the creation of the isolated
DNAs in this case to the removal of a kidney from the human body, indicating
that the latter does not create patent-eligible subject matter, hence the
claimed isolated DNAs also do not. Such an analogy is misplaced. Extracting
a kidney from a body does not result in a patent-eligible composition, as an
isolated gene has been and should be. A kidney is an organ, not a well
defined composition of matter or an article of manufacture specified by <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect;
101</a>. No one could confuse extensive research needed to locate, identify, and
isolate a gene with the extraction of an organ from a body. One is what
patents are intended to stimulate research on and hence are properly patent
eligible, and the other, while obviously essential to human wellbeing, is
not what patents are understood to cover under the patent statute. An
isolated DNA is properly characterized as a composition of matter under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect;
101</a>; no one would so characterize an isolated body organ.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, our decision that isolated DNA molecules are patent eligible
comports with the longstanding practice of the PTO and the courts. The
Supreme Court has repeatedly stated that changes to longstanding practice
should come from Congress, not the courts. In <i>J.E.M. Ag Supply, Inc. v.</i>
<i>Pioneer Hi-Bred International, Inc.</i>, the Court rejected the argument that
plants did not fall within the scope of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>, relying in part on the fact
that "the PTO has assigned utility patents for plants for at least 16 years
and there has been no indication from either Congress or agencies with
expertise that such coverage is inconsistent with [federal law]."
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XAU2R6?jcsearch=534%20us%20124&amp;summary=yes#jcite">534 U.S. 124</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XAU2R6?jcsearch=534%20us%20124&amp;summary=yes#jcite">144-15</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XAU2R6?jcsearch=122%20supreme%20court%20593&amp;summary=yes#jcite">122 S.Ct. 593</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XAU2R6?jcsearch=151%20l%20ed%202d%20508&amp;summary=yes#jcite">151 L.Ed.2d 508</a> (2001); <i>see</i>
<span CLASS="page_no" data-cite="689 f 3d 1333" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1333" data-primary-citation="689 F.3d 1303">[*1333]</span> 
<i>also Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=535%20us%20722&amp;summary=yes#jcite">535 U.S. 722</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=535%20us%20722&amp;summary=yes#jcite">739</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=122%20supreme%20court%201831&amp;summary=yes#jcite">122 S.Ct. 1831</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=152%20l%20ed%202d%20944&amp;summary=yes#jcite">152 L.Ed.2d 944</a> (2002) ("[C]ourts must be cautious before
adopting, changes that disrupt the settled expectations of the inventing
community." (citing <i>Warner-Jenkinson Co. v. Hilton Davis Chem. Co.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CCSV?jcsearch=520%20us%2017&amp;summary=yes#jcite">520 U.S. 17</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CCSV?jcsearch=520%20us%2017&amp;summary=yes#jcite">28</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CCSV?jcsearch=117%20supreme%20court%201040&amp;summary=yes#jcite">117 S.Ct. 1040</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CCSV?jcsearch=137%20l%20ed%202d%20146&amp;summary=yes#jcite">137 L.Ed.2d 146</a> (1997))); <i>Ariad Pharms.,</i>
<i>Inc. v. Eli Lilly &amp; Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">598 F.3d 1336</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">1347</a> (Fed.Cir.2010) (en banc)
(upholding a written description requirement separate from enablement based
in part on <i>stare decisis</i>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In this case, the PTO has issued patents relating to DNA molecules for
almost thirty years. <span CLASS="page_no" data-cite="2012 bl 210726 p 28" data-cite-type="Bloomberg" data-cite-pageno="28" data-primary-citation="">[***28]</span> In the early 1980s, the Office granted the first human
gene patents. <i>See</i> Eric J. Rogers, <i>Can You Patent Genes? Yes and No</i>, 93 J.
Pat. &amp; Trademark Off. Soc'y 19 (2010). It is estimated that the PTO has
issued 2,645 patents claiming "isolated DNA" over the past twenty-nine
years, J.A. 3710, and that by 2005, had granted 40,000 DNA-related patents
relating to, in non-native form, genes in the human genome, Rogers, <i></i><cite>supra at
40</cite>. In 2001, the PTO issued <i>Utility Examination Guidelines</i>, which reaffirmed
the agency's position that isolated DNA molecules are patent <span CLASS="page_no" data-cite="103 uspq 2d 1703" data-cite-type="ReporterOfDecisions" data-cite-pageno="1703" data-primary-citation="103 U.S.P.Q.2d 1681">[**1703]</span> eligible,
<cite>66 Fed.Reg. 1092-94</cite> (Jan. 5, 2001), and Congress has not indicated that the
PTO's position is inconsistent with <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>. If the law is to be changed, and
DNA inventions excluded from the broad scope of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>, contrary to the
settled expectation of the inventing and investing communities, the decision
must come, not from the courts, but from Congress. The dissent mentions
possible "adverse effects" that may occur if isolated DNAs are held to be
patent eligible. But, respectfully, it is the adverse effects on innovation
that a holding of ineligibility might cause. Patents encourage innovation
and even encourage inventing around; we must be careful not to rope off
far-reaching areas of patent eligibility.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, we once again conclude that claims 1, 2, 5, 6, and 7 of the
&prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>; claims 1, 6, and 7 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2I0CE44GGJ?jcsearch=usp%205837492&amp;summary=yes#jcite">492 patent</a>; and claim 1 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HH4643GOJ?jcsearch=usp%205693473&amp;summary=yes#jcite">473
patent</a> directed to isolated DNA molecules recite patent-eligible subject
matter under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>. <i>Mayo</i> does not change that result. In so doing, we
reiterate that the issue before us is <i>patent eligibility</i>, not <i>patentability</i>,
about which we express no opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III. Method Claims
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We turn next to Myriad's challenged method claims. This court in its
now-vacated decision of July 29, 2011, had held method claims 1 of the &prime;999,
&prime;001, and &prime;441 patents, as well as method claims 1 and 2 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X300C682HOJ?jcsearch=usp%206033857&amp;summary=yes#jcite">857 patent</a>
&mdash; all of which consist of analyzing and comparing certain DNA sequences &mdash;
not to be patent-eligible subject matter on the ground that they claim only
abstract mental processes. In light of the Supreme Court's decision in <i>Mayo</i>,
we reaffirm that prior holding. The Court made clear that such diagnostic
methods in that case essentially claim natural laws that are not eligible
for patent. Without expressly analyzing the instant method claims in the
context of the Court's reasoning, but in light of the Court's holding, and
in view of our own prior reasoning, set forth herein below, those method
claims cannot stand.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In our prior decision, however, we reversed the district court's holding
that claim 20 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> was not eligible for patent. We did so on
the ground, <i>inter alia</i>, that, in addition to the step of comparing the
cells' growth rates, the claim also recites the steps of growing transformed
cells and determining those growth rates. We relied on the fact that those
steps were transformative. Although the Court has now held that certain
transformative
<span CLASS="page_no" data-cite="689 f 3d 1334" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1334" data-primary-citation="689 F.3d 1303">[*1334]</span> 
steps are not necessarily sufficient under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a> if the recited steps only
rely on natural laws, we once again, even in light of <i>Mayo</i>, arrive at the
same conclusion <span CLASS="page_no" data-cite="2012 bl 210726 p 29" data-cite-type="Bloomberg" data-cite-pageno="29" data-primary-citation="">[***29]</span> of patent-eligibility because at the heart of claim 20 is a
transformed cell, which is made by man, in contrast to a natural material.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. Methods of "Comparing" or "Analyzing" Sequences
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad argued that its claims to methods of "comparing" or "analyzing"
<i>BRCA</i> sequences satisfy the machine-or-transformation test because each
requires a transformation &mdash; extracting and sequencing DNA molecules from a
human sample &mdash; before the sequences can be compared or analyzed. According
to Myriad, the district court failed to recognize the transformative nature
of the claims by (1) misconstruing the claim term "sequence" as merely
information, rather than a physical molecule; and (2) erroneously
concluding, in the alternative, that Myriad's proposed transformations were
mere data-gathering steps, rather than central to the purpose of the claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Plaintiffs responded that these method claims are drawn to the abstract
idea of comparing one sequence to a reference sequence and preempt a
phenomenon of nature &mdash; the correlation of genetic mutations with a
predisposition to cancer. And, according to the Plaintiffs, limiting the
claims' application to a specific technological field, <i>i.e., BRCA</i> gene
sequences, is insufficient to render the claims patent eligible. Plaintiffs
also assert that the claims do not meet the machine-or-transformation test
because the claims' plain language includes just the one step of "comparing"
or "analyzing" two gene sequences.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924792" href="#headnote_pq2-dec_924792">[8]</a> We renew our conclusion that Myriad's claims to "comparing" or "analyzing"
two gene sequences fall outside the scope of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a> because they claim only
abstract mental processes. <i>See Benson</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=409%20us%2063&amp;summary=yes#jcite">409 U.S. at 67</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=93%20supreme%20court%20253&amp;summary=yes#jcite">93 S.Ct. 253</a>
("Phenomena of nature, . . . mental processes, and abstract intellectual
concepts are not patentable, as they are the basic tools of scientific and
technological work."). The claims recite, for example, a "method for
screening a tumor sample," by "comparing" a first <i>BRCA1</i> sequence from a
tumor sample and a second <i>BRCA1</i> sequence from a non-tumor sample, wherein a
difference in sequence indicates an alteration in the tumor sample. &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO400008J?jcsearch=usp%205710001&amp;summary=yes#jcite">001
patent</a> claim 1. This claim thus recites nothing more than the abstract
mental steps necessary to compare two different nucleotide sequences: one
looks at the first position in a first sequence; <span CLASS="page_no" data-cite="103 uspq 2d 1704" data-cite-type="ReporterOfDecisions" data-cite-pageno="1704" data-primary-citation="103 U.S.P.Q.2d 1681">[**1704]</span> determines the nucleotide
sequence at that first position; looks at the first position in a second
sequence; determines the nucleotide sequence at that first position;
determines if the nucleotide at the first position in the first sequence and
the first position in the second sequence are the same or different, wherein
the latter indicates an alteration; and repeats the process for the next
position.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Limiting the comparison to just the <i>BRCA</i> genes or, as in the case of claim
1 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO0I94I8J?jcsearch=usp%205709999&amp;summary=yes#jcite">999 patent</a>, to just the identification of particular alterations,
fails to render the claimed process patent-eligible. As the Supreme Court
has held, "the prohibition against patenting abstract ideas 'cannot be
circumvented by attempting to limit the use of the formula to a particular
technological environment.'" <span CLASS="page_no" data-cite="2012 bl 210726 p 30" data-cite-type="Bloomberg" data-cite-pageno="30" data-primary-citation="">[***30]</span> <i>Bilski</i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20supreme%20court%203218&amp;summary=yes#jcite">130 S.Ct. at 3230</a> (quoting <i>Diehr</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA2P?jcsearch=450%20us%20175&amp;summary=yes#jcite">450 U.S. at 191-92</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA2P?jcsearch=101%20supreme%20court%201048&amp;summary=yes#jcite">101 S.Ct. 1048</a>); <i>see also </i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20S.%20Ct.%203218&amp;summary=yes#jcite">id. at 3231</a> ("<i>Flook</i>
established that limiting an abstract idea to one field of use . . . did not
make the concept patentable."). Although the <i>application</i> of a formula or
abstract idea in a process may describe patent-eligible subject matter, <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20S.%20Ct.%203218&amp;summary=yes#jcite">id.
at 3230</a>, Myriad's
<span CLASS="page_no" data-cite="689 f 3d 1335" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1335" data-primary-citation="689 F.3d 1303">[*1335]</span> 
claims do not apply the step of comparing two nucleotide sequences in a
process. Rather, the step of comparing two DNA sequences is the entire
process that is claimed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To avoid this result, Myriad attempts to read into its method claims
additional, allegedly transformative steps. As described above, Myriad reads
into its claims the steps of (1) extracting DNA from a human sample, and (2)
sequencing the <i>BRCA</i> DNA molecule, arguing that both steps necessarily
precede the step of comparing nucleotide sequences. The claims themselves,
however, do not include either of these steps. The claims do not specify any
action prior to the step of "comparing" or "analyzing" two sequences; the
claims recite just the one step of "comparing" or "analyzing." Moreover,
those terms' plain meaning does not include Myriad's proposed
sample-processing steps; neither comparing nor analyzing means or implies
"extracting" or "sequencing" DNA or otherwise "processing" a human sample.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad claims that "comparing" and "analyzing" take on such meaning when
read in light of the patent specifications. Specifically, Myriad argues that
the specifications show that the claim term "sequence" refers not to
information, but rather to a physical DNA molecule, whose sequence must be
determined before it can be compared. That may be true, but the claims only
recite mental steps, not the structure of physical DNA molecules.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, Myriad's challenged method claims are indistinguishable from
the claims the Supreme Court found invalid under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a> in <i>Mayo.</i> In <i>Mayo</i>, the
patents claimed methods for optimizing the dosage of thiopurine drugs
administered to patients with gastrointestinal disorders. <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">132 S.Ct. at 1295</a>.
As written, the claimed methods included the steps of (a) "administering" a
thiopurine drug to a subject, and/or (b) "determining" the drug's metabolite
levels in the subject, wherein the measured metabolite levels are compared
with predetermined levels to optimize drug dosage. <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20S.%20Ct.%201289&amp;summary=yes#jcite">Id</a>.</i> In holding that the
claims satisfied <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>, this court concluded that, in addition to the
"administering" step being transformative, the "determining" step was both
transformative and central to the purpose of the claims. <i>Prometheus</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1ENQ84003?jcsearch=628%20f%203d%201347&amp;summary=yes#jcite">628 F.3d at 1357</a>. However, the Supreme Court held that the steps of
administering and determining, combined with a correlative "wherein" clause,
were not sufficiently transformative of what was otherwise a claim to a
natural law. That holding governs Myriad's claims to methods of "comparing"
and "analyzing" DNA sequences.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad's other claims do not even include a <i>Mayo-like</i> step of
"determining" the sequence <i>BRCA</i> genes by, <i>e.g.</i>, isolating the genes from a
blood sample and sequencing them, or any other putatively transformative
step. Rather, the comparison between the two sequences can be accomplished
by mere <span CLASS="page_no" data-cite="2012 bl 210726 p 31" data-cite-type="Bloomberg" data-cite-pageno="31" data-primary-citation="">[***31]</span> inspection alone. Accordingly, Myriad's claimed methods of comparing
or analyzing nucleotide sequences are only directed to the abstract mental
process of comparing two nucleotide sequences. As such, we hold claims 1 of
the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO0I94I8J?jcsearch=usp%205709999&amp;summary=yes#jcite">999 patent</a>, &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HO400008J?jcsearch=usp%205710001&amp;summary=yes#jcite">001 patent</a>, and &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOK64208J?jcsearch=usp%205753441&amp;summary=yes#jcite">441 patent</a> and claims 1 and 2 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X300C682HOJ?jcsearch=usp%206033857&amp;summary=yes#jcite">857
patent</a> invalid under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a> for claiming patent-ineligible processes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B. Method of Screening Potential Cancer Therapeutics
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924793" href="#headnote_pq2-dec_924793">[9]</a> Lastly, we turn to claim 20 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>, directed to a method for
screening potential cancer therapeutics via changes in cell growth rates of
transformed cells. The parties agree that those transformed cells arose from
human effort; <i>i.e.</i>, they are not natural products. Plaintiffs nonetheless
challenge claim 20 as directed to the abstract idea of comparing
<span CLASS="page_no" data-cite="689 f 3d 1336" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1336" data-primary-citation="689 F.3d 1303">[*1336]</span> 
the growth rates of two cell populations and as preempting a basic
scientific principle &mdash; that a slower growth rate in the presence of a
potential therapeutic compound suggests that the compound is a cancer
therapeutic. Plaintiffs <span CLASS="page_no" data-cite="103 uspq 2d 1705" data-cite-type="ReporterOfDecisions" data-cite-pageno="1705" data-primary-citation="103 U.S.P.Q.2d 1681">[**1705]</span> therefore contend that claim 20 is indistinguishable
from the claims held ineligible in <i>Mayo.</i> We disagree.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Claim 20 recites a method that comprises the steps of (1) growing host
cells <i>transformed</i> with an altered <i>BRCA1</i> gene in the presence or absence of a
potential cancer therapeutic, (2) determining the growth rate of the host
cells with or without the potential therapeutic, and (3) comparing the
growth rate of the host cells. Claim 20 thus recites a screening method
premised on the use of "transformed" host cells. Those cells, like the
patent-eligible cells in <i>Chakrabarty</i>, are not naturally occurring. Rather,
they are derived by altering a cell to include a foreign gene, resulting in
a man-made, transformed cell with enhanced function and utility. <i>See</i> &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282
patent</a> col.27 ll.28-33. The claim thus includes more than the abstract
mental step of looking at two numbers and "comparing" two host cells' growth
rates.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Mayo</i>, the Supreme Court invalidated claims directed to the relationship
between concentrations of certain metabolites in the blood and the
likelihood that a particular dosage of a thiopurine drug will be optimum,
stating that steps of "administering" and "determining," coupled with a
correlative "wherein" clause, were insufficient to differentiate the claimed
method from the natural laws encompassed by the claims. In short, "to
transform an unpatentable law of nature into a patent-eligible <i>application</i>
of such a law, one must do more than simply state the law of nature while
adding the words 'apply it'." <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">132 S.Ct. at 1294</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, claim 20 does do more; it does not simply apply a law of nature. Of
course, all activity, whether chemical, biological, or physical, relies on
natural laws. But, more to the point here is that claim 20 applies certain
steps to transformed cells that, as has been pointed out above, are a
product of man, not of nature. The Court, in its evaluation of the <i>Mayo</i>
method claims, found that the additional steps of those claims were not
sufficient to "transform" the nature of the claims from mere expression of
natural laws to patent-eligible <span CLASS="page_no" data-cite="2012 bl 210726 p 32" data-cite-type="Bloomberg" data-cite-pageno="32" data-primary-citation="">[***32]</span> subject matter. By definition, however,
performing operations, even known types of steps, on, or to create, novel,
<i>i.e.</i>, transformed subject matter is the stuff of which most process or
method invention consists. All chemical processes, for example, consist of
hydrolyzing, hydrogenating, reacting, etc. In situations where the objects
or results of such steps are novel and nonobvious, they should be
patent-eligible. It is rare that a new reaction or method is invented; much
process activity is to make new compounds or products using established
processes. Thus, once one has determined that a claimed composition of
matter is patent-eligible subject matter, applying various known types of
procedures to it is not merely applying conventional steps to a law of
nature. The transformed, man-made nature of the underlying subject matter in
claim 20 makes the claim patent-eligible. The fact that the claim also
includes the steps of determining the cells' growth rates and comparing
growth rates does not change the fact that the claim is based on a man-made,
non-naturally occurring transformed cell &mdash; patent-eligible subject matter.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Furthermore, the claim does not cover all cells, all compounds, or all
methods of determining the therapeutic effect of a compound. Rather, it is
tied to specific host cells <i>transformed</i> with specific genes
<span CLASS="page_no" data-cite="689 f 3d 1337" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1337" data-primary-citation="689 F.3d 1303">[*1337]</span> 
and grown in the presence or absence of a specific type of therapeutic.
Accordingly, we hold that claim 20 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> recites
patent-eligible subject matter under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>. Whether such processes,
including claim 20, meet other tests for patentability, such as novelty or
nonobviousness, is not before us.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For the foregoing reasons, we affirm the district court's decision to
exercise declaratory judgment jurisdiction over this case, we reverse the
district court's grant of summary judgment with regard to Myriad's
composition claims to isolated DNAs, including cDNAs, we affirm the district
court's grant of summary judgment with regard to Myriad's method claims
directed to comparing or analyzing gene sequences, and we reverse the
district court's grant of summary judgment with regard to Myriad's method
claim to screening potential cancer therapeutics via changes in cell growth
rates of novel, man-made transformed cells.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED IN PART and REVERSED IN PART</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  COSTS
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Costs to Myriad.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> In addition to representative claims 1, 2, and 5 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>,
other claims to isolated DNA molecules at issue in this appeal include:
claims 6 and 7 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>; claims 1, 6, and 7 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2I0CE44GGJ?jcsearch=usp%205837492&amp;summary=yes#jcite">492 patent</a>;
and claim 1 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HH4643GOJ?jcsearch=usp%205693473&amp;summary=yes#jcite">473 patent</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> The claims currently before us that recite methods of "analyzing" or
"comparing" <i>BRCA</i> sequences are: claims 1 of the &prime;999, &prime;001, and &prime;441 patents
and claims 1 and 2 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X300C682HOJ?jcsearch=usp%206033857&amp;summary=yes#jcite">857 patent</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> The district court's opinion, <i>SJ Op.</i>, 702 <i>F.Supp.2d at 192-203,</i>
<i>contains a detailed</i> and comprehensive discussion of the science involved in
this case. We repeat only the basics here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> Covalent bonds are chemical bonds characterized by the sharing of
electrons between atoms in a molecule.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> Myriad filed the first patent application leading to the patents in
suit covering isolated BRCA1 DNA and associated diagnostic methods in August
1994. The first resulting patent, the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HH4643GOJ?jcsearch=usp%205693473&amp;summary=yes#jcite">473 patent</a>, issued on December 2,
1997. Myriad filed the first application leading to the patents in suit
covering isolated BRCA2 DNA and associated diagnostic methods in December
1995, and the first such patent, the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2I0CE44GGJ?jcsearch=usp%205837492&amp;summary=yes#jcite">492 patent</a>, issued on November 17,
1998.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> On July 27, 2011, two days before we issued our initial, now-vacated
decision in this case, Myriad notified the court that Dr. Ostrer was leaving
NYU to assume a position at the Albert Einstein College of Medicine and
Montefiore Medical Center, effective August 29, 2011. In response,
Plaintiffs submitted a supplemental declaration from Dr. Ostrer stating
that, in his new position, he still seeks to undertake BRCA diagnostic
testing, still has the resources and expertise to conduct such testing, and
would immediately do so if Myriad's patents were invalidated. Following
remand from the Supreme Court, we have also received from Myriad a related
"suggestion of mootness" and motion to remand or dismiss. We declined the
suggestion and denied the motion. We now review this case on the facts and
arguments briefed and presented to us.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> Certain patients also allege an injury based on their inability to
gain access to affordable <i>BRCA</i> genetic testing because of Myriad's patent
dominance of such services. While denial of health services can, in certain
circumstances, state a judicially cognizable injury, <i>see Simon</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C956?jcsearch=426%20us%2026&amp;summary=yes#jcite">426 U.S. at 40-41</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C956?jcsearch=96%20supreme%20court%201917&amp;summary=yes#jcite">96 S.Ct. 1917</a>, Plaintiffs have not pressed this as an
independent ground for standing. Moreover, we fail to see how the inability
to afford a patented invention could establish an invasion of a legally
protected interest for purposes of standing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> Myriad's analogy to laches is also unconvincing. Laches bars the
recovery of pre-filing damages; it does not preclude a patent action for
prospective relief, the type of relief sought here. <i>See A.C. Aukerman Co. v.</i>
<i>R.L. Chaides Const. Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X3JUKS?jcsearch=960%20f%202d%201020&amp;summary=yes#jcite">960 F.2d 1020</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X3JUKS?jcsearch=960%20f%202d%201020&amp;summary=yes#jcite">1041</a> (Fed. Cir.1992) (<i>en banc</i>)
("[L]aches bars relief on a patentee's claim only with respect to damages
accrued prior to suit.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> According to the government, several of the composition claims at
issue in this suit, including claim 2 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>, are limited to
cDNA and thus patent eligible. We agree.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> Other Supreme Court decisions cited by the parties and amici relating
to patented manufactures and compositions of matter were decided based on
lack of novelty, not patent-eligible subject matter. In <i>American Wood-Paper</i>
<i>Co. v. Fibre Disintegrating Co.</i>, the Court held the challenged patent "void
for want of novelty in the manufacture patented," because the "[p]aper-pulp
obtained from various vegetable substances was in common use before the
original patent was granted and whatever may be said of their process for
obtaining it, the product was in no sense new." <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XM0MD7?jcsearch=90%20us%20566&amp;summary=yes#jcite">90 U.S. 566</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XM0MD7?jcsearch=90%20us%20566&amp;summary=yes#jcite">596</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XM0MD7?jcsearch=23%20Wall.%20566&amp;summary=yes#jcite">23 Wall. 566</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XM0MD7?jcsearch=23%20l%20ed%2031&amp;summary=yes#jcite">23 L.Ed. 31</a> (1874). Similarly, in <i>Cochrane v. Badische Anilin</i>
<i>&amp; Soda Fabrik</i>, the Court held that a claim to artificial alizarine covered
an old and well-known substance, the alizarine of madder, which could not be
patented although made artificially for the first time. <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1KKJ3QNB5G0?jcsearch=111%20us%20293&amp;summary=yes#jcite">111 U.S. 293</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1KKJ3QNB5G0?jcsearch=111%20us%20293&amp;summary=yes#jcite">311</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1KKJ3QNB5G0?jcsearch=4%20supreme%20court%20455&amp;summary=yes#jcite">4 S.Ct. 455</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1KKJ3QNB5G0?jcsearch=28%20l%20ed%20433&amp;summary=yes#jcite">28 L.Ed. 433</a> (1884); <i>see also </i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1KKJ3QNB5G0?jcsearch=111%20U.S.%20293&amp;summary=yes#jcite">id. at 308-09</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1KKJ3QNB5G0?jcsearch=4%20supreme%20court%20455&amp;summary=yes#jcite">4 S.Ct. 455</a> ("It
is very plain that the specification of the original patent, <cite>No. 95,465</cite>,
states the invention to be a process for preparing alizarine, <i>not as a new</i>
<i>substance prepared for the first time</i>, but as the substance already known as
alizarine, to be prepared, however, by the new process, which process is to
be the subject of the patent, and is the process of preparing the <i>known</i>
<i>product</i> alizarine from anthracine." (emphases added)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> <i>In re Bergy</i>, relating to a purified microorganism, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIIGOJ?jcsearch=596%20f%202d%20952&amp;summary=yes#jcite">596 F.2d 952</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIIGOJ?jcsearch=596%20f%202d%20952&amp;summary=yes#jcite">967-68</a> (CCPA 1979), was once a companion case to <i>Chakrabarty</i> but was vacated
by the Supreme Court and remanded for dismissal as moot when the inventors
withdrew their claim from the pending application. <i>Diamond v. Chakrabarty</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5H371?jcsearch=444%20us%201028&amp;summary=yes#jcite">444 U.S., 1028</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5H371?jcsearch=100%20supreme%20court%20696&amp;summary=yes#jcite">100 S.Ct. 696</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5H371?jcsearch=62%20l%20ed%202d%20664&amp;summary=yes#jcite">62 L.Ed.2d 664</a> (1980). Other CCPA cases cited
by the parties and amici were not decided based on patent eligibility. In <i>In</i>
<i>re Bergstrom</i>, the court held that pure prostaglandin compounds, PGE(2) and
PGE(3), were improperly rejected as lacking novelty. 57 CCPA 1240,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIHP17?jcsearch=427%20f%202d%201394&amp;summary=yes#jcite">427 F.2d 1394</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIHP17?jcsearch=427%20f%202d%201394&amp;summary=yes#jcite">1394</a> (1970); <i>see Bergy</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIIGOJ?jcsearch=596%20f%202d%20952&amp;summary=yes#jcite">596 F.2d at 961</a> (recognizing
<i>Bergstrom</i> as a case decided under <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVC003?jcsearch=35%20U.S.C.%20%20102&amp;summary=yes#jcite">&sect; 102</a>). Similarly in <i>In re Kratz</i>, the
court held nonobvious claims to synthetically produced, substantially pure
2-methyl-2-pentenoic acid, a chemical that gives strawberries their flavor.
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIJ7MB?jcsearch=592%20f%202d%201169&amp;summary=yes#jcite">592 F.2d 1169</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIJ7MB?jcsearch=592%20f%202d%201169&amp;summary=yes#jcite">1170</a> (CCPA 1979); <i>see also In re King</i>, 27 CCPA 754,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIFETV?jcsearch=107%20f%202d%20618&amp;summary=yes#jcite">107 F.2d 618</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIFETV?jcsearch=107%20f%202d%20618&amp;summary=yes#jcite">619</a> (1939) (holding claims to vitamin C invalid for lack of
novelty, as "[a]ppellants were not the first to discover or produce [vitamin
C] in its pure form"); <i>In re Merz</i>, 25 CCPA 1314, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIEJ1F?jcsearch=97%20f%202d%20599&amp;summary=yes#jcite">97 F.2d 599</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIEJ1F?jcsearch=97%20f%202d%20599&amp;summary=yes#jcite">601</a> (1938)
(holding claims to artificial ultramarine that contains non-floatable
impurities invalid as not "inventive," and thus obvious).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1200" name="fn1200">[fn12]</a></span> Claims 2 and 7 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> and claim 7 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2I0CE44GGJ?jcsearch=usp%205837492&amp;summary=yes#jcite">492 patent</a>
recite isolated cDNA molecules.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1300" name="fn1300">[fn13]</a></span> Specifically, the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOK64208J?jcsearch=usp%205753441&amp;summary=yes#jcite">441 patent</a> will expire on August 12, 2014; the
&prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HH4643GOJ?jcsearch=usp%205693473&amp;summary=yes#jcite">473 patent</a> will expire on December 2, 2014; the &prime;999 and &prime;001 patents will
expire on January 20, 2015; the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> will expire on May 5, 2015; and
the &prime;492 and &prime;857 patents will expire on December 18, 2015.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  MOORE, Circuit Judge, concurring in part.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I join the majority opinion with respect to standing and the patentability
of the method claims at issue. I join the majority with respect to claims to
isolated cDNA sequences, and concur in the judgment with respect to <span CLASS="page_no" data-cite="103 uspq 2d 1706" data-cite-type="ReporterOfDecisions" data-cite-pageno="1706" data-primary-citation="103 U.S.P.Q.2d 1681">[**1706]</span> isolated
DNA sequences. I write separately to explain my reasoning.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Patent Act, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20usc%20101&amp;summary=yes#jcite">35 U.S.C. &sect; 101</a>, allows "[w]hoever invents or discovers
any new and useful process, machine, manufacture, or composition of matter,
or any new and useful improvement thereof to obtain a patent. The plain
language of this statute only requires that an invention be "new and
useful," and fall into one of four categories: a "process, machine,
manufacture, or composition of matter." "Congress intended statutory subject
matter to 'include <span CLASS="page_no" data-cite="2012 bl 210726 p 33" data-cite-type="Bloomberg" data-cite-pageno="33" data-primary-citation="">[***33]</span> anything under the sun that is made by man.'" <i>Diamond v.</i>
<i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. 303</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">309</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=65%20l%20ed%202d%20144&amp;summary=yes#jcite">65 L.Ed.2d 144</a> (1980)
(quoting the statutory history).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While the plain language used by Congress did not limit the scope of
patentable subject matter in the statute, the "Court's precedents provide
three specific exceptions to <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20U.S.C.%20%20101&amp;summary=yes#jcite">&sect; 101</a>'s broad patent-eligibility principles:
'laws of nature, physical phenomena, and abstract ideas.'" <i>Bilski v. Kappos</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20S.Ct.%203218&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20supreme%20court%203218&amp;summary=yes#jcite">130 S.Ct. 3218</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20supreme%20court%203218&amp;summary=yes#jcite">3226</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=177%20l%20ed%202d%20792&amp;summary=yes#jcite">177 L.Ed.2d 792</a> (2010) (quoting
<i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 309</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>). These exceptions "rest[], not
on the notion that natural phenomena are not processes [or other articulated
statutory categories], but rather on the more fundamental understanding that
they are not the kind of 'discoveries' that the statute was enacted to
protect." <i>Parker v. Flook</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C9KM?jcsearch=437%20us%20584&amp;summary=yes#jcite">437 U.S. 584</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C9KM?jcsearch=437%20us%20584&amp;summary=yes#jcite">593</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C9KM?jcsearch=98%20supreme%20court%202522&amp;summary=yes#jcite">98 S.Ct. 2522</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C9KM?jcsearch=57%20l%20ed%202d%20451&amp;summary=yes#jcite">57 L.Ed.2d 451</a>
(1978).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Applying the judicially created exception to the otherwise broad
demarcation of statutory subject matter in section 101 can be difficult. <i>See</i>
<i>Funk Bros. Seed Co. v. Kalo Inoculant Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">333 U.S. 127</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">134-35</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=92%20l%20ed%20588&amp;summary=yes#jcite">92 L.Ed. 588</a> (1948) (Frankfurter, J., concurring) ("[S]uch
terms as 'the work of nature' and the 'laws of nature' . . . are vague and
malleable. . . . Arguments drawn from such terms for ascertaining
patentability could fairly be employed to challenge almost every patent.").
The analysis is relatively simple if the invention previously existed
<span CLASS="page_no" data-cite="689 f 3d 1338" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1338" data-primary-citation="689 F.3d 1303">[*1338]</span> 
in nature exactly as claimed. For example, naturally existing minerals, a
plant found in the wild, and physical laws such as gravity or E=mc<sub>2</sub> are not
patentable subject matter, even if they were "discovered" by an enterprising
inventor. <i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 309</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Even when an invention does not exist in nature in the claimed state, it
may still be directed to subject matter that is not patentable. For example,
in <i>Funk Brothers</i>, the Supreme Court held a patent to a combination of
multiple naturally occurring bacterial strains was not patentable. Although
there was "an advantage in the combination," which was apparently "new and
useful," none of the bacterial strains "acquire[ed] a different use" in
combination. <i>Funk Bros.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">333 U.S. at 131-32</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>. The aggregation
of the bacterial strains into a single product produced "no new bacteria, no
change in the six species of bacteria, and no enlargement of the range of
their utility. Each species has the same effect it always had. The bacteria
perform in their natural way. . . . They serve the ends nature originally
provided and act quite independently of any effort of the patentee." <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20U.S.%20127&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In contrast, the Supreme Court held bacteria that included extra genetic
material introduced by the inventor were "a nonnaturally occurring
manufacture or composition of matter &mdash; a product of human ingenuity 'having
a distinctive name, character [and] use'" and therefore patentable.
<i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 309-310</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a> (quoting <i>Hartranft v.</i>
<i>Wiegmann</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=121%20us%20609&amp;summary=yes#jcite">121 U.S. 609</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=121%20us%20609&amp;summary=yes#jcite">615</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=7%20supreme%20court%201240&amp;summary=yes#jcite">7 S.Ct. 1240</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=30%20l%20ed%201012&amp;summary=yes#jcite">30 L.Ed. 1012</a> (1887)).
<i>Chakrabarty</i> explained that there is no distinction between inventions based
on living and inanimate objects for the purpose of the patent statute;
instead, the "relevant distinction" for the section 101 analysis is "between
products of nature . . . and human-made inventions." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id. at 312-13</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>. Even if the invention was based on nature, arid resulted in
a living organism, it may fall within the scope of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20U.S.C.%20%20101&amp;summary=yes#jcite">section 101</a>. For example,
"the work of the plant breeder In <span CLASS="page_no" data-cite="2012 bl 210726 p 34" data-cite-type="Bloomberg" data-cite-pageno="34" data-primary-citation="">[***34]</span> aid of nature' was patentable invention"
because "'a plant discovery resulting from cultivation is unique, isolated,
and is not repeated by nature, nor can it be reproduced by nature unaided by
man.'" <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id.</a></i> (quoting S.Rep. No. 315, 71st Cong., 2d Sess., 6-8 (1930)). In
<i>Chakrabarty</i>, the intervention of man resulted in bacteria with "markedly
different characteristics" from nature and "the potential for significant
utility," resulting in patentable subject matter. <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id.</a></i> at <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=310&amp;summary=yes#jcite">310</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Funk Brothers</i> and <i>Chakrabarty</i> do not stake out the exact bounds of
patentable subject matter. Instead, each applies a flexible test to the
specific question presented in order to determine whether the claimed
invention falls within one of the judicial exceptions to patentability. <i>Funk</i>
<i>Brothers</i> indicates that an invention which "serve[s] the ends nature
originally provided" is likely unpatentable subject matter, but an invention
that is an "enlargement of the range of . . . utility" as compared to nature
may be patentable. <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">333 U.S. at 131</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>. Likewise, <i>Chakrabarty</i>
illustrates that an invention <span CLASS="page_no" data-cite="103 uspq 2d 1707" data-cite-type="ReporterOfDecisions" data-cite-pageno="1707" data-primary-citation="103 U.S.P.Q.2d 1681">[**1707]</span> with a distinctive name, character, and use,
e.g., markedly different characteristics with the potential for significant
utility, is patentable subject matter. <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 309-10</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.
Although the two cases result in different outcomes, the inquiry itself is
similar.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Courts applied an analogous patentability inquiry long before <i>Funk</i>
<i>Brothers</i> or <i>Chakrabarty.</i> In one notable case, Judge Learned Hand held that
purified adrenaline, a natural product, was patentable subject matter. Judge
Hand explained that even if the claimed purified adrenaline
<span CLASS="page_no" data-cite="689 f 3d 1339" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1339" data-primary-citation="689 F.3d 1303">[*1339]</span> 
were "merely an extracted product without change, there is no rule that such
products are not patentable." <i>Parke-Davis &amp; Co. v. H.K. Mulford Co.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XFLB0H?jcsearch=189%20f%2095&amp;summary=yes#jcite">189 F. 95</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XFLB0H?jcsearch=189%20f%2095&amp;summary=yes#jcite">103</a> (S.D.N.Y.1911). This is because "while it is of course
possible logically to call this a purification of the principle" the
resulting purified adrenaline was "for every practical purpose a new thing
commercially and therapeutically." <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XFLB0H?jcsearch=189%20F.%2095&amp;summary=yes#jcite">Id</a>.</i> Similarly, in a case applying the
Patent Act of 1952,<a HREF="#fn101" name="fnref_fn101">[fn1]</a> purified vitamin B-12, another natural product, was
also held patentable subject matter within the meaning of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20U.S.C.%20%20101&amp;summary=yes#jcite">section 101</a>. <i>Merck</i>
<i>&amp; Co. v. Olin Mathieson Chem. Corp.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X44LSI?jcsearch=253%20f%202d%20156&amp;summary=yes#jcite">253 F.2d 156</a> (4th Cir.1958). The Fourth
Circuit explained that purified vitamin B-12 was "far from the premise of
the [naturally occurring] principle. . . . The new product, not just the
method, had such advantageous characteristics as to replace the [naturally
occurring] liver products. What was produced was, in no sense, an old
product." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X44LSI?jcsearch=253%20F.2d%20156&amp;summary=yes#jcite">Id. at 162-63</a>. These purified pharmaceutical cases are both
consistent with Supreme Court precedent: the purified substance was "a new
thing . . . therapeutically," <i>Parke-Davis</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XFLB0H?jcsearch=189%20f%2095&amp;summary=yes#jcite">189 F. at 103</a>, and had such
"advantageous characteristics" that what was produced by purification "was,
in no sense, an old product." <i>Merck</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X44LSI?jcsearch=253%20f%202d%20156&amp;summary=yes#jcite">253 F.2d at 162-63</a>. In other words, the
purified natural products were held to have "markedly different
characteristics," as compared to the impure products, which resulted in "the
potential for significant utility." <i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 310</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In contrast, mere purification of a naturally occurring element is
typically insufficient to make <span CLASS="page_no" data-cite="2012 bl 210726 p 35" data-cite-type="Bloomberg" data-cite-pageno="35" data-primary-citation="">[***35]</span> it patentable subject matter. For example,
our predecessor court held that claims to purified vanadium and purified
uranium were not patentable subject matter since these were naturally
occurring elements with inherent physical properties unchanged upon
purification. <i>See In re Marden</i>, 18 CCPA 1057, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIE30V?jcsearch=47%20f%202d%20958&amp;summary=yes#jcite">47 F.2d 958</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIE30V?jcsearch=47%20f%202d%20958&amp;summary=yes#jcite">959</a> (1931)
("[P]ure vanadium is not new in the inventive sense, and, it being a product
of nature, no one is entitled to a monopoly of the same."); <i>In re Marden</i>,
18 CCPA 1046, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIDRLV?jcsearch=47%20f%202d%20957&amp;summary=yes#jcite">47 F.2d 957</a> (1931) ("ductile uranium" not patentable because
uranium is inherently ductile). Likewise, claims to purified ductile
tungsten were not patentable subject matter since pure tungsten existed in
nature and was inherently ductile. <i>General Electric Co. v. De Forest Radio</i>
<i>Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X449IM?jcsearch=28%20f%202d%20641&amp;summary=yes#jcite">28 F.2d 641</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X449IM?jcsearch=28%20f%202d%20641&amp;summary=yes#jcite">643</a> (3d Cir.1928). In each of these cases, purification
did not result in an element with new properties. Instead, the court held
the naturally occurring element inherently had the same characteristics and
utility (e.g. ductility) as the claimed invention. Consistent with <i>Funk</i>
<i>Brothers</i> and <i>Chakrabarty</i>, the claims all fell within the laws of nature
exception.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As illustrated by these examples, courts have long applied the principles
articulated in <i>Funk Brothers</i> and <i>Chakrabarty</i> to different factual scenarios
in order to determine whether an invention, as claimed, falls into the laws
of nature exception. I see no reason to deviate from this longstanding
flexible approach in this case.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We reconsider whether the claims at issue in this case are directed to
patentable subject matter following the remand from the Supreme Court in
light of its opinion in <i>Mayo Collaborative Services v. Prometheus</i>
<i>Laboratories, Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=132%20S.%20Ct.%201794&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">132 S.Ct. 1289</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HCFF6003?jcsearch=182%20l%20ed%202d%20321&amp;summary=yes#jcite">182 L.Ed.2d 321</a> (2012)
(<i>Prometheus</i>). While the <i>Prometheus</i>
<span CLASS="page_no" data-cite="689 f 3d 1340" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1340" data-primary-citation="689 F.3d 1303">[*1340]</span> 
decision does not control the outcome in this case, it is nonetheless
instructive regarding the scope of the law of nature exception. As an
initial matter, the <i>Prometheus</i> discussion of laws of nature (process claims)
clearly ought to apply equally to manifestations of nature (composition
claims). Myriad's argument that <i>Prometheus</i> is constrained to methods is an
untenable position.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the <i>Prometheus</i> court explained: "If a law of nature is not patentable,
then neither is a process reciting a law of nature, unless that process has
additional features that provide practical assurance that the process is
more than a drafting effort designed to monopolize the law of nature
itself." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20S.%20Ct.%201289&amp;summary=yes#jcite">Id. at 1297</a>. <i>Prometheus</i> did not, however, overturn <i>Funk Brothers</i> or
<i>Chakrabarty</i>; cases clearly more <span CLASS="page_no" data-cite="103 uspq 2d 1708" data-cite-type="ReporterOfDecisions" data-cite-pageno="1708" data-primary-citation="103 U.S.P.Q.2d 1681">[**1708]</span> analogous to the one before us. Using the
framework of <i>Funk Brothers</i> and <i>Chakrabarty</i> in conjunction with the direction
of <i>Prometheus</i>, the applicable principles are: (1) laws of
nature/manifestations of nature are not patentable; (2) a composition of
matter with "markedly different characteristics" from that found in nature
with the potential for significant utility is directed to patentable subject
matter.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Does the isolation process change the DNA from an unpatentable
manifestation of nature into a patentable composition of matter? <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20S.%20Ct.%201289&amp;summary=yes#jcite">Id. at
1299</a>. Does the claimed isolated DNA have markedly <span CLASS="page_no" data-cite="2012 bl 210726 p 36" data-cite-type="Bloomberg" data-cite-pageno="36" data-primary-citation="">[***36]</span> different characteristics
with the potential for significant utility, e.g., an "enlargement of the
range of . . . utility" as compared to nature? <i>Chakrabarty</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 309-310</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>; <i>Funk Bros.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">333 U.S. at 131</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The isolated DNA claims of the patents in suit fall into two categories.
The first category of claims is directed to isolated sequences that are
identical to naturally <i>occurring gene</i> sequences. These include claims
encompassing both the isolated full length gene sequence (e.g. claim 1 of
&prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>), which are thousands of nucleotides, and claims to shorter
isolated DNA strands, with as few as fifteen nucleotides, whose nucleotide
sequence is found on the chromosome (e.g. claim 5 of &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>). The
second category of claims is directed to isolated DNA sequences that are
different from the naturally occurring gene sequences. These include claims
to isolated cDNA molecules (e.g. claim 2 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>), which differ
from the natural gene sequence in that the introns are removed, and are the
opposite (complementary) sequence of the naturally occurring RNA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The cDNA claims present the easiest analysis. Although the plaintiffs (now
plaintiff) in the suit argue, and the district court held, that cDNA falls
within the "laws of nature" exception to <cite>section 101</cite> patentability, the
claimed cDNA sequences do <i>not</i> exist in nature. Moreover, since cDNA has all
of the introns removed, and only contains the coding nucleotides, it can be
used to express a protein in a cell which does <i>not</i> normally produce it. Of
course, the claimed isolated cDNA is inspired by nature &mdash; after all
naturally occurring RNA is the template upon which cDNA is constructed.
Because it is used as a template, however, cDNA has a complementary sequence
of nucleotides, and therefore has a <i>completely different</i> nucleotide sequence
than the RNA. Moreover, DNA has a different chemical structure than RNA,
including a different base (T instead of U, respectively) and sugar units
(deoxyribose instead of ribose, respectively). This results in, among other
things, greater stability for the DNA sequence as compared to the RNA
sequence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DNA sequences thus have a distinctive character and use, with markedly
different chemical characteristics from either the naturally occurring RNA
or any continuous
<span CLASS="page_no" data-cite="689 f 3d 1341" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1341" data-primary-citation="689 F.3d 1303">[*1341]</span> 
DNA sequence found on the chromosome. The claimed isolated cDNA sequences
are the creation of man, made using biological tools and the naturally
occurring mRNA as a template cDNA is therefore not one of the
"'manifestations of . . . nature, free to all men and reserved exclusively
to none'" that falls outside of the patent system. <i>Chakrabarty</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 309</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a> (quoting <i>Funk Bros.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">333 U.S. at 130</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>). I decline to extend the laws of nature exception to reach
entirely manmade sequences of isolated cDNA, even if those sequences are
inspired by a natural template. I therefore join the majority opinion with
respect to the claims to cDNA sequences.<a HREF="#fn201" name="fnref_fn201">[fn2]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DNA sequences that have the same pattern of DNA bases as a natural gene,
in whole or in part, present a more difficult issue. Unlike the isolated
cDNA molecules, whose sequence is not present in nature, the isolated DNA
claims <span CLASS="page_no" data-cite="2012 bl 210726 p 37" data-cite-type="Bloomberg" data-cite-pageno="37" data-primary-citation="">[***37]</span> include nucleotide sequences which are found in the human body,
albeit as part of a much larger molecule, the chromosome. To the extent the
majority rests its conclusion on the chemical differences between genomic
and isolated DNA (breaking the covalent bonds), I cannot agree that this is
sufficient to hold that the claims to human genes are directed to patentable
subject matter. I agree that isolated genes are a different molecule and are
therefore not squarely analogous to unpatentable minerals, created by nature
without the assistance of man. The claimed isolated DNA molecules, which are
truncations (with different ends) of the naturally occurring DNA found as
part of the chromosome in nature, are not naturally produced without the
intervention of man.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I begin with the short isolated sequences such as those covered by claim 5
which is directed to "an isolated DNA having at least 15 nucleotides of the
DNA of claim 1." This claim covers a sequence as short as 15 nucleotides and
arguably as long as the entire gene. <span CLASS="page_no" data-cite="103 uspq 2d 1709" data-cite-type="ReporterOfDecisions" data-cite-pageno="1709" data-primary-citation="103 U.S.P.Q.2d 1681">[**1709]</span> For this claim to be patent eligible,
all of the sequences ranging from the 15 nucleotide sequence to the full
gene must be patentable subject matter. The shorter isolated DNA sequences
have a variety of applications and uses in isolation that are new and
distinct as compared to the sequence as it occurs in nature. For example,
these sequences can be used as primers in a diagnostic screening process to
detect gene mutations. These smaller isolated DNA sequences &mdash; including
isolated radiolabeled sequences mirroring those on the chromosome &mdash; can also
be used as the basis for probes. Naturally occurring DNA cannot do this.
Unlike the isolated DNA, naturally occurring DNA simply does not have the
requisite chemical and physical properties needed to perform these
functions.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The ability to use isolated DNA molecules as the basis for diagnostic
genetic testing is clearly an "enlargement of the range of . . . utility" as
compared to nature. <i>Funk Bros.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">333 U.S. at 131</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>. In
<i>Prometheus</i>, the Supreme Court held that the claims at issue were not
directed to patentable subject matter because they merely "set forth laws of
nature &mdash; namely, relationships between concentrations of certain metabolites
in the blood and the likelihood that a dosage of a thiopurine drug will
prove ineffective or cause harm." <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">132 S.Ct. at 1296-97</a>. The claimed
relationship was "a consequence of
<span CLASS="page_no" data-cite="689 f 3d 1342" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1342" data-primary-citation="689 F.3d 1303">[*1342]</span> 
the ways in which thiopurine compounds are metabolized by the body &mdash;
entirely natural processes." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20S.%20Ct.%201289&amp;summary=yes#jcite">Id. at 1297</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There is no suggestion that the human body naturally uses 15-mers as
primers to synthesize DNA, or that the attendant process of "probing" a
patient's DNA to detect a mutation is somehow a natural law. The ability to
use a short strand of DNA as a primer or probe to determine whether a
patient has a mutation is a new and important utility substantially
different from the role of that DNA as it occurs in nature. Indeed, many of
the plaintiffs in this case submitted declarations indicating that they
wanted to either offer such testing or receive such testing. Unlike
<i>Prometheus</i>, the claims <span CLASS="page_no" data-cite="2012 bl 210726 p 38" data-cite-type="Bloomberg" data-cite-pageno="38" data-primary-citation="">[***38]</span> to short isolated strands of DNA are not directed to
the relationship between the mutation and cancer, but rather to a new tool
that can be used to determine if that relationship exists. The short
isolated DNA sequences have markedly different properties which are directly
responsible for their new and significant utility. <i>Chakrabarty</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 309-10</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>. It is not the chemical change alone, but
that change combined with the different and beneficial utility that leads me
to conclude that small isolated DNA fragments are patentable subject matter.
<i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id. at 310</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In fact, much of the dissent's analysis with regard to the full gene would
seem to support my conclusion that small isolated DNA molecules are directed
to patent-eligible subject matter. The dissent explains why the baseball bat
is directed to patent eligible subject matter: "man has defined the parts
that are to be retained and the parts that are to be discarded, and he has
molded the retained portion into a product that bears little resemblance to
that which occurs naturally." Dissent at 1353. The exact same thing is true
with regard to primer and probe claims. Man has whittled the chromosomal DNA
molecule down to a 15 nucleotide sequence &mdash; defining the parts to be
retained and discarded.<a HREF="#fn301" name="fnref_fn301">[fn3]</a> And the result is a product with a function
(primer or probe) that is entirely different from the full gene from which
it was obtained.<a HREF="#fn401" name="fnref_fn401">[fn4]</a> I conclude that the small, isolated DNA molecules are
an alteration of the natural product "with markedly different
characteristics from any found in nature and one having the potential for
significant utility." <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 310</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Turning now to the longer strands of isolated DNA, isolated strands which
include most or all of the gene present a more difficult case. Some of the
claims at issue, for example &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> claim 5, are genus claims, drafted
broadly enough to include both short fragments as well as the entire
isolated gene sequence. While I ultimately conclude that these longer
isolated sequences, including the isolated
<span CLASS="page_no" data-cite="689 f 3d 1343" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1343" data-primary-citation="689 F.3d 1303">[*1343]</span> 
gene sequence as a whole, are also patentable subject matter, I do so for a
reason different than for the shorter sequences.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  All of the same structural arguments apply to any length of isolated DNA
so, like the shorter strands, an isolated DNA coding for a <span CLASS="page_no" data-cite="103 uspq 2d 1710" data-cite-type="ReporterOfDecisions" data-cite-pageno="1710" data-primary-citation="103 U.S.P.Q.2d 1681">[**1710]</span> gene does have a
literal chemical difference from the gene as it appears on the chromosome.
Unlike the shorter strands of isolated DNA, the chemical and structural
differences in the isolated gene do not clearly lead to an "enlargement of
the range of . . . utility" as compared to nature. <i>Funk Bros.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">333 U.S. at 131</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>. For example, the full length gene is too
large to be used as a probe. <i>See</i> J.A. 4322 (a probe is a DNA molecule
usually 100-1,000 bases long). Likewise, an entire isolated gene appears
unsuitable for use as a primer in genetic screening for mutations in that
same gene. <i>See</i> J.A. 4323 (Primers "are complementary to an exact location of
a much larger target DNA molecule."). The isolated full length gene does not
clearly have a new utility and appears to simply serve the same ends devised
by nature, namely to act as a gene encoding a protein <span CLASS="page_no" data-cite="2012 bl 210726 p 39" data-cite-type="Bloomberg" data-cite-pageno="39" data-primary-citation="">[***39]</span> sequence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  If I were deciding this case on a blank canvas, I might conclude that an
isolated DNA sequence that includes most or all of a gene is not patentable
subject matter. The scope of the law of nature/manifestation of nature
exception was certainly enlarged in <i>Prometheus.</i> But we do not decide this
case on a blank canvas. Congress has, for centuries, authorized an expansive
scope of patentable subject matter. Likewise, the United States Patent
Office has allowed patents on isolated DNA sequences for decades, and, more
generally, has allowed patents on purified natural products for centuries.
There are now thousands of patents with claims to isolated DNA, and some
unknown (but certainly large) number of patents to purified natural products
or fragments thereof.<a HREF="#fn501" name="fnref_fn501">[fn5]</a> As I explain below, I believe we must be
particularly wary of expanding the judicial exception to patentable subject
matter where both settled expectations and extensive property rights are
involved.<a HREF="#fn601" name="fnref_fn601">[fn6]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For more than a decade the Patent Office's policy has been that "[a]n
isolated and purified DNA molecule that has the same sequence as a naturally
occurring gene is eligible for a patent because . . . that DNA molecule does
not occur in that isolated form in nature. . . ." <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/1?citation=66%20Fed.Reg.%201092&amp;summary=yes#jcite">66 Fed.Reg. 1092</a>, 1093
(Jan. 5, 2001). I do not agree
<span CLASS="page_no" data-cite="689 f 3d 1344" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1344" data-primary-citation="689 F.3d 1303">[*1344]</span> 
with the dissent's characterization of the PTO position as perfunctory. The
PTO concluded that isolated DNA is patentable because it is different from
what is found in nature &mdash; the process of synthesizing it or isolating it
changes it. While the PTO lacks substantive rule making authority, it is not
without expertise in this area. The explicit statement of the Patent
Office's position on isolated DNA, however, is simply a continuation of a
longstanding and consistent policy of allowing patents for isolated natural
products. <i>See <cite>id</cite>.</i> (noting <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X8G203GGJ?jcsearch=U.S.%20Patent%20141,%20072&amp;summary=yes#jcite">U.S. Patent 141, 072</a>, claiming "[y]east, free from
organic germs of disease," issued to Louis Pasteur in 1873); <i>cf. In re</i>
<i>Bergstrom</i>, 57 CCPA 1240, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIHP17?jcsearch=427%20f%202d%201394&amp;summary=yes#jcite">427 F.2d 1394</a> (1970) (isolated prostaglandins
patentable). According to the Patent Office, isolated DNA is no different
from the isolated natural products of <i>Parke-Davis. See</i><cite>66 Fed.Reg. at 1093</cite>
(quoting <i>Parke-Davis</i>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Even before the current guidelines formalized the Patent Office's
position, it granted patents to human genes in the early 1980s, and
subsequently issued thousands of patents on "isolated DNA." Majority at
1332-33. In fact, claims similar to the ones at issue in this case have been
the focal point of important litigation. For example, <i>Amgen, Inc. v. Chugai</i>
<i>Pharmaceutical Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X31TSG?jcsearch=927%20f%202d%201200&amp;summary=yes#jcite">927 F.2d 1200</a> (Fed.Cir.1991) involved a claim to "'[a]
purified and isolated DNA sequence consisting essentially of a DNA sequence
encoding human erythropoietin.'" <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X31TSG?jcsearch=927%20F.2d%201200&amp;summary=yes#jcite">Id. at 1203-04</a> (quoting <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X21O060020J?jcsearch=usp%204703008&amp;summary=yes#jcite">U.S. Patent No.
4,703,008</a>, claim 2). We affirmed that this claim was valid and infringed.
<i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X31TSG?jcsearch=927%20F.2d%201200&amp;summary=yes#jcite">Id. at 1219</a>. Erythropoietin, also known as EPO, went on to become the
biggest-selling biotechnology drug developed to that point, resulted in
billions of dollars in sales, and accounted for over 50% of Amgen's revenue
in 1997. <i>Amgen, Inc. v. Hoechst Marion Roussel, Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X27RTO?jcsearch=126%20f%20supp%202d%2069&amp;summary=yes#jcite">126 F.Supp.2d 69</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X27RTO?jcsearch=126%20f%20supp%202d%2069&amp;summary=yes#jcite">77</a>
(<span CLASS="page_no" data-cite="103 uspq 2d 1711" data-cite-type="ReporterOfDecisions" data-cite-pageno="1711" data-primary-citation="103 U.S.P.Q.2d 1681">[**1711]</span> D.Mass.2001). Isolated DNA claims, at <span CLASS="page_no" data-cite="2012 bl 210726 p 40" data-cite-type="Bloomberg" data-cite-pageno="40" data-primary-citation="">[***40]</span> least in the case of Amgen, represent
crucial and exceedingly valuable property rights.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The settled expectations of the biotechnology industry &mdash; not to mention
the thousands of issued patents &mdash; cannot be taken lightly and deserve
deference. This out-pouring of scientific creativity, spurred by the patent
system, reflects a substantial investment of time and money by the
biotechnology industry to obtain property rights related to DNA sequences.
The type of fundamental alteration in the scope of patentable subject matter
argued in this case "risk[s] destroying the legitimate expectations of
inventors in their property." <i>Festo Corp. v. Shoketsu Kinzoku Kogyo</i>
<i>Kabushiki Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=535%20us%20722&amp;summary=yes#jcite">535 U.S. 722</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=535%20us%20722&amp;summary=yes#jcite">739</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=122%20supreme%20court%201831&amp;summary=yes#jcite">122 S.Ct. 1831</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=152%20l%20ed%202d%20944&amp;summary=yes#jcite">152 L.Ed.2d 944</a> (2002). I
believe leaving intact the settled expectations of property owners is
particularly important in light of the large number of property rights
involved, both to isolated DNA and to purified natural products generally.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court has warned that "courts must be cautious before adopting
changes that disrupt the settled expectations of the inventing community."
<i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=535%20U.S.%20722&amp;summary=yes#jcite">Id. at 739</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=122%20supreme%20court%201831&amp;summary=yes#jcite">122 S.Ct. 1831</a>. The settled expectations of the inventing
community with respect to isolated DNA claims are built upon the broad
language of the statute, judicial precedent, such as <i>Parke-Davis</i> and <i>Merck</i>,
and the Patent Office's longstanding policy and practice. Neither <i>Funk</i>
<i>Brothers</i> nor <i>Chakrabarty</i> purported to overrule either the early cases or the
Patent Office's practice; indeed, as discussed <i>supra</i>, these cases weigh the
same considerations as <i>Parke-Davis</i> and <i>Merck</i>. "'To change so substantially
the rules of the game now,'" after more than a century of practice, "'could
very well subvert the
<span CLASS="page_no" data-cite="689 f 3d 1345" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1345" data-primary-citation="689 F.3d 1303">[*1345]</span> 
various balances the PTO sought to strike when issuing the numerous patents
which have not yet expired and which would be affected by our decision.'"
<i>Festo</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=535%20us%20722&amp;summary=yes#jcite">535 U.S. at 739</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=122%20supreme%20court%201831&amp;summary=yes#jcite">122 S.Ct. 1831</a> (quoting <i>Warner-Jenkinson Co. v.</i>
<i>Hilton Davis Chem. Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CCSV?jcsearch=520%20us%2017&amp;summary=yes#jcite">520 U.S. 17</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CCSV?jcsearch=520%20us%2017&amp;summary=yes#jcite">32</a> n. 6, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CCSV?jcsearch=117%20supreme%20court%201040&amp;summary=yes#jcite">117 S.Ct. 1040</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CCSV?jcsearch=137%20l%20ed%202d%20146&amp;summary=yes#jcite">137 L.Ed.2d 146</a> (1997)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although the Patent Office has consistently followed the same policy for a
decade (and arguably a century or more), the United States, as an amicus,
now argues that the Patent Office's published guidelines are incorrect and a
misstatement of the law. In place of these guidelines, the government
suggested that a "magic microscope" would provide a useful metaphor for
guiding our <cite>section 101</cite> analysis. The magic microscope, however, would not
see the claimed DNA molecules at issue in this case. An isolated DNA
molecule has different chemical bonds as compared to the "unisolated"
sequence in the chromosome (the ends are different). In short, the claimed
molecules cannot be seen in nature through the magic microscope. While you
may be able to see the order of DNA nucleotides in the chromosome, the
isolated fragment of DNA is a different molecule. Creating the claimed
isolated DNA sequences therefore results in a distinctly unnatural
molecule.<a HREF="#fn701" name="fnref_fn701">[fn7]</a> Even the dissent agrees that the isolated DNA molecules at
issue require cleaving chemical bonds, though it disputes the importance of
the resulting distinct "'molecular species.'" Dissent at 1350-51 (quoting
Linus Pauling, <i>The Nature of the Chemical <span CLASS="page_no" data-cite="2012 bl 210726 p 41" data-cite-type="Bloomberg" data-cite-pageno="41" data-primary-citation="">[***41]</span> Bond</i> 6 (3d ed.1960)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The dissent claims that the Patent Office's past views are "substantially
undermined by the position the government has taken in this case." Dissent
at 1357-58. The Patent Office's prior practice, however, is particularly
important since it resulted in a large number of property rights over the
past decades. If the government decided to change course in the Patent
Office, and decline to issue new patents to isolated genes, it would not
impact these existing property rights. This, however, is not what the
government argues in this case. Instead the government argues for an
entirely different interpretation of the law that would destroy existing
property rights. Although the dissent points out that <i>Chakrabarty</i> overturned
the Patent Office's practice of denying patents to microorganisms, there is
a clear difference between allowing additional patent protection where none
previously existed, and denying patent protection decades (or centuries)
after the fact, thereby eliminating a large number of property rights.
<i>Chakrabarty</i>, consistent with the broad language of the statute, allowed
additional patents where none previously existed. In contrast, the
government proposes to <span CLASS="page_no" data-cite="103 uspq 2d 1712" data-cite-type="ReporterOfDecisions" data-cite-pageno="1712" data-primary-citation="103 U.S.P.Q.2d 1681">[**1712]</span> destroy existing property rights based on a judge
made exception to that same broad language. This is a dramatic step that I
believe is best left to the Congress.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nevertheless, the government claims that "this is a pure question of law"
and
<span CLASS="page_no" data-cite="689 f 3d 1346" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1346" data-primary-citation="689 F.3d 1303">[*1346]</span> 
that we can therefore feel free to ignore the years of Patent Office
practice and the accompanying expectations that practice created within the
industry. The government argues that we should not defer to the broad
language (all but unchanged since 1793) provided by Congress in the patent
statute, or allow Congress to decide whether it is necessary to correct the
Patent Office's practice through legislation. It is tempting to use our
judicial power in this fashion, especially when the patents in question
raise substantial moral and ethical issues related to awarding a property
right to isolated portions of human DNA &mdash; the very thing that makes us
humans, and not chimpanzees.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The invitation is tempting, but I decline the opportunity to act where
Congress has chosen not to. Congress at least implicitly approved of the
Patent Office's policy of awarding patents on genes and DNA sequences. For
example, Congress included, as part of the Patent Office's appropriations,
language affirming the Patent Office's interpretation of section 101 to
prohibit patents on human organisms. Consolidated Appropriations Act, 2004,
Pub.L. No. <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/1?citation=USACTS%20108-199&amp;summary=yes#jcite">108-199</a>, <cite>&sect; 634</cite>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/1?citation=118%20stat%203&amp;summary=yes#jcite">118 Stat. 3</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/1?citation=118%20stat%203&amp;summary=yes#jcite">101</a>. Although Congress was aware
"that there are many institutions . . . that have extensive patents on human
genes," 149 Cong. Rec. H7248, H7274, it explicitly declined to implement
legislation to "affect any of those current existing patents." 149 Cong.
Rec. E2417-01. To the contrary, it made clear that the language related to
"human organisms" was not intended to change the Patent Office's policy with
respect to claims to genes, stem cells, or other similar inventions.<a HREF="#fn801" name="fnref_fn801">[fn8]</a>
Far from <span CLASS="page_no" data-cite="2012 bl 210726 p 42" data-cite-type="Bloomberg" data-cite-pageno="42" data-primary-citation="">[***42]</span> oblivious to the patenting of genes, Congress introduced and
declined to pass several bills which would put a moratorium on gene
patents,<a HREF="#fn901" name="fnref_fn901">[fn9]</a> authorize funding for the study of whether genes ought to be
patentable,<a HREF="#fn1001" name="fnref_fn1001">[fn10]</a> and exempt from patent infringement anyone who uses
patented genes for non-commercial research purposes or medical practitioners
who use genetic diagnostic tests.<a HREF="#fn1101" name="fnref_fn1101">[fn11]</a> Congress is obviously aware of the
issues presented in this case and I believe "[a]ny recalibration of the
standard of [patentability] remains in its hands." <i>Microsoft Corp. v. i4i</i>
<i>Ltd.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1FI916003?jcsearch=131%20S.Ct.%202238&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. 2238</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">2252</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1FI916003?jcsearch=180%20l%20ed%202d%20131&amp;summary=yes#jcite">180 L.Ed.2d 131</a> (2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The judiciary cannot engage in an <i>ad hoc</i> innovation-based analysis, which
is why the exceptions to patentability apply
<span CLASS="page_no" data-cite="689 f 3d 1347" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1347" data-primary-citation="689 F.3d 1303">[*1347]</span> 
only to the clearest cases: a new mineral discovered in the earth, or a new
plant found in the wild, or E=mc<sub>2</sub>, or the law of gravity. It is Congress,
with "the constitutional authority and the institutional ability to
accommodate fully the varied permutations of competing interests that are
inevitably implicated by such new technology," <i>Sony Corp. of America v.</i>
<i>Universal City Studios, Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CAPO?jcsearch=464%20us%20417&amp;summary=yes#jcite">464 U.S. 417</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CAPO?jcsearch=464%20us%20417&amp;summary=yes#jcite">431</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CAPO?jcsearch=104%20supreme%20court%20774&amp;summary=yes#jcite">104 S.Ct. 774</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CAPO?jcsearch=78%20l%20ed%202d%20574&amp;summary=yes#jcite">78 L.Ed.2d 574</a> (1984), who must decide whether it is necessary to change the
scope of section 101 to exclude the kind of isolated DNA claims at issue
here. It is not clear to me that <i>Chakrabarty, Funk Brothers</i>, or <i>Prometheus</i>
leads inexorably to the conclusion that isolated DNA molecules are not
patentable subject matter. I decline the invitation to broaden the law of
nature exception.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Given the complicated technology and conflicting incentives at issue here,
any change must come from Congress. <i>See Gottschalk v. Benson</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=409%20us%2063&amp;summary=yes#jcite">409 U.S. 63</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=409%20us%2063&amp;summary=yes#jcite">72-73</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=93%20supreme%20court%20253&amp;summary=yes#jcite">93 S.Ct. 253</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C8B8?jcsearch=34%20l%20ed%202d%20273&amp;summary=yes#jcite">34 L.Ed.2d 273</a> (1972) (A section 101 analysis raises
"considerable problems . . . which only committees of Congress can manage,
for broad powers of investigation are needed, including hearings which
canvass the wide variety of views which those operating in this field
entertain. The technological problems tendered [by the <span CLASS="page_no" data-cite="103 uspq 2d 1713" data-cite-type="ReporterOfDecisions" data-cite-pageno="1713" data-primary-citation="103 U.S.P.Q.2d 1681">[**1713]</span> parties] . . .
indicate to us that considered action by the Congress is needed.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  IV.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "The rule that the discovery of a law of nature cannot be patented rests .
. . on the . . . fundamental understanding that they are not the kind of
'discoveries' that the statute was enacted to protect." <i>Flook</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C9KM?jcsearch=437%20us%20584&amp;summary=yes#jcite">437 U.S. at 593</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C9KM?jcsearch=98%20supreme%20court%202522&amp;summary=yes#jcite">98 S.Ct. 2522</a>. Is an isolated kidney patentable? Probably
not, but as far as I can tell nobody ever thought isolating organs from
someone's body was the kind of discovery "that the statute was enacted to
protect." In contrast, purifying or isolating natural products has
historically been exactly the kind of discovery protected by the patent
statutes. There is a century-long history of affirming patent protection for
isolated and purified biological products ranging from hormones to vitamins
to proteins to antibiotics. These inventions must have seemed miraculous at
the time, providing previously unknown therapeutic options to treat
sickness. The fact that these molecules might have existed in nature did not
foreclose patent protection in view of the extraordinary benefits accessible
to man after isolation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Patent Office has, for more than a decade, affirmatively stated its
belief that <span CLASS="page_no" data-cite="2012 bl 210726 p 43" data-cite-type="Bloomberg" data-cite-pageno="43" data-primary-citation="">[***43]</span> isolated DNA is patentable for the same reasons as isolated
vitamins or hormones. There is no indication from Congress that this view is
wrong; to the contrary, it appears Congress also believes DNA is patentable.
This long-term policy of protecting isolated DNA molecules has resulted in
an explosion of innovation in the biotechnology industry, an industry which,
unlike the financial services industry or even the software industry,
depends on patents to survive. Holding isolated DNA not patentable would
destroy long settled industry expectations for no reason other than a gut
feeling that DNA is too close to nature to be patentable, an arbitrary
decision based on a judge-made exception. I believe that isolated DNA
fragments, which have both chemical changes from the naturally occurring
genomic DNA as well as new utility, are "the kind of 'discoveries' that the
statute was enacted to protect." I therefore decline to extend the "laws of
nature" exception to include isolated DNA sequences.
<span CLASS="page_no" data-cite="689 f 3d 1348" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1348" data-primary-citation="689 F.3d 1303">[*1348]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This case typifies an observation by the late Chief Judge Markey, our
first Chief Judge, that "[o]nly God works from nothing. Men must work with
old elements." <i>Fromson v. Advance Offset Plate, Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X3HVSQ?jcsearch=755%20f%202d%201549&amp;summary=yes#jcite">755 F.2d 1549</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X3HVSQ?jcsearch=755%20f%202d%201549&amp;summary=yes#jcite">1556</a> n.
3 (Fed.Cir.1985) (quotation, citations omitted). Human DNA is, for better or
worse, one of the old elements bequeathed to men to use in their work. The
patents in this case revealed a new molecular understanding about ourselves;
"the inventions most benefiting mankind are those that 'push back the
frontiers of chemistry, physics, and the like.'" <i>Chakrabarty</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 316</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a> (quoting <i>Great A &amp; P. Tea Co. v. Supermarket</i>
<i>Corp.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C1RO?jcsearch=340%20us%20147&amp;summary=yes#jcite">340 U.S. 147</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C1RO?jcsearch=340%20us%20147&amp;summary=yes#jcite">154</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C1RO?jcsearch=71%20supreme%20court%20127&amp;summary=yes#jcite">71 S.Ct. 127</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C1RO?jcsearch=95%20l%20ed%20162&amp;summary=yes#jcite">95 L.Ed. 162</a> (1950)). We cannot,
after decades of patents and judicial precedent, now call human DNA fruit
from the poisonous tree, and punish those inquisitive enough to investigate,
isolate, and patent it. "Our task . . . is the narrow one of determining
what Congress meant by the words it used in the statute; once that is done
our powers are exhausted." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id. at 318</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>. This inquiry does not
have moral, ethical, or theological components. <i>Cf. </i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">id. at 316-17</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a> ("[W]e are without competence to entertain" arguments about
"the grave risks" generated by genetic research.). "The choice we are urged
to make is a matter of high policy for resolution within the legislative
process after the kind of investigation, examination, and study that
legislative bodies can provide and courts cannot." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id. at 317</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>. The patents in this case might well deserve to be excluded
from the patent system, but that is a debate for Congress to resolve. I will
not strip an entire industry of the property rights it has invested in,
earned, and owned for decades unchallenged under the facts of this case.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn101" name="fn101">[fn1]</a></span> The Patent Act of 1952 was the first time patentable subject matter
(the current <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20U.S.C.%20%20101&amp;summary=yes#jcite">section 101</a>) was separated out from novelty (the current
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVC003?jcsearch=35%20U.S.C.%20%20102&amp;summary=yes#jcite">section 102</a>). Previously, these two concepts were combined into a single
section.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn201" name="fn201">[fn2]</a></span> To the extent the claims to shorter portions of cDNA include only
naturally occurring sequences found in the chromosome, for example claim 6
of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>, my reasoning is the same as for the isolated sequences
of claim 5, discussed below.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn301" name="fn301">[fn3]</a></span> If adding functionality to a naturally occurring molecule, for example
adding a lipid chain, is a creation of man then removing functionality, for
example truncating a natural DNA sequence or protein to yield smaller
molecules with new properties should also be. In either case, it is the
intervention of man that created a new molecule. After all, the hand of man
is just as apparent in the David, created by removing stone from a block of
marble, as the ceiling of the Sistine Chapel, created by adding layers of
paint to an existing structure.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn401" name="fn401">[fn4]</a></span> The dissent analogizes the full BRCA gene to a slab of marble found in
the earth as distinct from the sculpture carved into it &mdash; which the dissent
indicates would be worthy of intellectual property protection. If the
multi-thousand nucleotide BRCA gene is the slab, isn't the 15 nucleotide
primer the sculpture?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn501" name="fn501">[fn5]</a></span> <i>See, e.g.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1G0OE04I8J?jcsearch=usp%203067099&amp;summary=yes#jcite">U.S. Patent 3,067,099</a> (claiming vancomycin, an antibiotic
produced by bacteria found in soil) and <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X218K47008J?jcsearch=usp%204552701&amp;summary=yes#jcite">U.S. Patent 4,552,701</a> (claiming a
vancomycin fragment produced by removing a sugar unit). A natural product
fragment, for example a naturally occurring antibiotic with a sugar moiety
removed, is highly analogous to isolated DNA. In each case, the claimed
molecule is a smaller fragment of a naturally occurring molecule, with some
naturally occurring functionality removed. <i>See</i> <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X218K47008J?jcsearch=usp%204552701&amp;summary=yes#jcite">U.S. Patent 4,552,701</a>,
col.3-4 (compare entry 2 with entries 10 and 13).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn601" name="fn601">[fn6]</a></span> My analysis of the claims at issue assumes that they do not include an
isolated, full length chromosome. I do not believe that a claim to an entire
chromosome, for example chromosome 17, is patentable subject matter. First,
there is no indication that the chromosome in isolation has markedly
different characteristics compared to the chromosome in nature. Second,
unlike claims to isolated genes, there is no indication of either settled
expectations or extensive property rights for claims to isolated
chromosomes. This is undoubtedly due to the small number of chromosomes as
compared to the number of genes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn701" name="fn701">[fn7]</a></span> This also illustrates why the government's analogies to situations
dealing with elements, for example lithium, are inapposite. Even assuming
the government's contention that lithium does not currently exist in
isolated form in nature, it is nevertheless clear that elemental lithium, a
basic building block provided by nature, at some point must have reacted
with, e.g., water to form the naturally occurring lithium salts. In
contrast, an isolated DNA sequence did not necessarily exist before reacting
further to produce the corresponding naturally occurring chromosomal DNA.
Unlike a lithium salt, the chromosome does not imply that an isolated DNA
molecule of 15 nucleotides &mdash; or even a gene &mdash; necessarily previously existed
as an isolated molecule in nature.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn801" name="fn801">[fn8]</a></span> "What I want to point out is that <i>the U.S. Patent Office has already</i>
<i>issued patents on genes</i>, stem cells, animals with human genes, and a host of
non-biologic products used by humans, but it has not issued patents on
claims directed to human organisms, including human embryos and fetuses. <i>My</i>
<i>amendment would not affect the former</i>, but would simply affirm the latter."
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/1?citation=149%20Cong.%20Rec.%20E2417&amp;summary=yes#jcite">149 Cong. Rec. E2417</a>-01 (emphasis added); <i>see also</i> <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/1?citation=157%20Cong.%20Rec.%20E1177&amp;summary=yes#jcite">157 Cong. Rec. E1177</a>-04
(resubmitting this testimony in the context of the current patent reform
legislation).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn901" name="fn901">[fn9]</a></span> At least one bill was introduced in Congress to put a moratorium on
patents to human genes or gene sequences. <i>See, e.g.</i>, The Animal and Gene
Patent Moratorium Bill (S.387 1993).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1001" name="fn1001">[fn10]</a></span> The Genomic Science and Technology Innovation Act of 2002
(H.R.3966).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1101" name="fn1101">[fn11]</a></span> The Genomic Research and Diagnostic Accessibility Act of 2002
(H.R.3967). As the bill's sponsor explained: "It is important to note that
this section would not overturn the commercial rights of patent holders. If
a research [organization] utilizing the exemption makes a commercially
viable finding, he or she would still have to negotiate any rights to market
the new discovery with the patent holder." <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/1?citation=148%20Cong.%20Rec.%20E353&amp;summary=yes#jcite">148 Cong. Rec. E353</a>-03.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  BEYSON, Circuit Judge, concurring in part and dissenting in part:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I concur with the portions of this court's judgment that are directed to
standing, the patentability of the cDNA claims, and the patentability of the
method claims. I respectfully dissent from the court's holding that Myriad's
BRCA gene claims and its claims to gene fragments are patent-eligible. In my
view, those claims are not directed to patentable subject matter, and the
court's decision, if sustained, will likely have broad consequences, <span CLASS="page_no" data-cite="2012 bl 210726 p 44" data-cite-type="Bloomberg" data-cite-pageno="44" data-primary-citation="">[***44]</span> such as
preempting methods for whole-genome sequencing, even though Myriad's
contribution to the field is not remotely consonant with such effects.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In its simplest form, the question in this case is whether an individual
can obtain patent rights to a human gene. From a common-sense point of view,
most observers would answer, "Of course not. Patents are for inventions. A
human gene is not an invention." The essence of Myriad's argument in this
case is to say that it has not patented a human <span CLASS="page_no" data-cite="103 uspq 2d 1714" data-cite-type="ReporterOfDecisions" data-cite-pageno="1714" data-primary-citation="103 U.S.P.Q.2d 1681">[**1714]</span> gene, but something quite
different &mdash; an <i>isolated</i> human gene, which differs from a native gene because
the process of extracting it results in changes in its molecular structure
(although not in its genetic code). We are therefore required to decide
whether the process of isolating genetic material from a human DNA molecule
makes the isolated genetic material a patentable invention. The court
concludes that it does; I conclude that it does not.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At the outset, it is important to identify the inventive contribution
underlying Myriad's patents. Myriad was not the first to map a BRCA gene to
its chromosomal location. That discovery was made by a team of researchers
led by Dr. Mary-Claire <i>King. See Jeff M.</i> Hall et al., <i>Linkage</i>
<span CLASS="page_no" data-cite="689 f 3d 1349" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1349" data-primary-citation="689 F.3d 1303">[*1349]</span> 
<i>of Early-Onset Familial Breast Cancer to Chromosome 17q21</i>, 250 Science 1684
(1990). And Myriad did not invent a new method of nucleotide sequencing.
Instead, it applied known sequencing techniques to identify the nucleotide
order of the BRCA genes.<a HREF="#fn102" name="fnref_fn102">[fn1]</a> Myriad's discovery of those sequences entailed
difficult work, and the identified sequences have had important applications
in the fight against breast cancer. But the discovery of the sequences is an
unprotectable fact, just like Dr. King's discovery of the chromosomal
location of the BRCA1 gene.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Of course, Myriad is free to patent applications of its discovery. As the
first party with knowledge of the sequences, Myriad was in an excellent
position to claim applications of that knowledge. Many of its unchallenged
claims are limited to such applications. <i>See, e.g.</i>, &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOK64208J?jcsearch=usp%205753441&amp;summary=yes#jcite">441 patent</a>, claim 21;
&prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2I0CE44GGJ?jcsearch=usp%205837492&amp;summary=yes#jcite">492 patent</a>, claim 22; &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>, claim 9. Yet some of Myriad's challenged
composition claims effectively preempt any attempt to sequence the BRCA
genes, including whole-genome sequencing. In my view, those claims encompass
unpatentable subject matter, and a contrary ruling is likely to have
substantial adverse effects on research and treatment in this important
field.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the majority and concurring opinions explain, the DNA claims at issue
in this case fall into three categories: claims that cover the isolated BRCA
genes (claim 1 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>, claim 1 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HH4643GOJ?jcsearch=usp%205693473&amp;summary=yes#jcite">473 patent</a>, and claims 1
and 6 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2I0CE44GGJ?jcsearch=usp%205837492&amp;summary=yes#jcite">492 patent</a>); claims that cover only, the BRCA cDNA (claims 2
and 7 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> and claim 7 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2I0CE44GGJ?jcsearch=usp%205837492&amp;summary=yes#jcite">492 patent</a>); and claims that
cover portions of the BRCA genes and cDNA as small as 15 nucleotides long
(claims 5 and 6 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>). I first address the claims to the BRCA
genes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the seminal case of <i>Diamond v. Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. 303</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=65%20l%20ed%202d%20144&amp;summary=yes#jcite">65 L.Ed.2d 144</a> (1980), the Supreme Court held that an
artificial life form could be patented. In the course of <span CLASS="page_no" data-cite="2012 bl 210726 p 45" data-cite-type="Bloomberg" data-cite-pageno="45" data-primary-citation="">[***45]</span> its opinion, and
critically for purposes of its reasoning, the Court stated that not all
living things or other items found in nature were subject to patenting. The
Court explained that although the language of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20U.S.C.%20%20101&amp;summary=yes#jcite">section 101</a> of the Patent Act
is broad, it is not the case that it "has no limits or that it embraces
every discovery." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id. at 309</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>. The Court then set forth the
general proposition that "laws of nature, physical phenomena, and abstract
ideas have been held not patentable." <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id</a>.</i> As examples, the Court noted that
"a new mineral discovered in the earth or a new plant found in the wild is
not patentable subject matter." Thus, even though a mineral or a plant is a
"composition of matter," and could be viewed as falling within a broad
construction of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20U.S.C.%20%20101&amp;summary=yes#jcite">section 101</a>, the Court explained that those "manifestations
of . . . nature" are not patentable subject matter, but are "free to all men
and reserved exclusively to none." <i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20U.S.%20303&amp;summary=yes#jcite">Id</a>.</i>, quoting <i>Funk Bros. Seed Co. v. Kalo</i>
<i>Inoculant Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">333 U.S. 127</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">130</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=92%20l%20ed%20588&amp;summary=yes#jcite">92 L.Ed. 588</a> (1948); <i>see</i>
<i>also Bilski v. Kappos</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20S.Ct.%203218&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20supreme%20court%203218&amp;summary=yes#jcite">130 S.Ct. 3218</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=130%20supreme%20court%203218&amp;summary=yes#jcite">3225</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DIKU0003?jcsearch=177%20l%20ed%202d%20792&amp;summary=yes#jcite">177 L.Ed.2d 792</a>
(2010).
<span CLASS="page_no" data-cite="689 f 3d 1350" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1350" data-primary-citation="689 F.3d 1303">[*1350]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Court in <i>Chakrabarty</i> held the artificial life form at issue in that
case to be patentable because the claim was "not to a hitherto unknown
natural phenomenon, but to a nonnaturally occurring manufacture or
composition of matter &mdash; a product of human ingenuity 'having a distinctive
name, character [and] use.'" <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 309-10</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>, quoting
<i>Hartranft v. Wiegmann</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=121%20us%20609&amp;summary=yes#jcite">121 U.S. 609</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=121%20us%20609&amp;summary=yes#jcite">615</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=7%20supreme%20court%201240&amp;summary=yes#jcite">7 S.Ct 1240</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BCV9?jcsearch=30%20l%20ed%201012&amp;summary=yes#jcite">30 L.Ed. 1012</a> (1887).
In distinguishing between naturally occurring substances and nonnaturally
occurring manufactures, the Court relied heavily on its earlier decision in
<i>Funk Brothers</i>, in which the inventor discovered that certain useful
bacterial strains did not exert an inhibitive effect on one another. Based
on that discovery, the inventor obtained a patent on a mixed culture of
those non-inhibitive strains. The Supreme Court held the product
unpatentable, however, because the bacteria remained structurally and
functionally the same as in their natural state. <span CLASS="page_no" data-cite="103 uspq 2d 1715" data-cite-type="ReporterOfDecisions" data-cite-pageno="1715" data-primary-citation="103 U.S.P.Q.2d 1681">[**1715]</span> <i>Funk Bros.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=333%20us%20127&amp;summary=yes#jcite">333 U.S. at 131</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5C19U?jcsearch=68%20supreme%20court%20440&amp;summary=yes#jcite">68 S.Ct. 440</a>. By contrast, because Chakrabarty had produced
"a new bacterium with markedly different characteristics from any found in
nature and one having the potential for significant utility," the Court held
Chakrabarty's invention to be patentable. <i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 310</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad's claims to the isolated BRCA genes seem to me to fall clearly on
the "unpatentable" side of the line the Court drew in <i>Chakrabarty.</i> Myriad is
claiming the genes themselves, which appear in nature on the chromosomes of
living human beings. The only material change made to those genes from their
natural state is the change that is necessarily incidental to the extraction
of the genes from the environment in which they are found in nature. While
the process of extraction is no doubt difficult, and may itself be
patentable, the isolated genes are not materially different from the native
genes. In this respect, the genes are analogous to the "new mineral
discovered in the earth," or the "new plant found in the wild" that the
Supreme Court referred to in <i>Chakrabarty.</i> It may be very difficult to
extract the newly found mineral or to find, extract, and propagate the newly
discovered plant. But that <span CLASS="page_no" data-cite="2012 bl 210726 p 46" data-cite-type="Bloomberg" data-cite-pageno="46" data-primary-citation="">[***46]</span> does not make those naturally occurring items the
products of invention.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The same is true for human genes. Like some minerals, they are hard to
extract from their natural setting. Also like minerals, they can be used for
purposes that would be infeasible if they remained in their natural setting.
And the process of extracting minerals, or taking cuttings from wild plants,
like the process of isolating genetic material, can result in some physical
or chemical changes to the natural substance. But such changes do not make
extracted minerals or plant cuttings patentable, and they should not have
that effect for isolated genes. In each case, merely isolating the products
of nature by extracting them from their natural location and making those
alterations that are attendant to their extraction does not give the
extractor the right to patent the products themselves.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority characterizes the isolated genes as new molecules and
considers them different substances from the corresponding native DNA.<a HREF="#fn202" name="fnref_fn202">[fn2]</a>
Because the native BRCA genes are chemically bonded to other
<span CLASS="page_no" data-cite="689 f 3d 1351" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1351" data-primary-citation="689 F.3d 1303">[*1351]</span> 
genes and histone proteins, the majority concludes that cleaving those bonds
to isolate the BRCA genes turns the isolated genes into "different
materials." Yet there is no magic to a chemical bond that requires us to
recognize a new product when a chemical bond is created or broken, but not
when other atomic or molecular forces are altered.<a HREF="#fn302" name="fnref_fn302">[fn3]</a> A chemical bond is
merely a force between two atoms or groups of atoms strong enough "to make
it convenient for the chemist to consider [the aggregate] as an independent
molecular species." Linus Pauling, <i>The Nature of the Chemical Bond</i> 6 (3d
ed.1960). Weaker interatomic forces will be broken when, for example, a
dirty diamond is cleaned with water or another solvent, but that does not
make the clean diamond a human-made invention. <i>See Am. Fruit Growers, Inc.</i>
<i>v. Brogdex Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BUCI?jcsearch=283%20us%201&amp;summary=yes#jcite">283 U.S. 1</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BUCI?jcsearch=283%20us%201&amp;summary=yes#jcite">12</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BUCI?jcsearch=51%20supreme%20court%20328&amp;summary=yes#jcite">51 S.Ct. 328</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5BUCI?jcsearch=75%20l%20ed%20801&amp;summary=yes#jcite">75 L.Ed. 801</a> (1931) (cleaning
a shell by acid and then grinding off a layer with an emery wheel did not
convert it into a different product). Nor should it make a difference for
purposes of patentability if the portion of a wild plant that is collected
for purposes of later regeneration is separated from the original plant by
chemical means or by scissors.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  If the changes in the DNA molecule that occur as part of the process of
isolation render the gene claims patentable, the same analysis would seem to
apply to chemical elements that do not appear in their atomic form in
nature. For example, isolated lithium does not occur naturally because it
reacts with air and water and thus is found in nature only as part of a
chemical compound, ionically bound to other elements. Robert E. Krebs, <i>The</i>
<i>History and Use of Our Earth's Chemical Elements</i> 48 (2d ed.2006). Once
isolated, lithium has many industrial applications, and in order to isolate
lithium, it is necessary to break ionic bonds in the lithium compounds that
are found in nature. But it seems plain that elemental <span CLASS="page_no" data-cite="103 uspq 2d 1716" data-cite-type="ReporterOfDecisions" data-cite-pageno="1716" data-primary-citation="103 U.S.P.Q.2d 1681">[**1716]</span> lithium (like other
elements) would not be patentable subject matter, even if it could only be
extracted from nature through <span CLASS="page_no" data-cite="2012 bl 210726 p 47" data-cite-type="Bloomberg" data-cite-pageno="47" data-primary-citation="">[***47]</span> an isolation process.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The principles underlying that analysis apply to genetic material as well.
In order to isolate the BRCA gene, it is necessary to break chemical bonds
that hold the gene in its place in the body, but the genetic coding sequence
that is the subject of each of the BRCA gene claims remains the same whether
the gene is in the body or isolated. If we are to apply the conventional
nomenclature of any field to determine whether Myriad's isolated DNA claims
are "new," it would seem to make more sense to look to genetics, which
provides the language of the claims, than to chemistry. Aside from Myriad's
cDNA claims, its composition claims are not defined by any particular
chemical formula. For example, claim 1 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> covers all
isolated DNAs coding for the BRCA1 protein, with the protein being
<span CLASS="page_no" data-cite="689 f 3d 1352" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1352" data-primary-citation="689 F.3d 1303">[*1352]</span> 
defined by the amino acid sequence encoded by the naturally occurring BRCA1
gene. From a molecular perspective, that claim covers a truly immense range
of substances from the cDNA that is 5,914 nucleotides long to the isolated
gene that contains more than 120,000 nucleotides. And the patent does not
define the upper end of that range because the patent does not identify a
unique nucleotide sequence for the 120,000-nucleotide-long isolated BRCA1
gene. Instead, the patent contains a sequence that is just 24,000
nucleotides long with numerous gaps denoted "vvvvvvvvvvvv." &prime;282 patent,
fig. 10. An almost incalculably large number of new molecules could be
created by filling in those gaps with almost any nucleotide sequence, and
all of those molecules would fall within the scope of claim 1. Included in
that set are many important molecular variations to the BRCA1 gene that
Myriad had not yet discovered and could not have chemically described. Yet
those molecules would share only one unifying characteristic: each would
code for the same protein as the naturally occurring BRCA1 gene.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  From a genetic perspective, that claim covers one "composition of matter"
&mdash; the BRCA1 gene. The isolated BRCA genes are identical to the BRCA genes
found on chromosomes 13 and 17. They have the same sequence, they code for
the same proteins, and they represent the same units of heredity. It is true
that the claimed molecules have been cleaved and that they possess terminal
groups that differ from those found on naturally occurring genes. The
majority attaches significance to those facts. But the function of the
isolated DNA molecules is attributable not to the nature of the isolation
process or to the identity of the terminal groups on the molecules; the
function of the claimed molecules is dictated by the nucleotide sequence of
the gene &mdash; a sequence that is determined by nature and that appears in
nature exactly as it appears in the claimed isolated DNA. During the
transcription phase of protein synthesis, the BRCA genes are separated from
chromosomal proteins. The transcription process then proceeds from a
starting point called the promoter to a stopping point often called the
terminator. James D. Watson et al., <i>Molecular Biology <span CLASS="page_no" data-cite="2012 bl 210726 p 48" data-cite-type="Bloomberg" data-cite-pageno="48" data-primary-citation="">[***48]</span> of the Gene</i> 382,
394-96 (6th ed.2008). The only difference between the naturally occurring
BRCA genes during transcription and the claimed isolated DNA is that the
claimed genes have been isolated according to nature's predefined
boundaries, i.e., at points that preserve the ability of the gene to express
the protein for which it is coded.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In that respect, extracting a gene is akin to snapping a leaf from a tree.
Like a gene, a leaf has a natural starting and stopping point. It buds
during spring from the same place that it breaks off and falls during
autumn. Yet prematurely plucking the leaf would not turn it into a
human-made invention. <i>See Intervet Inc. v. Merial Ltd.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DTGRQ003?jcsearch=617%20f%203d%201282&amp;summary=yes#jcite">617 F.3d 1282</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1DTGRQ003?jcsearch=617%20f%203d%201282&amp;summary=yes#jcite">1295</a>
(Fed. Cir.2010) (Dyk, J., concurring in part and dissenting in part). That
would remain true if there were minor differences between the plucked leaf
and the fallen autumn leaf, unless those differences imparted "markedly
different characteristics" to the plucked leaf. <i>Chakrabarty</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 310</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Another example underscores the problem with characterizing the isolated
gene as a patentable invention. A human kidney is a product of nature; it
does not become a patentable invention when it is removed from the body,
even if the patentee has developed an improved procedure for extracting the
kidney, and even <i>if</i> the
<span CLASS="page_no" data-cite="689 f 3d 1353" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1353" data-primary-citation="689 F.3d 1303">[*1353]</span> 
improved procedure results in some physical or chemical changes to the
kidney at the points where the kidney was attached to the host body. But if
that is so, then why should an isolated gene be treated differently for
purposes of <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20U.S.C.%20%20101&amp;summary=yes#jcite">section 101</a>? While the isolation of a gene involves the
alteration of a single molecule, it is difficult to accept that it should
make a difference, for purposes of patentability, whether the isolated
substance is part of a single molecule, as in the case of the <span CLASS="page_no" data-cite="103 uspq 2d 1717" data-cite-type="ReporterOfDecisions" data-cite-pageno="1717" data-primary-citation="103 U.S.P.Q.2d 1681">[**1717]</span> BRCA genes, or
part of a very large aggregation of molecules, as in the case of a kidney.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Both the majority and the concurring opinions attach significant weight to
the fact that the claimed coding portions of the native BRCA genes are part
of a much larger molecule and that the isolated BRCA genes, being smaller
molecules extracted from the larger one; are therefore man-made inventions.
But to argue that the isolated BRCA gene is patentable because in its native
environment it is part of a much larger structure is no more persuasive than
arguing that although an atom may not be patentable, a subatomic particle is
patentable because it was previously part of a larger structure, or that
while a tree is not patentable, a limb of the tree becomes a patentable
invention when it is removed from the tree.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Of course, it is an oversimplification to say that something that can be
characterized as "isolated" or "extracted" from its natural setting always
remains a natural product and is not patentable. One could say, for example,
that a baseball bat is "extracted" or "isolated" from an ash tree, but in
that case the process of "extracting" the baseball bat necessarily changes
the nature, form, and use of the ash tree and thus results in a manmade
manufacture, not a naturally occurring product. In that setting, man has
<span CLASS="page_no" data-cite="2012 bl 210726 p 49" data-cite-type="Bloomberg" data-cite-pageno="49" data-primary-citation="">[***49]</span> defined the parts that are to be retained and the parts that are to be
discarded, and he has molded the retained portion into a product that bears
little resemblance to that which occurs naturally. The result of the process
of selection is a product with a function that is entirely different from
that of the raw material from which it was obtained. In the case of the BRCA
genes, by contrast, nature has defined the genes as independent entities by
virtue of their capacity for protein synthesis and, ultimately, trait
inheritance. Biochemists extract the target genes along lines defined by
nature so as to preserve the structure and function that the gene possessed
in its natural environment. In such a case, the extraction of a product in a
manner that retains the character and function of the product as found in
nature does not result in the creation of a human invention.<a HREF="#fn402" name="fnref_fn402">[fn4]</a> That
principle was captured by the Supreme Court's statement in <i>Chakrabarty</i> that
the invention in that case was not to "a hitherto unknown natural
phenomenon, but to a nonnaturally occurring manufacture or composition of
matter 'haying a distinctive name, character [and] use.'"
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 309-10</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Cases involving the "purification" of a natural substance employ similar
analysis. Our predecessor court recognized that merely purifying a naturally
occurring substance does not render the substance
<span CLASS="page_no" data-cite="689 f 3d 1354" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1354" data-primary-citation="689 F.3d 1303">[*1354]</span> 
patentable unless it results in a marked change in functionality. <i>In re</i>
<i>Merz</i>, 25 CCPA 1314, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIEJ1F?jcsearch=97%20f%202d%20599&amp;summary=yes#jcite">97 F.2d 599</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIEJ1F?jcsearch=97%20f%202d%20599&amp;summary=yes#jcite">601</a> (1938) (holding that there was no right
to a patent on a purer version of ultramarine, but recognizing that if a
claimed article is "of such purity that it differs not only in degree but in
kind it may be patentable"); <i>see also In re King</i>, 27 CCPA 754, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIFETV?jcsearch=107%20f%202d%20618&amp;summary=yes#jcite">107 F.2d 618</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIFETV?jcsearch=107%20f%202d%20618&amp;summary=yes#jcite">620</a> (1939) (same, for purified vitamin C); <i>In re Marden</i>, 18 CCPA 1057,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIE30V?jcsearch=47%20f%202d%20958&amp;summary=yes#jcite">47 F.2d 958</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XIE30V?jcsearch=47%20f%202d%20958&amp;summary=yes#jcite">959</a> (1931) (same, for purified vanadium); <i>Gen. Elec. Co. v.</i>
<i>DeForest Radio Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X449IM?jcsearch=28%20f%202d%20641&amp;summary=yes#jcite">28 F.2d 641</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X449IM?jcsearch=28%20f%202d%20641&amp;summary=yes#jcite">643</a> (3d Cir.1928) (same, for purified
tungsten). On the other hand, the purified natural substance is patentable
if the "purification" results in a product with such distinct
characteristics that it becomes "for every practical purpose a new thing
commercially and therapeutically." <i>Parke-Davis &amp; Co. v. H.K. Mulford Co.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XFLB0H?jcsearch=189%20f%2095&amp;summary=yes#jcite">189 F. 95</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XFLB0H?jcsearch=189%20f%2095&amp;summary=yes#jcite">103</a> (C.C.S.D.N.Y.1911); <i>see also Merck &amp; Co. v. Olin Mathieson</i>
<i>Chem. Corp.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X44LSI?jcsearch=253%20f%202d%20156&amp;summary=yes#jcite">253 F.2d 156</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X44LSI?jcsearch=253%20f%202d%20156&amp;summary=yes#jcite">161-64</a> (4th Cir.1958) (holding that a purified
composition of vitamin B-12 was patentable because the purification process
resulted in a product that was therapeutically effective, whereas the
natural form was not).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In sum, the test employed by the Supreme Court in <i>Chakrabarty</i> requires us
to focus on two things: (1) the similarity in structure between what is
claimed and what is found in nature and (2) the similarity in utility
between what is claimed and what is found in nature. What is claimed in the
BRCA genes is the genetic coding material; that material is the same,
structurally and functionally, in both the native gene and the isolated form
of the gene.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The structural differences between the claimed "isolated" genes and the
corresponding portion of the native genes are irrelevant to the claim
limitations, to the functioning of the genes, and to their utility in their
isolated form. The use to which the genetic <span CLASS="page_no" data-cite="2012 bl 210726 p 50" data-cite-type="Bloomberg" data-cite-pageno="50" data-primary-citation="">[***50]</span> material can be put, i.e.,
determining its sequence in a clinical setting, is not a new use; it is only
a consequence of possession. In order to sequence an isolated gene, each
gene must function <span CLASS="page_no" data-cite="103 uspq 2d 1718" data-cite-type="ReporterOfDecisions" data-cite-pageno="1718" data-primary-citation="103 U.S.P.Q.2d 1681">[**1718]</span> in the same manner in the laboratory as it does in the
human body. Indeed, that identity of function in the isolated gene is the
key to its value. The naturally occurring genetic material thus has not been
altered in a way that would matter under the standard set forth in
<i>Chakrabarty.</i> For that reason, the isolation of the naturally occurring
genetic material does not make the claims to the isolated BRCA genes
patent-eligible.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court's recent decision in <i>Mayo Collaborative Services v.</i>
<i>Prometheus Laboratories, Inc.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20S.Ct.%201289&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">132 S.Ct. 1289</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">1293</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=182%20l%20ed%202d%20321&amp;summary=yes#jcite">182 L.Ed.2d 321</a> (2012), does not decide this case, but the Court's analysis
is nonetheless instructive. In <i>Mayo</i>, which involved method claims, the
representative claim involved the steps of administering a drug to a
subject, determining a metabolite concentration in the subject's blood, and
inferring the need for a change in dosage based on that metabolite
concentration. <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20S.%20Ct.%201289&amp;summary=yes#jcite">Id. at 1295</a>. The Court found that the method was not directed
to patent-eligible subject matter because it contributed nothing "inventive"
to the law of nature that lay at the heart of the claimed invention, i.e.,
"the relationships between the concentration in the blood of certain
thiopurine metabolites and the likelihood that the drug dosage will be
ineffective or induce harmful side-effects." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20S.%20Ct.%201289&amp;summary=yes#jcite">Id. at 1294</a>. The Court examined
"whether the claims do significantly more than simply describe these natural
relations" and whether the "claims add <i>enough</i> to their statements of the
correlations to allow the
<span CLASS="page_no" data-cite="689 f 3d 1355" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1355" data-primary-citation="689 F.3d 1303">[*1355]</span> 
processes they described to qualify as patent-eligible processes that apply
natural laws." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20S.%20Ct.%201289&amp;summary=yes#jcite">Id. at 1297</a> (emphasis in original). In concluding that the
claims did not add "enough" to the natural laws, the Court was particularly
persuaded by the fact that "the steps of the claimed processes . . . involve
well-understood, routine, conventional activity previously engaged in by
researchers in the field." <i></i><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20S.%20Ct.%201289&amp;summary=yes#jcite">Id. at 1294</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Just as a patent involving a law of nature must have an "inventive
concept" that does "significantly more than simply describe . . . natural
relations," <i>Mayo</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">132 S.Ct. at 1294</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">1297</a>, a patent involving a product of
nature should have an inventive concept that involves more than, merely
incidental changes to the naturally occurring product. In cases such as this
one, in which the applicant claims a composition of matter that is nearly
identical to a product of nature, it is appropriate to ask whether the
applicant has done "enough" to distinguish his alleged invention from the
similar product of nature. Has the applicant made an "inventive"
contribution to the product of nature? Does the claimed composition involve
more than "well-understood, routine, conventional" elements? Here, the
answer to those questions is no.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Neither isolation of the naturally occurring material nor the resulting
breaking of covalent bonds makes the claimed molecules patentable. We have
previously stated that "isolation <span CLASS="page_no" data-cite="2012 bl 210726 p 51" data-cite-type="Bloomberg" data-cite-pageno="51" data-primary-citation="">[***51]</span> of interesting compounds is a mainstay of
the chemist's art," and that "[i]f it is known how to perform such an
isolation doing so 'is likely the product not of innovation but of ordinary
skill and common sense.'" <i>Aventis Pharma Deutschland GmbH v. Lupin, Ltd.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X17KB8A003?jcsearch=499%20f%203d%201293&amp;summary=yes#jcite">499 F.3d 1293</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X17KB8A003?jcsearch=499%20f%203d%201293&amp;summary=yes#jcite">1302</a> (Fed.Cir.2007), quoting <i>KSR Int'l Co. v. Telefax, Inc.</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">421</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a> (2007). Similarly, the
structural changes ancillary to the isolation of the gene do not render
these claims patentable. The cleaving of covalent bonds incident to
isolation is itself not inventive, and the fact that the cleaved molecules
have terminal groups that differ from the naturally occurring nucleotide
sequences does nothing to add any inventive character to the claimed
molecules. The functional portion of the composition &mdash; the nucleotide
sequence &mdash; remains identical to that of the naturally occurring gene.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority suggests that I have "focus[ed] not on the differences
between isolated and native DNAs, but on one similarity: their informational
content." In light of <i>Mayo</i>, that approach seems appropriate. The
informational content of the nucleotide sequences is the critical aspect of
these molecules; the terminal groups added to the molecules when the
covalent bonds are broken &mdash; to which the majority and concurring opinions
attribute such significance &mdash; are not even mentioned in the claims. The
nucleotide sequences of the claimed molecules are the same as the nucleotide
sequences found in naturally occurring human genes. In my view, that
structural similarity dwarfs the significance of the structural differences
between isolated DNA and naturally occurring DNA, especially where the
structural differences are merely ancillary to the breaking of covalent
bonds, a process that is itself not inventive.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As noted, in addition to the BRCA gene claims discussed above, the claims
at issue in this appeal include four claims to BRCA cDNA and two claims to
portions of the <span CLASS="page_no" data-cite="103 uspq 2d 1719" data-cite-type="ReporterOfDecisions" data-cite-pageno="1719" data-primary-citation="103 U.S.P.Q.2d 1681">[**1719]</span> BRCA genes and cDNA as small as 15 nucleotides long.
<span CLASS="page_no" data-cite="689 f 3d 1356" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1356" data-primary-citation="689 F.3d 1303">[*1356]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I agree with the court that the claims to BRCA cDNA are eligible for
patenting. The cDNA cannot be isolated from nature, but instead must be
created in the laboratory.<a HREF="#fn502" name="fnref_fn502">[fn5]</a> The end product is a human-made invention
with distinct structure because the introns that are found in the native
gene are removed from the cDNA segment. Additionally, the cDNA has a utility
not present in the naturally occurring BRCA DNA and mRNA because cDNA can be
attached to a promoter and inserted into a non-human cell to drive protein
expression.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  However, I disagree with the court as to the two claims to short segments
of DNA having at least 15 nucleotides. Claim 6 of the &prime;282 patent covers any
sequence of the BRCA1 cDNA that is at least 15 nucleotides long. That claim
encompasses each BRCA1 exon, even though each exon is naturally defined by
transcription. Moreover, because small sequences of DNA are repeated
throughout the three billion nucleotides of the human genome, the claim
covers portions of the cDNA of more than 4% of human genes. It also covers
portions of the DNA of nearly all human genes. Accordingly, efforts <span CLASS="page_no" data-cite="2012 bl 210726 p 52" data-cite-type="Bloomberg" data-cite-pageno="52" data-primary-citation="">[***52]</span> to
sequence almost any gene could infringe claim 6 even though Myriad's
specification has contributed nothing to human understanding of other genes.
Myriad is not entitled to such broad protection. <i>See Mayo</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">132 S.Ct. at 1301</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1HB8JM003?jcsearch=132%20supreme%20court%201289&amp;summary=yes#jcite">1303</a> (examining "how much future innovation is foreclosed
relative to the contribution of the inventor" and warning of the "danger"
that overly broad patent claims might "foreclose[] more future invention
than the underlying discovery could reasonably justify").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Myriad could easily have claimed more narrowly to achieve the utility it
attaches to segments of cDNA. It contends that those segments can be used as
probes and primers. DNA probes must be chemically altered or "tagged" before
they can be so used, and Myriad could have claimed the tagged segments to
achieve probe functionality. A claim to tagged segments would not encompass
the BRCA1 exons. As to primer functionality, many of the cDNA segments will
not work. Some will be too long. Some will be too short. Some will be
palindromic and fold in on themselves. Myriad could have identified a subset
of the segments that work as primers, and such a claim could be patentable
if it were limited to species with "markedly different characteristics from
any found in nature and . . . having the potential for significant utility."
<i>Chakrabarty</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 310</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>. The problem with claim 6 is
that it is so broad that it includes products of nature (the BRCA1 exons)
and portions of other genes; its validity is not salvaged because it
includes some species that are not natural. Accordingly, I would hold claim
6 unpatentable.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The other claim to a short segment of DNA, claim 5 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a>, is
breathtakingly broad. That claim covers any segment of the DNA defined by
claim 1, provided that the segment is at least 15 nucleotides long. Claim 1,
in turn, covers any isolated DNA that codes for the BRCA1 polypeptide. Thus,
claim 5 would cover not only the isolated BRCA1 gene in each of its numerous
molecular variations, but also any sub-sequence of those molecules,
including portions that fall in the
<span CLASS="page_no" data-cite="689 f 3d 1357" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1357" data-primary-citation="689 F.3d 1303">[*1357]</span> 
undefined range of those molecules denoted "vvvvvvvvvvvv." Claim 5 would
therefore be unpatentable for the same reasons as claim 1 and claim 6.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Of course, in light of its breadth, claim 5 of the &prime;<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X2HOGE240GJ?jcsearch=usp%205747282&amp;summary=yes#jcite">282 patent</a> is likely
to be invalid on other grounds, and thus a ruling as to patent eligibility
with respect to that claim may be superfluous. Nonetheless, it is important
to consider the effects of such broad patent claims on the biotechnology
industry. While Myriad has emphasized the biotechnology industry's need of
patent protection to encourage and reward research in this difficult and
important field, there is another side to the coin. Broad claims to genetic
material present a significant obstacle to the next generation of innovation
in genetic medicine &mdash; multiplex tests and whole-genome sequencing. New
technologies are being developed to sequence many genes or even an entire
human genome rapidly, but firms developing those technologies are
encountering a thicket of patents. Secretary's Advisory Comm. on Genetics,
<span CLASS="page_no" data-cite="2012 bl 210726 p 53" data-cite-type="Bloomberg" data-cite-pageno="53" data-primary-citation="">[***53]</span> Health, and Society, Dep't of Health &amp; Human Servs., <i>Gene Patents and</i>
<i>Licensing Practices and Their Impact on Patient Access to Genetic Tests</i>
49-62 (2010). In order to sequence an entire genome, a firm would have to
license thousands of patents from many different licensors. <i>See </i><cite>id. at
50-51</cite>. Even if many of those patents include claims that are invalid for
anticipation or obviousness, the costs involved in determining the scope of
all of those <span CLASS="page_no" data-cite="103 uspq 2d 1720" data-cite-type="ReporterOfDecisions" data-cite-pageno="1720" data-primary-citation="103 U.S.P.Q.2d 1681">[**1720]</span> patents could be prohibitive. <i>See </i><cite>id. at 51-52</cite>; Rebecca S.
Eisenberg, <i>Noncompliance, Nonenforcement, Nonproblem? Rethinking the</i>
<i>Anticommons in Biomedical Research</i>, 45 Hou. L.Rev. 1059, 1076-1080 (2008)
(concluding that existing studies "have focused relatively little attention
on downstream product development" and that interviews accompanying those
studies suggest that, though smaller than initially feared, the costs
associated with the patent thicket are "quite real in the calculations of
product-developing firms").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  My colleagues assign significant weight to the fact that since 2001 the
PTO has had guidelines in place that have allowed patents on entire human
genes. They conclude that those guidelines, and the PTO's earlier practice,
are entitled to deference from this court as to the question whether patents
to isolated human genes constitute patent-eligible subject matter. I think
the PTO's practice and guidelines are not entitled to significant weight,
for several reasons.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  First, as we have recognized, the PTO lacks substantive rulemaking
authority as to issues such as patentability. <i>Animal Legal Def. Fund v.</i>
<i>Quigg</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X544BC?jcsearch=932%20f%202d%20920&amp;summary=yes#jcite">932 F.2d 920</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X544BC?jcsearch=932%20f%202d%20920&amp;summary=yes#jcite">930</a> (Fed.Cir.1991). In areas of patent scope, we owe
deference only commensurate with "the thoroughness of its consideration and
the validity of its reasoning." <i>Merck &amp; Co. v. Kessler</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XAC7P5?jcsearch=80%20f%203d%201543&amp;summary=yes#jcite">80 F.3d 1543</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XAC7P5?jcsearch=80%20f%203d%201543&amp;summary=yes#jcite">1550</a>
(Fed.Cir.1996). The comments that the PTO issued at the time of its 2001
guidelines in response to suggestions that isolated human genes were not
patentable are, frankly, perfunctory. <i>See</i> John M. Conley &amp; Roberte Makowski,
<i>Back to the Future: Rethinking the Product of Nature Doctrine as a Barrier</i>
<i>to Biotechnology Patents</i>, 85 J. Pat. &amp; Trademark Off. Soc'y 301 (2003).
Because those comments, at least on their face, do not reflect thorough
consideration and study of the issue, I do not regard them as worthy of much
weight in the analysis of this complex question.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, whatever force the PTO's views on the issue of patent eligibility
may have had in the past has, at the very least, been substantially
undermined by the position
<span CLASS="page_no" data-cite="689 f 3d 1358" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1358" data-primary-citation="689 F.3d 1303">[*1358]</span> 
the government has taken in this case. The Department of Justice has twice
filed a brief on behalf of the United States in this court taking the
position that Myriad's gene claims (other than the cDNA claims) are not
patent-eligible. Although the PTO did not "sign" the brief on either
occasion and we are left to guess about the status of any possible
continuing inter-agency disagreements about the issue, the Department of
Justice speaks for the Executive Branch, and the PTO is part of the
Executive Branch, so it is fair to conclude that the Executive Branch has
modified its position from the one <span CLASS="page_no" data-cite="2012 bl 210726 p 54" data-cite-type="Bloomberg" data-cite-pageno="54" data-primary-citation="">[***54]</span> taken by the PTO in its 2001 guidelines
and, informally, before that.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, prior to the Supreme Court's decision in <i>Chakrabarty</i>, the PTO had
determined that microorganisms were not subject to patenting, but the
Supreme Court gave no indication that it regarded that view as entitled to
deference. Moreover, the Court gave short shrift to the Commissioner's
contention (which was made the lead argument in the government's brief in
that case) that the patentability of life-forms was an issue that should be
left to Congress. Citing <i>Marbury v. Madison</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XJLPEN?jcsearch=5%20us%20137&amp;summary=yes#jcite">5 U.S. (1 Cranch) 137</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XJLPEN?jcsearch=2%20l%20ed%2060&amp;summary=yes#jcite">2 L.Ed. 60</a> (1803), the Court explained that "Congress has performed its
constitutional role in defining patentable subject matter in <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XEIVVA003?jcsearch=35%20USC%20101&amp;summary=yes#jcite">&sect; 101</a>; we
perform ours in construing the language Congress has employed." <i>Chakrabarty</i>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=447%20us%20303&amp;summary=yes#jcite">447 U.S. at 315</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CA06?jcsearch=100%20supreme%20court%202204&amp;summary=yes#jcite">100 S.Ct. 2204</a>. We have the same responsibility and should
not shy away from deciding the issues of law that the parties have brought
to us. Although my colleagues believe our analysis of the legal question in
this case should be influenced by purported expectations of the inventing
community based on the PTO's past practice of issuing patents on human
genes, that is in effect to give the PTO lawmaking authority that Congress
has not accorded it.<a HREF="#fn602" name="fnref_fn602">[fn6]</a> There is no collective right of adverse possession
to intellectual property, and we should not create one. Our role is to
interpret the law that Congress has written in accordance with the governing
precedents. I would do so and would affirm the district court's rulings as
to the BRCA gene and BRCA gene segment claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn102" name="fn102">[fn1]</a></span> There is some dispute over whether other inventors helped Myriad
discover the BRCA sequences or discovered the BRCA2 sequence before Myriad.
Because those disputes are irrelevant to the question of patentable subject
matter. I refer to the discovery of the BRCA sequences as Myriad's work.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn202" name="fn202">[fn2]</a></span> Although I recognize that Judge Lourie and Judge Moore, while reaching
the same ultimate conclusions, have taken analytical paths that differ in
some respects, for convenience I will refer to Judge Lourie's opinion as the
majority opinion and Judge Moore's opinion as the concurring opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn302" name="fn302">[fn3]</a></span> The majority characterizes the question in this case as turning on the
breaking of covalent bonds linking the BRCA genes to the rest of the DNA in
chromosomes 13 and 17, but its analysis appears to place patentable weight
on the breaking of other chemical bonds, such as the hydrogen bonds that are
broken when separating DNA from histones or &mdash; in an example unrelated to
this case &mdash; the ionic bonds that are broken when lithium is derived from a
salt. It is difficult to see why differences between types of chemical bonds
should matter for patentability purposes, and I see little support for such
a distinction in the governing precedents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn402" name="fn402">[fn4]</a></span> By analogy, extracting a slab of marble from the earth does not give
rise to protectable intellectual property rights, but "extracting" a piece
of sculpture from that slab of marble does. In the case of the BRCA gene
claims, what Myriad has claimed is more akin to the slab of marble found in
the earth than to the sculpture carved from it after its extraction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn502" name="fn502">[fn5]</a></span> The appellees argue that the BRCA1 cDNA can be isolated from nature,
and they refer to a BRCA1 pseudogene called BRCA1P1 that is found in the
human genome. However, the appellees have failed to demonstrate that the
pseudogene consists of the same sequence as the BRCA1 cDNA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn602" name="fn602">[fn6]</a></span> Because the asserted reliance interest is based on PTO practice and
not on prior judicial decisions, this case is not analogous to
<i>Warner-Jenkinson Co. v. Hilton Davis Chemical Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CCSV?jcsearch=520%20us%2017&amp;summary=yes#jcite">520 U.S. 17</a>,
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CCSV?jcsearch=117%20supreme%20court%201040&amp;summary=yes#jcite">117 S.Ct. 1040</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X5CCSV?jcsearch=137%20l%20ed%202d%20146&amp;summary=yes#jcite">137 L.Ed.2d 146</a> (1997), or <i>Festo Corp. v. Shoketsu Kinzoku</i>
<i>Kogyo Kabushiki Co.</i>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=535%20us%20722&amp;summary=yes#jcite">535 U.S. 722</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=122%20supreme%20court%201831&amp;summary=yes#jcite">122 S.Ct. 1831</a>, <a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/XG4UTV?jcsearch=152%20l%20ed%202d%20944&amp;summary=yes#jcite">152 L.Ed.2d 944</a> (2002),
where the expectations of the inventing community were based on longstanding
Supreme Court precedent.
</p></div>
<!--BBLS DD 1722479673347-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I45SK003/history">Direct History (8)</a>
</div>
<div class='sidebarItemLabel bold'>
Negative Direct History
</div>
<div class='bcite'>
<div class='sidebarItemLabel'>
Judgment affirmed (in part) and judgment reversed (in part) by
</div>
<div class='citationAnalysisSideBarLabel'>
<a class="icon citation distinguished" href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1JOVHQ003" title="Distinguished"></a>
<a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1JOVHQ003">Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 186 L. Ed. 2d 124, 106 U.S.P.Q.2d 1972 (2013)</a>
</div>
</div>

</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I45SK003/analysis">Case Analysis (9)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I45SK003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
7
</span>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/distinguished.png'>
<div class='citation distinguished icon printHide' title='Distinguished'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I45SK003/analysis?analysis=distinguished'>
Distinguished
</a>
<span class='citationNumberLabel'>
2
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed (In Part), Judgment Reversed (In Part), Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Health &amp; Medical</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/document/X1Q6LC8P4N82">10-01406 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Constitutional Law</div><div class='facetItemLabel'>Copyright Law</div><div class='facetItemLabel'>Patent Law</div><div class='facetItemLabel'>Trademark Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/be1a650e379e823802dd9ef4a4e4ed93/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "be1a650e379e823802dd9ef4a4e4ed93";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYb4db77&previousPageId=&previousActivityInstanceId=ENTITY67a14b&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:15:56-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1I45SK003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY67a14b&previousPageId=&previousActivityInstanceId=ENTITYb74aa8&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:15:48-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1I45SK003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1I45SK003";
$('#page_loader').show().spin();
JUDGE_IDS=["15753020","1718421","3027440"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
